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Rheumatoid arthritis (RA) is a symmetric polyarticular arthritis that most commonly af-
fects the small joints of the hands and the feet, but may involve every synovial joint.
Infl ammation of the synovial membrane (the joint lining) and destruction of articular 
structures characterize the disease process that is considered to have an autoimmune na-
ture. Normally, the synovium is relative acellular and has a delicate intimal lining. In RA, 
the synovium is invaded by infl ammatory and immune cells as macrophages, CD4+ T 
cells and B cells; an increase in macrophage-like synoviocytes and fi broblast-like synovio-
cytes lead to synovial hyperplasia. Pannus tissue, formed by hypertrophic synovial tissue, 
subsequently contributes to cartilage destruction by the formation of degrading enzymes 
and fi nally the underlying bone of the joint is eroded.
IMPACT OF RHEUMATOID ARTHRITIS
RA is the most common chronic infl ammatory arthritis that has a large impact on physi-
cal, social and emotional functioning and also creates a large burden of economic costs. 
RA affects 0.5-1.0% of the adult population in Europe and North America (1,2). In the 
Netherlands the ‘Standaard Diagnose-registratie van Reumatische ziekten’ of TNO reports 
a prevalence of 1.1 per 1,000 men and 2.3 per 1,000 women, standardized for the Dutch 
population in 2000 (3). From the patient’s perspective RA is characterised by pain, stiff-
ness and fatigue (4) and at examination the features are infl ammation and destruction of 
joints. Although the course of RA is highly variable among patients, the physical symp-
toms often have important functional consequences. The prevalence of work disability as-
cribed to RA is impressive. Follow-up of patients enrolled in the NOAR cohort (UK) found 
that in the early years after disease onset about 30% of patients permanently stopped 
working due to RA, and that patients with RA were 32 times more likely to stop work on 
health grounds compared to matched controls (5). Albers et al observed in a Dutch cohort 
of early RA patients work disability in 42% (6). They also stressed the broader impact of 
RA on daily life as over 40% of patients needed extra rest during day time and 50-60% 
of patients experienced signifi cant impairment in transport mobility and leisure activi-
ties (6). The costs of RA have been studied in detail but estimates vary largely between 
countries and health systems. The direct costs per patients are estimated at €1,821-11,792 
annually and indirect costs at €1,260-37,994 annually (7). The mentioned estimates are 
means, which mask major inter-individual differences because the distribution of costs is 
skewed with a small minority of patients accounting for a large proportion of costs (7). 









The prevalence and the huge social consequences of RA underline the importance of thor-
ough understanding of the pathogenesis of RA and the development of effective therapeu-
tic strategies. The last decade it has been recognised that RA needs to be diagnosed early 
and treated promptly with disease modifying antirheumatic drugs in order to successfully 
interfere with the disease process and with the progression to joint damage and disability. 
This new treatment paradigm in combination with new treatment options, have already 
improved the prospects for patients with RA in general, with improved global disease ac-
tivity, retardation of joint destruction, prevention of disability and reduction of mortality 
(9). At present, the ultimate aim of therapeutic interventions in patients with a chronic 
arthritis is remission. Hopefully, in the future better understanding of the disease process 
will result in a further shift in treatment strategies. Ideally, the development of RA can 
be recognised in a very early stage and treatment in this phase is able to hamper progres-
sion to the chronic disorder. However, currently, prevention of RA is miles away and the 
genetic and environment factors that result in RA are far from completely understood.
PATHOPHYSIOLOGY OF AND RISK FACTORS FOR RHEUMATOID ARTHRITIS
Genetic factors
The most important genetic risk factor for RA was documented almost 30 years ago by 
Stastny by the recognition that HLA-DR4 (HLA-DRB1*04) is associated with RA (10). Later 
studies showed that also several (other) HLA-DRB1 alleles (*0101, *0102, *0401, *0404, 
*0405, *0408, *1001 and *1402) were associated with the disease (11-13). The products 
of these alleles appeared to share an amino acid sequence at position 70-74 in the third 
hypervariable region of the DRβ1 chain of the HLA-DRB1 molecule (QKRAA, QRRAA or 
RRRAA). These residues are part of one side of the antigen presenting binding site (Figure 
1). The Shared Epitope hypothesis postulates that the shared epitope motif itself is di-
rectly involved in the pathogenesis of RA by allowing the presentation of an arthritogenic 
peptide to T cells (14). Unfortunately, specifi c arthritogenic peptides that bind to the DR 
proteins in RA have not been identifi ed. Refi nement of the Shared Epitope hypothesis, 
as well as alternative roles for the shared epitope motif have been proposed (15-17). Al-
though the exact role of the shared epitope in the pathophysiology of RA is still elusive, 
there is extensive evidence showing an association between the shared epitope encoding 
alleles and susceptibility to RA as well as severity of RA (18-20). The total genetic contribu-
tion to RA has been quantifi ed by the comparison of monozygotic and dizygotic twins 
and is estimated to be 50-60% (21). The HLA class II molecules are so far the most power-
ful genetic factor that account for about 30% of the total genetic effect (22).
Introduction 11
Autoantibodies
An important reason why RA is considered to be an autoimmune disease is the presence of 
autoantibodies. The classical autoantibody associated with RA is rheumatoid factor (RF), 
an autoantibody that is directed at the Fc-part of immunoglobulin G. RF is not unique 
for RA, and can be found in other autoimmune diseases, infectious diseases and healthy 
(elderly) persons. The sensitivity of RF varies between 60-70% and the specifi city between 
50-90% (24).
The latest years, there has been a considerable interest in the observation that the 
presence of antibodies to citrulline-containing proteins is highly specifi c for RA. The 
observation that these antibodies appear early in RA and can be found years before the 
disease onset (25,26), as well as the fi nding that citrullinated proteins are expressed in the 
infl amed joint (27,28), leads to the hypothesis that the anti-cyclic citrullinated peptides 
(anti-CCP) antibodies are of pathophysiological importance in RA. Citrullination is the 
posttranslational modifi cation of protein-bound arginine into the non-standard amino-
acid citrulline. This process is mediated by the enzym peptidylarginine deiminase and 
results in a small change in molecular mass and the loss of a positive charge. Although the 
role of citrullination remains to be determined, it has been proposed that citrullination 
plays a pivotal role in preparing intracellular proteins for degradation during apoptosis 
(29,30) and in the regulation of transcription through citrullination of histones (31). Even 
though citrullination seems to be a nonspecifi c feature of infl ammation, it is not yet clear 
Figure 1. Structure of the HLA-DRB1 molecule. The HLA-DRB1 molecule is composed of an 
α-chain and a highly polymorphic β-chain. The antigen-presenting binding site is formed by a β
sheet (fl oor) and two helices at both sides. The amino acid residues at position 70-74 are indicated. 








which circumstances lead to breaking tolerance to citrullinated proteins and the develop-
ment of anti-CCP antibodies. The sensitivity of anti-CCP antibodies for RA is 54-64% and 
the specifi city is about 90-97% (32,33).
UNDIFFERENTIATED ARTHRITIS
In only a minority of the patients that present with recent-onset arthritis to an early ar-
thritis clinic a defi nite diagnosis can be made directly. Only 22% of the patients that were 
included in the Leiden Early Arthritis Clinic were diagnosed with RA at the two weeks 
visit (34) and in a considerable number of patients (about 40%) no diagnosis according 
to one of the ACR-criteria could be made (34); these patients are identifi ed as undiffer-
entiated arthritis (UA). The disease course of the patients with UA is variable (Figure 3). 
From several inception cohort studies it is known that about 40-50% of the UA-patients 
remit spontaneously, whereas one-third develops RA (35-37). The analysis of the clinical 
evolution of patients with UA is extremely interesting as the analysis of the disease course 
in combination with genetical and serological factors may allow insight in the factors 
that are associate with progression towards RA or towards remission. Investigation of 
UA-patients and the disease course is not only relevant as it may reveal pathophysiologi-
cal aspects of RA, it also allows the identifi cation of predictive factors for progression to 
RA. Recognition of independent predictive variables and knowledge on the predictive 
power of these variables are ingredients to create a prediction model that estimates the 
chance on RA-development in individual patients with UA. Recent research indicates that 
Figure 2. Conversion of arginine to citrulline, mediated by the enzym 
peptidylarginine deiminase (PAD).
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treatment with methotrexate in very early disease stages as UA is effective in hampering 
progression to RA (38), providing evidence for the use of disease modifying antirheumatic 
drugs in UA. Conversely, a considerable amount of UA-patients remit spontaneously and 
these patients should not be treated with potential toxic drugs. These data underline that 
at present support for clinicians in treatment decisions in patients with recent-onset UA 
is urgently needed.
AIM AND OUTLINE OF THE THESIS
The aims of this thesis were mainly three-fold:
1. To investigate the association of several genetic factors with RA.
2. To elucidate the role of the HLA Class II alleles in the development of both anti-CCP 
antibodies and RA.
3. To identify predictive factors for the development of RA and to develop a prediction 
model that determines the risk to progress from UA to RA in individual patients.
This thesis is devided in four parts.
In Part 1 the association between several genetic factors and RA susceptibility and 
severity is examined.
Although the predisposing effects of the shared epitope encoding HLA-DRB1 alleles are 
generally accepted, controversy existed regarding the possible protective effects of certain 
HLA-DRB1 alleles. These alleles contain instead of the shared epitope another common 
anchor region consisting of the amino acids DERAA. Although some evidence for the pro-
tective effect of the presence of DERAA-encoding alleles existed, it was not clear whether 
the effect of DERAA is really protective or whether the protective effect is attributable to 
the concomitant absence of predisposing shared epitope alleles. Chapter 2 investigated 
the effect of the DERAA-encoding HLA-DRB1 alleles on RA susceptibility and severity and 
differentiated the protective effect from non-predisposition by comparing subgroups of 
patients with an equal amount of predisposing alleles.
General Undifferentiated Chronic destructive 














Tumor necrosis factor (TNF)-alpha is a pro-infl ammatory cytokine that plays a signifi -
cant role in promoting joint infl ammation in RA and TNF-alpha blockers are the most 
effective drugs in the treatment of RA. In 2001 and 2002 two separate groups reported on 
the association of a Single Nucleotide Polymorphism (SNP) in the TNF-receptor 2 gene in 
familial RA. Controversy existed on the association of this SNP with RA severity. Chapter 
3 assessed the effect of the TNFR2 196 M/R SNP on RA severity by taking advantage of the 
extremes of the phenotypes that exist in rheumatoid arthritis: the genotype frequencies 
of the patients that achieved remission and the patients that developed severe destructive 
disease were compared.
Chapter 4 investigated the association between the C1858T SNP in the protein tyro-
sine phosphatase non-receptor 22 (PTPN22) gene and RA susceptibility, RA severity and 
UA. This PTPN22 gene is located at chromosome 1 and encodes for a lymphoid tyrosine 
phosphatase that mediates the inhibition of T-cell-receptor signaling. The 1858C→T SNP 
changes the aminoacid at position 620 from arginine (R) to tryptophan (W) and has 
recently been identifi ed as a risk factor for RA (39). The study described in chapter 4 aimed 
to replicate the association between this SNP and RA and to extend this fi nding by study-
ing whether this SNP is also correlated with RA severity and UA.
In Chapter 5 it is explored whether the receptor for advanced glycation end products 
(RAGE) G82S polymorphism is an independent risk factor for RA. There are fi ndings that 
suggest a role for RAGE signaling in the pathogenesis of RA. RAGE seems to be important 
in its ability to amplify pro-infl ammatory immune responses and several RAGE ligands 
display increased levels in synovial tissue or synovial fl uid in patients with RA (40-42). 
In addition, the G82S SNP has been found to be more prevalent in RA patients compared 
to controls (43). As this SNP is in strong linkage disequilibrium with the HLA-DR4 allele, 
chapter 5 examined whether the reported association can be explained through linkage 
with HLA-DR4.
Chapter 6 reviewed recently identifi ed genetic factors and their contribution to RA.
In Part 2 associations between the HLA Class II alleles and autoantibodies are de-
scribed. 
Considering the high specifi city of anti-CCP antibodies for RA, the fi nding that the 
presence of shared epitope encoding HLA-DRB1 alleles correlate with the presence of 
autoantibodies in RA and the assumption that anti-CCP antibodies are of pathophysi-
ological importance for RA, the nature of the association between HLA and anti-CCP 
antibodies is further explored. Chapter 7 compared the shared epitope frequencies of 
healthy controls and RA patients without and with anti-CCP antibodies in two indepen-
dent cohorts using two different methods: association and linkage.
In chapter 8 the association between the non-shared epitope encoding HLA-DRB1 
alleles and anti-CCP antibody negative RA is investigated.
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The most prominent environmental risk for RA is smoking: smokers have increased 
levels of RF (44-46) and are more prone to develop RA (46-48). Recently, a gene-environ-
mental interaction between smoking and the shared epitope was described, providing 
risk for RF-positive but not for RF-negative RA (49). In chapter 9 it is studied whether a 
gene-environmental interaction is present for the anti-CCP antibody response. Second, 
this study investigated whether the interaction between smoking and the shared epitope 
alleles is unique for RA or is also present in UA.
In chapter 7 it is shown that the shared epitope alleles are only a risk factor for anti-CCP 
positive RA and not associated with anti-CCP negative RA. As the contribution of the 
shared epitope containing HLA-alleles to the pathogenesis of RA is not well understood, 
the fi ndings of chapter 7 led us to evaluate the hypothesis that the shared epitope alleles 
are mainly a risk factor for anti-CCP antibodies rather than for (anti-CCP positive) RA. To 
this end, the disease course of patients presenting with UA in combination with the HLA 
class II alleles and autoantibodies was studied. The results on this analysis, as well as data 
on the association between the shared epitope alleles and the level of anti-CCP antibodies 
are described in chapter 10.
The results described in chapters 7-10 strongly suggest that the pathogenic mechanisms 
underlying anti-CCP antibody positive and negative RA are different. These observations 
inspired subsequent research addressing the question whether anti-CCP-positive RA and 
anti-CCP-negative RA are different disease entities or have different phenotypical proper-
ties. Therefore, in chapter 11 anti-CCP antibody positive and negative RA patients are 
compared for several aspects of their phenotype: initial symptoms, signs and acute phase 
reactants and distribution of joint swelling and severity of radiological joint destruction 
during the course of the disease.
In part 3 two different aspects of RA severity are studied.
Chapter 12 investigated in vitro characteristics of fi broblast-like synoviocytes (FLS) in 
relation with the level of joint destruction in patients with RA. FLS are a major constitu-
ent of the hyperplastic synovial pannus and in vitro studies have shown that the FLS in 
RA have a transformed behaviour: they express large amount of proteases, express onco-
genes and invade normal cartilage. In chapter 12 it is assessed whether the degree of in 
vitro measured invasion is associated with the degree of radiological joint destruction in 
patients with RA.
Chapter 13 studied the contribution of genetics to RA severity by comparing radiologi-
cal data of monozygotic and dizygotic twins and unrelated RA-patients. Current research 
on genetic factors associated with RA is focussed on disease susceptibility. Although the 
effects of genetic factors on RA severity are of equal interest, so far the contribution of 








Part 4 of this thesis deals with the question whether the disease course in arthritis can be 
predicted. First, in chapter 14 the current knowledge on risk factors for RA development 
is reviewed.
The study described in chapter 15 analysed whether the distribution of arthritic joints 
at fi rst presentation has a predictive value for the disease course in RA. 
Finally, chapter 16 presents the development of a prediction model for the disease 
outcome in patients with recent-onset UA and the validation of this model in an inde-
pendent cohort of UA-patients.
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Objectives. The most important genetic risk factor for rheumatoid arthritis (RA) is lo-
cated within the Human Leucocyte Antigen (HLA)-region. HLA-DRB1 alleles encoding 
for the shared epitope (SE) predispose to RA and to more severe disease. Other HLA-DRB1 
alleles harbouring a different epitope, encoded by the amino acids DERAA, have been 
associated with protection. Due to small cohort sizes, the protective effect on disease 
severity is still controversial and has never been discerned from non-predisposition (not 
carrying SE-alleles). This study investigates the effect of the DERAA-encoding alleles on 
RA severity and susceptibility in a large prospective cohort and differentiates protective ef-
fects from non-predisposition by comparing subgroups of patients with an equal amount 
of predisposition alleles.
Methods. In 440 early RA patients and 423 healthy controls the HLA class II alleles were 
determined. To study the effect of HLA on disease severity, radiological joint destruction 
(modifi ed Sharp-van der Heijde method) was determined during 4-years follow-up. 
Results. The presence of DERAA-encoding HLA-DRB1-allelles conferred a lower risk to 
develop RA both in the presence and in the absence of SE-alleles (OR 0.6). In the presence 
of one SE-allele, the group of patients that carried DERAA had signifi cant less severe ra-
diological destruction at all time points compared to DERAA-negative patient-group with 
one SE-allele. Additionally, the protective effect of DERAA was detected in the groups of 
patients that were prone to more severe disease due to the presence of anti-CCP-antibod-
ies or smoking. 
Conclusions. DERAA-encoding HLA-DRB1-alleles independently protect against RA and 
are associated with less severe disease.
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INTRODUCTION
Rheumatoid arthritis (RA) is a complex genetic disorder with an estimated heritability 
of 60% (1). Human Leucocyte Antigens (HLA) Class II molecules are the most powerful 
recognized genetic factors and contribute to at least 30% of the total genetic effect (2). 
Extensive evidence exists showing the association between certain frequently occurring 
HLA-DRB1 alleles (*0101, *0102, *0401, *0404, *0405, *0408, *0410 *1001, *1402) and 
susceptibility to and severity of RA (3-5). The indicated alleles share a conserved amino 
acid sequence (QKRAA, QRRAA or RRRAA; also called the shared epitope) at position 
70-74 in the third hypervariable region of the DRβ1 chain. These residues are part of an 
α-helical domain forming one side of the antigen presenting binding site. The Shared 
Epitope hypothesis postulates that the shared epitope motif itself is directly involved in 
the pathogenesis of RA by allowing the presentation of a peptide to arthritogenic T cells.
Although the predisposing effects of shared epitope encoding HLA-DRB1 alleles are 
generally accepted, controversy exists on the existence of protective effects by certain 
HLA-DRB1 alleles. These alleles contain, instead of the shared epitope, another common 
anchor-region consisting of the amino acids DERAA. HLA-DRB1 alleles that express this 
DERAA sequence (DRB1*0103, *0402, *1102, *1103, *1301, *1302, *1304) may protect 
against RA (6-8). There is some evidence that patients carrying the DERAA sequence have 
also less erosive disease. However, there are few studies addressing the effect of DERAA 
on disease severity, and interpretation is hampered either by a retrospective design with 
variable disease duration (9,10) or by small numbers of patients carrying the DERAA-se-
quence. Wagner et al. performed a prospective study, but only 7 DERAA-positive patients 
were followed for 4 years (11). Moreover, it is not clear whether the effect of DERAA 
encoding HLA-DRB1 alleles is truly protective or is due to the effect of the concomitant 
absence of predisposing shared epitope encoding HLA-DRB1 alleles.
A number of the initial reports on the protective effects of the DERAA haplotype are based 
on the Leiden Early Arthritis Clinic (6,12). This cohort started in 1993 and has since then 
expanded considerably. Presently more than 1800 patients are included. By using this 
expanded cohort we aim to assess the association of DERAA encoding HLA-DRB1 alleles 
with 1) RA severity, taking advantage of the fact that at present a substantial number of 
patients is followed prospectively and 2) susceptibility to RA. This large cohort allows the 
determination of the possible protective effects of DERAA encoding HLA-DRB1 alleles in 
the presence of an equal number of shared epitope encoding HLA-DRB1 alleles, thereby 
permitting differentiation between protection and non-predisposition. Furthermore, the 
available clinical data allowed to determine whether RA patients exhibiting an extreme of 








of HLA-alleles compared to patients with persistent disease. The present data show that 
HLA-DRB1 alleles encoding the DERAA-sequence are associated with less severe disease at 
all time points during 4 years follow-up and confer a lower risk to develop RA.
PATIENTS AND METHODS
Study Population
In 1993 an Early Arthritis Clinic was started at the Department of Rheumatology of the 
Leiden University Medical Center, the only referral center for Rheumatology in a health 
care region of about 400,000 inhabitants in the western part of the Netherlands (13). Gen-
eral practitioners were encouraged to refer patients directly when arthritis was suspected. 
Patients referred to the early arthritis clinic could be seen within two weeks and were in-
cluded in the program when the physician’s examination of the patient revealed arthritis 
and the symptoms had lasted less then two years. For every patient, routine diagnostic 
laboratory screening was performed. A 44 joint count of swollen joints was performed on 
entering the study and yearly thereafter. The smoking history was assessed. In this study 
smokers were patients that smoked (cigarettes, cigars) at inclusion or patients that had 
smoked previously. The numbers of smoked pack years was not addressed. Non-smokers 
have never smoked. At present more than 1800 patients are included in the Early Arthritis 
Clinic, of which approximately 1650 patients have at least one year of follow-up. 440 of 
these patients fulfi lled the diagnosis of RA according to the American College of Rheuma-
tology 1 year after inclusion in the study (376 defi nite RA and 64 probable RA, according 
to the ACR criteria of 1987 and 1958 respectively) and had DNA available for genotyping. 
As it was observed that in the current inception cohort, over 2/3 of probable RA patients 
developed defi nite RA in the next year, these probable RA patients were included in the 
study. A small proportion of the patients involved in the present study (about one third) 
were also included in previous studies examining the association between HLA-DRB1 al-
leles and RA using the Leiden Early Arthritis Clinic (6). Informed patient consent was 
obtained and the study was approved by the local medical ethics committee. A random 
panel of 423 healthy unrelated Dutch individuals served as control.
HLA genotyping
The HLA class II alleles were determined in all RA patients and controls. The HLA-DRB1 
(sub)typing was performed by polymerase chain reaction using specifi c primers and 
hybridisation with sequence-specifi c oligonucleotides. The predisposing shared epitope 
alleles were DRB1 *0101, *0102, *0401, *0404, *0405, *0408, *0410 *1001, and *1402. 
The DERAA encoding alleles were HLA-DRB1*0103, *0402, *1102, *1103, *1301, *1302, 
and *1304. For clarity, this study uses consequently the term DERAA-encoding alleles. 
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However this study does not differentiate between the direct effect of these alleles and 
the effect of other alleles in linkage with the DERAA-encoding HLA-DRB1 alleles; the 
observed effects might therefore also be the result of a haplotype containing the DERAA-
encoding alleles. For the analysis a division in six groups according to the HLA-DRB1 
alleles was made: homozygous for shared epitope (SE/SE, group A), one shared epitope 
allele (SE/x, group B), one shared epitope and one DERAA allele (SE/DERAA, group C), no 
shared epitope or DERAA alleles (x/x, group D), one DERAA allele (x/DERAA, group E) and 
two copies of a DERAA encoding allele (DERAA/DERAA, group F), see Table 1. 
Radiographic progression
Radiographs of hands and feet were made at baseline, at one year and yearly thereafter. 
Radiographs were scored using the modifi ed Sharp-Van der Heijde method (14). The rheu-
matologist that scored the radiographs was blinded to the clinical data and unaware of 
the study question. At inclusion radiographs were scored of 324 patients, 305 patients had 
radiographs at 1 year follow-up, 259 patients at 2 year follow-up, 216 patients at 3 year fol-
low-up and 197 patients at 4 years follow-up. The fact that at the moment of analysis not all 
patients had achieved 4 years follow-up is inherent to the design of an inception cohort.
Extremes of the phenotypes: clinical remission 
Comparing the extreme phenotypes of a disease can elucidate the presence or absence of 
an association between an allele and disease severity (15,16). For this study patients that 
developed clinical remission, the best clinical course possible, were selected. Patients in 
remission had no signs of arthritis in the absence of disease-modifying drugs and were 
therefore discharged from the outpatient clinic. Patients were only discharged after they 
Table 1. HLA-DRB1 genotypes of RA patients and healthy controls






A SE/SE 70 15.9 26 4.9
B SE/x 187 42.5 124 30.5
C SE/DERAA 27 6.1 29 6.9
D x/x 112 25.5 149 35.2
E x/DERAA 36 8.2 87 20.6
F DERAA/DERAA 8 1.8 8 1.9
Group B vs. C: OR 0.6, 95%CI 0.3-1.1, p=0.1.
Group D vs. E+F: OR 0.6, 95%CI 0.4-0.97, p=0.03.
Group A+B vs. D: OR 2.3, 95%CI 1.6-3.2, p<0.001.
Patients and controls were categorized according to the HLA-DRB1 genotype.
SE alleles are DRB1 *0101, *0102, *0401, *0404, *0405, *0408, *1001, *1402.
DERAA alleles are DRB1*0103, *0402, *1102, *1103, *1301, *1302, *1304.








had been at least one year in remission without the use of disease-modifying drugs. Eighty 
patients achieved clinical remission; all had fulfi lled the ACR criteria for RA (62 patients 
for defi nite RA and 18 patients for probable RA, according to the ACR criteria of 1987 and 
1958 respectively).
Statistical analysis
To differentiate the protective effects from the effects due to non-predisposition, analysis 
was performed using subgroups of patients with an equal amount of predisposing shared 
epitope alleles. To determine the effect of the DERAA-encoding alleles in the presence of 
one shared epitope allele the subgroups SE/DERAA and SE/x were compared (group B vs. 
C, see table 1); to assess the effect of the DERAA-encoding alleles in the absence of shared 
epitope alleles the subgroups X/DERAA and DERAA/DERAA were compared with x/x 
(group E+F vs. D, see table 1). An alternative method to identify the causative HLA-factor 
truly responsible for the association is described by Svejgaard and Ryder (17). This method 
uses a two-by-four table that is subsequently analysed using various two-by-two tables 
involving stratifi cation of each of the two factors against each other. The association of 
DERAA with RA susceptibility was analysed and presented according to both methods. 
For the analysis of the severity data, subgroups with an equal amount of predisposing 
shared epitope alleles were compared. Odds ratio’s (OR) with 95% confi dence intervals 
(95% CI) were calculated using the method of Woolf Haldane; p values were calculated 
using the chi square test. Differences in means between groups were analysed with the 
Mann Whitney test or t-test when appropriate. In all tests, p values less than 0.05 were 
considered signifi cant. 
RESULTS
Susceptibility
To study the effect of the presence of DERAA on the susceptibility to RA, patients and 
controls were divided in 6 groups according to their HLA-DRB1 status (Table 1). In total 
71 RA patients (16%) and 124 controls (29%) carried DERAA encoding HLA-DRB1 alleles. 
(OR 0.5, 95%CI 0.3-0.7, p<0.0001) First, the effect of DERAA in the absence of shared 
epitope allele was assessed by comparing group D with E+F. DERAA positive persons had 
a signifi cantly lower risk to develop RA (OR 0.6, 95%CI 0.4-0.97, p=0.03). Comparing 
group B with group C revealed that in the presence of one shared epitope allele the DE-
RAA-encoding alleles reduce the risk to develop RA, although the observed effect was not 
statistically signifi cant (OR 0.6, 95%CI 0.3-1.1, p=0.1).
Additionally the same data were analysed according to the Svejgaard approach (see 
Table 2). The presence of DERAA conferred a signifi cant lower risk to develop RA both 
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in shared epitope negative and shared epitope positive patients (OR 0.6, 95%CI 0.4-0.97, 
p=0.03 and OR 0.5, 95%CI 0.3-0.99, p=0.03 respectively). 
As anti-CCP antibodies are highly associated with RA, we wished to analyse whether the 
presence of DERAA was correlated with the anti-CCP status of patients. Therefore the 
effect of DERAA on the risk to develop RA was assessed in anti-CCP positive and anti-CCP 
negative RA patients separately. The presence of DERAA conferred a lower risk to develop 
both anti-CCP positive RA (OR 0.3, 95%CI 0.1-0.4) and anti-CCP negative RA (OR 0.7, 
95%CI 0.5-1.0). 
The effect on disease susceptibility of shared epitope alleles in the absence of DERAA was 
assessed by comparing group A+B versus D (Table 1) and similarly according the Svejgaard 
approach (Table 2). Shared epitope positive persons had an odds of 2.3 to develop RA 
compared to shared epitope negative patients (95%CI 1.6-3.2, p< 0.001).
As the HLA-DRB1 alleles are in linkage disequilibrium with certain HLA-DQ alleles (DQ3 
and DQ5, see ref 22), the above-described analysis was also performed using HLA-DRB1-
DQ genotypes. Similar results on predisposition to RA were found using HLA-DRB1-DQ 
genotypes instead of using HLA-DRB1 alleles solely (Table 3).
Table 2. HLA-DRB1 genotypes of RA patients and healthy controls, analysed according to the 
approach of Svejgaard and Ryder (17)








+ + 27 29
+ – 257 150
– + 44 95
– – 112 149
Comparison Entries of 2x 2 table
a b c d
SE + vs. – 284 156 179 244 OR 2.5 95%CI 1.9-3.3, 
p<0.0001
DERAA + vs. – 71 369 124 299 OR 0.5 95%CI 0.3-0.7 
p<0.0001
SE in DERAA + 27 44 29 95 OR 2.0 95%CI 1.0-4.0, 
p=0.03
SE in DERAA – 257 112 150 149 OR 2.3 95%CI 1.6-3.2, 
p<0.0001
DERAA in SE + 27 257 29 150 OR 0.5 95%CI 0.3-0.99 
p=0.03









All the above-mentioned results did not change when the 64 patients with probable RA 
were excluded and the 376 patients with defi nite RA were analysed (comparison of group 
B with C OR 0.6, 95%CI 0.3-1.1, p=0.06; comparison of group D with E+F OR 0.6, 95%CI 
0.4-1.0, p=0.04; comparison of groups A+B with D OR 2.1, 95%CI 1.1-4.0, p=0.01).
Table 3. HLA-DRB1 and -DQ genotypes of RA patients and healthy controls




































































8 x/x x/x 93 21.4 131 31.0
9 x/x x/DERAA 32 7.3 80 18.9
10 x/x DERAA/
DERAA
8 1.8 8 1.9
Predisposition alleles + (gr1-5) 276 168#
Predisposition alleles – (gr8) 93 131#
Protection alleles – (gr 4b+5a) 171 120*
Protection alleles + (gr 6a+7a) 27 29*
Protection alleles – (gr 8) 93 131°
Protection alleles + (gr9+10) 40 88 °
Patients were categorized according to the presence or absence of DQ3 or DQ5 heterodimers and 
subdivided for DRB1 alleles. SE alleles are DRB1 *0101, *0102, *0401, *0404, *0405, *0408, *1001, 
*1402. DQ3 means DQB1*0301, *0302, *0303, *0304, *0401, or *0402 in combination with DQA1*03. 
DQ5 means DQB1*0501 in combination with DQA1*0101 or *01040. DERAA alleles are DRB1*0103, 
*0402, *1102, *1103, *1301, *1302, *1304. x means all other DQ or DRB1 alleles.
# OR 2.3 95%CI 1.7-3.3, p<0.001.
* OR 0.7, 95%CI 0.4-1.2, p=0.14
° OR 0.6, 95%CI 0.4-1.0, p=0.05
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In conclusion, these data show that carriership of DERAA-encoding HLA-DRB1 alleles 
protects to develop RA in individuals with a shared epitope allele as well as in individuals 
without shared epitope alleles.
Severity
To asses the infl uence of the presence of DERAA encoding HLA-DRB1 alleles on radio-
logical joint destruction, Sharp-van der Heijde scores during 4 years of follow-up were 
compared in subgroups of patients with an equal of amount of shared epitope encoding 
HLA-DRB1 alleles, thereby excluding a possible confounding effect due to a difference in 
predisposing alleles. Although the rate of joint destruction in the whole group of shared 
epitope negative patients was very low, the effect of carrying one or two DERAA alleles in 
the absence of shared epitope alleles was determined by comparing the radiological scores 
of group E+F versus D. The mean (± SEM) Sharp-van der Heijde scores at inclusion and 
1, 3 and 4 years of follow up were respectively 2.9 ± 0.6, 8.1 ± 1.8, 12.4 ± 2.4, and 15.1 ± 
3.6 in the patients not carrying a protection allele (group D) and 5.0 ± 2.2, 7.8 ± 3.4, 8.6 ± 
3.7, and 15.2 ± 7.3 in the patients with one or two protection alleles (group E+F) (p = 0.4, 
0.9, 0.3 and 0.9 respectively). Thus, the presence of DERAA-encoding alleles in patients 
with absence of shared epitope does not result in signifi cantly lower radiological scores. 
As anti-CCP antibodies are associated with more severe disease (18), we assessed the infl u-
ence of DERAA on disease severity in anti-CCP positive and negative patients separately. 
This analysis revealed that in shared epitope negative anti-CCP positive RA patients, the 
presence of DERAA associates with signifi cantly less severe disease at all points in time 
except inclusion (see Figure 1). In shared epitope negative, anti-CCP negative patients the 
rate of joint destruction was too low to observe differences between DERAA positive and 
negative patients.
Figure 1. Sharp-van der Heijde scores (mean and SEM) at inclusion and 4 years follow-
up of shared epitope negative anti-CCP positive RA patients in the presence and 








Because patients not carrying shared epitope alleles have a less destructive disease com-
pared to shared epitope positive patients (comparison of groups D versus A+B, Figure 2), 
we subsequently assessed the effect of DERAA on disease severity in shared epitope posi-
tive patients, as in this group of patients with more severe disease the window to read out 
an eventual protective effect is larger. Moreover, by analysing the subgroups of patients 
with an equal amount of shared epitope alleles a possible confounding effect due to dif-
ferences in predisposing alleles was excluded. Comparing the Sharp-van der Heijde scores 
of group B with group C (see Table 1 for the division in groups) showed signifi cant lower 
Sharp-van der Heijde scores at all time points during 4 years follow-up in the DERAA posi-
tive group (Figure 3, p<0.001 at inclusion, 1 and 2 years follow-up, p<0.01 at 3 years and 
p<0.05 at 4 years follow-up). Thus, DERAA-encoding alleles protect against severe disease 
in the presence of one shared epitope allele. 
Considering the association between anti-CCP antibodies and RA severity (18), we 
wished to assess whether the observed protective infl uence of DERAA is dependent on the 
presence or absence of anti-CCP antibodies. Therefore, the effect of DERAA in the pres-
ence of one shared epitope allele was analysed in anti-CCP positive and negative patients 
separately. The protective effect of DERAA remained in both anti-CCP positive and nega-
tive RA patients (Figure 4). Not only anti-CCP antibodies are known to associate with RA 
severity, also the environmental factor smoking is reported to correlate with more severe 
disease (19). To further confi rm the protective effects of the DERAA-encoding alleles we 
analysed the effects of DERAA in patients that were prone to more severe disease due 
to smoking. Therefore, the effect of DERAA in the presence of one shared epitope allele 
was assessed for smokers and non-smokers separately. Non-smoking patients that were 
DERAA-positive showed a trend for lower radiological scores (p=0.06 and 0.07 at 1 and 4 
Figure 2. Sharp- van der Heijde scores 
(mean and SEM) at inclusion and 4 years 
follow-up of RA patients with or without 
shared epitope alleles in the absence of 
DERAA –encoding alleles. * P<0.05.
Figure 3. Sharp- van der Heijde scores 
(mean and SEM) at inclusion and 4 
years follow-up of RA patients with and 
without DERAA-encoding HLA-DRB1 
alleles in the presence of one shared 
epitope allele. * P<0.05.
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year follow-up respectively). In smokers the presence of DERAA correlated with signifi cant 
lower Sharp-Van der Heijde scores at all time points except inclusion (p<0.05, Figure 5). As 
smoking might correlate with anti-CCP antibodies (non published data S. Linn -Rasker) 
a Mantel-Haenszel analysis revealed that a trend to a protective effect of DERAA in both 
anti-CCP positive and negative smoking RA patients was present (data not shown). 
In conclusion, 1) DERAA-encoding HLA-DRB1 alleles are associated with less severe 
joint destruction in patients that also carry a HLA-DRB1 encoding shared epitope allele, 
2) this protective effect remains after correction for anti-CCP antibodies and 3) DERAA-
encoding alleles also exhibit a protective effect in severe disease that is associated with 
smoking.
Extremes of the phenotypes: clinical remission
To assess a possible association between HLA and clinical remission, we identifi ed 80 pa-
tients that obtained clinical remission without the use of disease modifying drugs. Clini-
cal remission was achieved after a mean follow-up of 3.9 years (SD 2.5 years). The patients 
in the remission group were in 62% of cases female, had a mean age of 57.7 ± 15.4 years 
(mean ± SD) and were in 12% anti-CCP antibody positive. The 360 patients that did have 
persistent RA were in 66% of cases female, had a mean age of 55.4 ± 16.4 years and were 
in 57% anti-CCP antibody positive. There was no different distribution of DERAA-en-
coding HLA-DRB1 alleles in patients that obtained remission compared to patients with 
persistent RA. Overall, 18% of patients that obtained remission carried DERAA alleles, 
versus 16% of the RA patients with persistent disease. Likewise, when the distribution of 
DERAA in the presence or absence of shared epitope alleles was evaluated, no differences 
were found in the remission or persistent RA group. In addition, the distribution of shared 
epitope encoding HLA-DRB1 alleles in the absence of DERAA alleles was studied in the 
Figure 4. Sharp-van der Heijde scores 
(mean and SEM) at inclusion and 4 
years follow-up of RA patients with and 
without DERAA-encoding alleles in the 
presence of one shared epitope encoding 
allele, for anti-CCP positive and anti-CCP 
negative patients separately.
Figure 5. Sharp-van der Heijde scores 
(mean and SEM) at inclusion and 4 years 
follow-up of shared epitope positive 
smoking RA patients in the presence or 









remission and persistent RA group. Fifty-fi ve percent of patients that achieved clinical 
remission carried shared epitope alleles, compared to 73% of the patients with persistent 
RA. This indicates that shared epitope alleles occurred signifi cantly less frequent in the 
patients that achieved clinical remission (OR 0.5, 95%CI 0.3-0.8, p=0.003). In conclusion, 
RA patients that achieve clinical remission have signifi cantly less frequent shared epitope 
alleles but do not carry more DERAA-encoding HLA-DRB1 alleles.
DISCUSSION
This study investigates the associations between HLA Class II alleles and RA and describes 
the protective effects of DERAA-encoding HLA-DRB1 alleles on RA severity and susceptibil-
ity. The question whether the effect of DERAA is truly protective or only the result of the 
absence of predisposing shared epitope-encoding HLA-DRB1 alleles has been surrounded 
with some controversy. In the current study the comparison of subgroups allowed to 
differentiate the effects of protection and non-predisposition. This study shows that the 
DERAA-encoding HLA-DRB1 alleles independently reduce the risk to develop RA. 
More importantly however, our study shows in a large prospective cohort that DERAA 
encoding alleles are associated with less severe radiological destruction in patients that 
were predisposed to severe RA by the presence of shared-epitope alleles at all time point 
during 4 years of follow-up. The protective effect of DERAA remained after stratifi cation 
for anti-CCP antibodies. Stratifi cation for smoking, another risk factor for severe disease, 
showed that DERAA particularly protects in patients that are also predisposed to more se-
vere disease by smoking. All together, these data indicate that the protective infl uence of 
DERAA can be detected in patients that are prone to severe disease, by either the presence 
of shared epitope alleles, anti-CCP antibodies or smoking. In patients with a low rate of 
joint destruction such as shared epitope negative and anti-CCP negative RA patients, the 
current data set is not suffi ciently powered to answer the question whether a protective 
effect of DERAA is present in these patients. Intriguingly, the differences in Sharp-van der 
Heijde scores between DERAA-positive and negative patients (in presence of a shared epi-
tope allele) are as large as the differences in Sharp-van der Heijde scores between shared 
epitope positive and negative patients (see Figure 2 and 3). Thus, the protective effect of 
DERAA-encoding alleles on radiological joint destruction seems to be of a similar magni-
tude as the predisposing effect of shared epitope alleles. 
The chance to achieve clinical remission is lower for patients carrying a predisposition 
allele, but is not higher in patients carrying protection alleles. Although we cannot 
explain these observations at this moment, these fi ndings suggest that the disease-pro-
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moting mechanisms that are associated with shared epitope alleles are distinct from the 
mechanisms involved in tempering disease-progression. In this respect, it is tempting to 
speculate that the protective pathways associated with the expression of DERAA-encod-
ing HLA-alleles are able to dampen the effector pathways underlying bone and cartilage 
breakdown, but that they do not affect the principal pathway that drives chronicity.
Although the number of patients with 4 years follow-up in the current study is higher 
compared to previous studies on the protective effect of DERAA on RA severity, the pres-
ent study lacked suffi cient power to address the question of a dose effect of DERAA. This 
is due to the fi nding that homozygosity for DERAA in RA-patients is rare (2% of the RA 
patients in this cohort). Of these 8 patients, 5 patients had at the moment of analysis a 
follow-up of 2 years and only 2 had a follow-up of 4 years. Remarkably, the total Sharp-
van der Heijde score of these patients was 1.0 ± 1.0 at inclusion, 1.6 ± 1.0 and 0 ± 0 at 
2 and 4 years follow-up (mean ± SEM), indicating that RA patients with two copies of 
DERAA seems to have a non-destructive disease course. As the radiological scores of the 
patients that are homozygous for DERAA are lower than the patients heterozygous for 
DERAA, a gene-dose effect is possible. However, the number of homozygous patients is 
too low for defi nite conclusions.
Although so far not much data are available on the association between protective HLA 
Class II alleles and RA severity, well-designed studies are available on the association be-
tween protective HLA alleles and disease susceptibility (8,20,21). However, the defi nition 
of protective alleles differs in these studies. De Vries et al. considered alleles with amino 
acid D at position 70 as protecting. In this way more alleles than those encoding for 
D70ERAA were classifi ed as protective (e.g HLA-DRB1 *07, *1201, *1501) (20). Reviron et al. 
concluded on a different hypothesis (electric charge of the HLA pocket) that alleles with 
a neutral or negative charge in their P4 pocket protect to develop RA. These alleles con-
tain not only the DERAA-encoding HLA-DRB1 alleles but also other HLA- alleles, among 
which HLA-DRB1*08 (21). Our results confi rm and extend these observations by focus-
sing on the DERAA-encoding HLA-alleles and by analysing the effects of these alleles on 
disease severity. The observed effects of the presence of DERAA might be the direct result 
of the DERAA-encoding alleles or might be the result of HLA-haplotypes that contain the 
DERAA-encoding HLA-DRB1 alleles.
The known predisposing effect of the shared epitope alleles on RA susceptibility and se-
verity is confi rmed in this study. Previously, it has been hypothesised by our group that 
predisposition to RA is not only controlled by shared epitope alleles but is also conferred 
by HLA-DQ alleles (22). Support for a role of HLA-DQ came from studies on collagen 








further implied that DERAA is only protective in the presence of certain DQ3 or DQ5 
heterodimers (22). The data of the current study were analysed both using HLA-DRB1 
genotypes and using HLA-DR-DQ genotypes, revealing similar results. The predisposing 
HLA-DQ and -DRB1 alleles are strongly associated in our population; therefore differen-
tiation of the individual effects of HLA-DR and HLA-DQ was not feasible. As the pres-
ent study reveals that DERAA protects against RA not only in patients with predisposing 
HLA-DR alleles or HLA-DR-DQ genotypes but also confers a lower risk to develop RA in 
patients without these predisposing genotypes, the previously published RA-protection 
hypothesis should be amended.
It has been demonstrated that peptides carrying the DERAA motif are naturally processed 
by human APC and it has been suggested that the protective effect of DERAA is mediated 
by a specifi c protective T cell response (24). Although our results clearly show that the 
presence of a predisposing haplotype is not required to observe the protective effect asso-
ciated with DERAA, it is conceivable that the DERAA-sequence itself is presented towards 
T-cells with protective activities. Interestingly alleles carrying the DERAA sequence, par-
ticularly DRB1*13 alleles, not only protect from (severe) RA but have also been associated 
with a milder disease outcome in other diseases, such as a reduced progression to active 
chronic hepatitis C and B (25,26), a lower incidence of cervical carcinoma (27) and a 
reduced rejection of renal transplants (28). These fi ndings are intriguing and point to the 
importance to elucidate the biological pathways underlying these associations, as they 
might unveil new insights on immune regulation in relation to the HLA-system. 
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Objectives. To assess the association between the tumor necrosis factor receptor 2 
(TNFR2) 196 M/R single nucleotide polymorphism and rheumatoid arthritis (RA) severity 
by taking advantage of the extremes of phenotypes that exist in arthritis. 
Methods. Out of the Leiden Early Arthritis Cohort (1700 patients), we selected patients 
that initially had the diagnosis of defi nite or probable RA according to ACR criteria and 
developed complete remission (71 patients) or had the worst progression to destructive 
disease (72 patients). A group of 135 healthy controls was included. In these groups the 
TNFR2 genotype was determined. 
Results. The extremes of phenotypes did not differ signifi cantly in genotype distribu-
tion. No difference in genotype distribution between rheumatoid arthritis patients and 
healthy controls was observed. 
Conclusions. Our study demonstrates that even by comparing the extremes of pheno-
types no association between the TNFR2 genotype and disease severity can be detected in 
Caucasian patients with sporadic RA. 
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INTRODUCTION
Recent reports have suggested an association between the tumor necrosis factor receptor 2 
(TNFR2) 196 M/R single nucleotide polymorphism (SNP) and susceptibility to rheumatoid 
arthritis (RA), restricted to familial RA (1,2). Two recent studies have reported confl icting 
results concerning the involvement of TNFR2 196 M/R SNP as a genetic factor of RA sever-
ity (3,4). Whereas Glossop et al. reports no association with this SNP and radiological and 
functional RA severity (3), Constantin et al. recently found a worse Health Assessment 
Questionnaire score in patients carrying the TNFR2 196R allele (4). However, in both stud-
ies the distribution of severity of RA in the relatively small number of patients is limited. 
An association between TNFR2 196M/R and severity would emerge best comparing pa-
tients with the best and the worst course, e.g. comparing the extreme phenotypes. There-
fore, out of a cohort of 1700 patients we selected RA patients who developed complete 
remission and those patients of this cohort that had the worst progression to destructive 
disease. In these two unique groups of patients the TNFR2 genotype was determined.
PATIENTS AND METHODS
The Leiden Early Arthritis Cohort consists of all patients that were referred to the Depart-
ment of Rheumatology of the Leiden University Medical Center with recent onset arthri-
tis. From 1993 till 2003 over 1700 patients have been included and followed. Follow-up 
included Health Assessment Questionnaire, Disease Activity Score, and radiographs of 
hands and feet at 0, 6 and 12 months and yearly thereafter (5). To detect the patients 
with the best course we selected those patients that at the enter of the cohort had 1) a 
symmetric arthritis of the small joints, 2) morning stiffness of at least one hour and 3) the 
diagnosis of defi nite or probable RA according to ACR criteria who 4) achieved long-term 
and complete remission (no signs of arthritis in the absence of disease modifying drugs) 
and were therefore discharged. Patients were not discharged when less than one year in 
remission without the use of disease modifying drugs. In total 78 patients fulfi lled the cri-
teria; of 71 patients DNA was available for TNFR2 genotyping. To select the patients with 
the most progressive disease, the RA patients with the highest rate of joint destruction 
as measured by the Sharp/van der Heijde method at radiographs of hands and feet after 
one year of follow-up were selected. 79 Patients had a total score > 15; of 72 patients was 
DNA available. All patients included reported to have Caucasian grandparents. A group of 
135 healthy controls was included; all these persons were Caucasian and had no family 
history of RA. Informed patient consent was obtained and the study was approved by the 








Genotyping of TNFR2 196 M/R polymorphism was performed blinded, by PCR-restric-
tion fragment polymorphism (N1a III) as previously described (6). Two samples of 71 and 
72 patients provides a power of 82% to detect differences with 95% confi dence and an 
odds ratio of 3 based on a 196R allele frequency of 22%. The X2-test was used to compare 
the genotype distribution between the two groups of RA patients. All allele and genotype 
frequencies were in Hardy Weinberg equilibrium.
RESULTS
The frequencies of the 196M and 196R alleles among the 143 RA patients were 78% and 
22% respectively. Table 1 depicts patients’ characteristics and the genotype distributions 
of both groups of RA patients and of the healthy controls. In the remission group, 49 
patients (69%) had fulfi lled the ACR-criteria for defi nite RA, and 22 patients (31%) the 
ACR criteria for probable RA. The extremes of phenotypes did not differ signifi cantly 
in genotype distribution, as well as determined in the total group of patients as when 
assessed in the fi rst half of patients and replicated in the second half. In addition, there 
was no signifi cant difference in Health Assessment Questionnaire and Disease Activity 
Score when the 196R and 196M alleles were compared (data not shown). No difference 
in genotype distribution between rheumatoid arthritis patients and healthy controls was 
Table 1. Characteristics of and TNFR2 196 M/R gene polymorphism in rheumatoid arthritis 
patients with complete remission and severe progression.
Complete Remission (No 71) Severe Progression (No 72)
Age (mean SD) 57.6 ± 16.9 55.6 ± 16.8
Male/Female, No (%) 30 (42.3) / 41 (57.7) 25 (34.7) / 47 (65.3)
RF positive, No (%) 7 (9.9) 30 (41.7)
Total Sharp/van der Heijde score at inclusion 3.1 ± 7.2 11.0 ± 15.9
 Total erosion score 0.8 ± 2.7 4.7 ± 9.2
 Total joint space narrowing score 2.3 ± 5.4 6.1 ± 8.2
Total Sharp/van der Heijde score after 1 year 
follow-up
5.3 ± 8.3 36.1 ± 24.5
 Total erosion score 1.9 ± 2.7 21.3 ± 17.0
 Total joint space narrowing score 3.4 ± 6.5 14.7 ± 11.0 
TNFR2 196 M/R genotype
 MM No (%) 43 (60.5) 50 (69.4)
 MR No (%) 23 (32.4) 19 (26.4)
 RR  No (%) 5 (7.0) 3 (4.2)
Shared Epitope positive No, (%) 30 (42) 57 (79)
The TNFR2 196 M/R genotype distributions in the 135 healthy controls was: MM 81 (60.0%), MR 44 
(32.6%), RR 10 (7.4%).
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observed as well (Table 1). Patients in the severe progression group were more frequent 
shared epitope positive than patients in the remission group (odds ratio 5.2, 95% confi -
dence interval 2.3-11.7) (Table 1).
DISCUSSION
In this study no association between the TNFR2 196 M/R gene polymorphism and severity 
in Caucasian patients with sporadic RA was observed. By comparing the genotypes of the 
patients with the worst and the best course out of a cohort of more than 1700 patients an 
association between TNFR2 and severity, if present, very likely would have been detected. 
With the sample sizes used we have a power of 82% to detect differences with an odds 
ratio of 3. In general the numbers used in a power calculation are based on the differ-
ence between a ‘normal’ population of rheumatoid arthritis patient that contains many 
phenotypes and healthy controls that contain some phenocopies. In this circumstance 
a power of 80% to detect differences with an odds ratio of 2 is usually accepted. In the 
present study the power was enhanced by selection of extremes of the phenotypes. This 
method is supposed to enlarge the difference and can make a study more powerful. There-
fore in this study we accept the magnitude of the odds ratio to be at least 3. The odds ratio 
for the association between HLA- Class II alleles and RA severity is about 3 in inception 
cohorts (7). In our design we observed an odds ratio for shared epitope positivity and RA 
severity of 5, indicating the power of the present approach.
The allele and genotype distributions in this Dutch study are similar to those in French 
(2,4), British (3), Italian (8) and Swedish (9) studies, in which allele frequencies of 75-79% 
are reported for the 196M allele and allele frequencies of 20-25% for the 196R allele. 
The fact that in the present study the gene distribution of patients and healthy controls 
were comparable confi rms previous fi ndings of an absent association between TNFR2 and 
susceptibility to sporadic RA (1,2). 
The TNFR2 gene is located on chromosome 1p36 and consists of 10 exons and 9 in-
trons. A SNP at codon 196 in exon 6 (ATG → AGG) results in a nonconservative amino 
acid substitution: methionine (M) → arginine (R). Little is known on the functionality 
of this amino acid substitution. In Japanese patients with systemic lupus erythematosus 
(SLE) it is demonstrated that the 196 TNFR2 SNP has no infl uence on receptor binding 
of TNF-α or on receptor shedding, but that the 196R allele more effectively transduces 
signals for IL-6 production than does 196 M allele (10). However also in these Japanese 
SLE patients the 196R allele was not associated with disease severity (10).
In summary, our study demonstrates that even by comparing the extremes of pheno-
types no association between the TNFR2 genotype and disease severity can be detected in 
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A missense SNP (rs2476601, C1858T) in PTPN22, which encodes a tyrosine phosphatase, 
has been associated with multiple autoimmune diseases including RA (1-3). This SNP 
results in the substitution of a conserved arginine with tryptophan at codon 620 (R620W) 
in the protein’s SH-3-binding domain. The 1858T risk allele, which results in disruption 
of the interaction between PTPN22 and the C-Src kinase, Csk, (3) potentially alters these 
proteins’ function as negative regulators of T-cell activation. In this study, we investgate 
the association of the PTPN22 C1858T SNP with RA, undifferentiated arthritis (UA) and 
both quantitative (rate of joint destruction) and qualitative (autoantibody status and re-
mission or progression) RA characteristics. 
All RA cases (n=416) were participants in the Leiden Early Arthritis Clinic (EAC), a popu-
lation-based inception cohort of recent onset arthritis described by van Aken et al (4), 
and fulfi lled ACR criteria for RA at one year follow-up. EAC participants who could not 
be properly classifi ed at one year (n=265) were categorized as UA cases. All patients and 
unrelated control individuals (described in reference 5) were Dutch whites. Appropriate 
institutional review boards approved the protocol. 
The C1858T SNP and HLA-DRB1 alleles were genotyped as described and genotyping 
accuracy was > 99.8% (1,6). An individual was considered positive for the shared epitope 
(SE) if they carried at least one copy of any of the following HLA-DRB1 alleles: 0101, 0102, 
0401, 0404, 0405, 0408, 1001 or 1402. X-rays of hands and feet were taken at baseline, six 
months, one year and annually thereafter. The χ2 test or Fisher’s exact test, unconditional 
logistic regression and tests for trend were used for statistical analysis. Reported p-values 
are two-tailed; values less than 0.05 were considered signifi cant. 
PTPN22 C1858T genotypes were generated for 416 RA cases, 265 UA cases, and 891 con-
trols, and were in Hardy-Weinberg equilibrium in all groups. The frequency of the PTPN22 
risk allele in our control group was similar to previously reported allele frequencies in US 
white controls (0.091 and 0.087 respectively)(1). We observed a higher frequency of the 
1858T risk allele in RA cases compared to controls (0.119 vs. 0.091; p=0.0257) (Table 1). 
Genotypic analysis showed an increase in risk of RA associated with having one or two 
copies of the 1858T allele (OR=1.37; p=0.0336). In agreement with previous reports (1-
2), TT homozygotes (OR=1.95) appeared to be at greater RA risk than TC heterozygous 
individuals (OR=1.34) when compared to CC homozygotes. 
Next we investigated this SNP in the patients stratifi ed according to autoantibody status 
(Table 1). Compared to the controls, the 1858T allele frequency was elevated in both RF 
positive (p=0.0091) and CCP positive (p=0.0132) RA patients but not in patients negative 
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at increased risk for RF positive (p=0.0173) and anti-CCP positive RA (0.0237). This was 
not the case for autoantibody negative patients suggesting an association between the 
PTPN22 1858T risk allele and autoantibody production in RA. Consistent with previous 
studies (1-2), PTPN22 C1858T genotype frequencies were similar in HLA-DRB1 shared 
epitope (SE)-positive and SE-negative cases (0.125 vs. 0.105; p=0.4022), suggesting that 
the PTPN22 risk allele acts independently of HLA-DRB1 susceptible alleles to infl uence 
RA risk. 
Allele frequencies of C1858T were similar in 45 RA patients who achieved remission (de-
fi ned as absence of arthritis with no use of DMARDs for at least one year) versus 319 
patients with persistent infl ammation (0.10 vs. 0.118, p=0.707)(7). Mean baseline and 
yearly Sharp-Van der Heijde scores of X-rays of hand and feet of RA patients with differ-
ent PTPN22 genotypes (Figure 1) were also similar in 1858T carriers and non-carriers (8). 
These data suggest no association of the PTPN22 risk allele with rate of joint destruction. 
The 1858T allele frequency was also elevated in UA cases compared controls (0.126 vs. 
0.091; p=0.0163) (Table 1). Genotypic analysis indicated that carriers of the 1858T allele 
were at signifi cantly higher risk of UA (OR=1.51). 
These results support the role of the PTPN22 C1858T SNP as a common, HLA-indepen-
dent, genetic risk factor for RA. Moreover, this study also replicated the dosage effect 


























Figure 1. Sharp-van der Heijde scores (mean ± SEM) over time among RA patients, by 
PTPN22 1858T carrier status (CT+TT vs. CC). Radiological data (X-rays of hands and feet) of 
220 CC and 68 CT+TT patients were available at baseline. Respectively, data for 254 and 72 patients 
at year 1, 178 and 56 patients at year 2, 117 and 36 patients at year 3, and 101 and 27 patients at 








association with RF positive RA (1-2) and provide the fi rst evidence that this SNP is also 
associated with anti-CCP positive RA. These fi ndings support the hypothesis that this 
variant may predispose individuals to autoimmunity by facilitating the production of 
certain disease-associated autoantibodies (1-2). Although no association between the 
PTPN22 C1858T SNP and the level of RA joint destruction and remission was observed 
in this study, the sample-size is too small to rule out the possibility of a type II error. Our 
results also indicate that the 1858T allele is a risk factor for UA. In conclusion, our data 
suggest the PTPN22 1858T variant acts as a susceptibility allele for autoantibody positive 
RA but does not appear to infl uence RA severity.
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The receptor for advanced glycation endproducts (RAGE) has been shown to play a role 
in several pathologies including Rheumatoid Arthritis (RA) (1). RAGE binding of ligands 
upregulated in RA synovial tissue, fl uid and serum, can lead to increased cell activation, 
including migration, hyperplasia and increased cytokine production. Several animal stud-
ies have described a possible role for RAGE in the onset and severity of arthritis. In these 
animal studies, blockade of the receptor showed suppression of arthritis, while admin-
istration of RAGE ligands induced arthritis in healthy mice (2,3). In addition, increased 
levels of RAGE ligands have been found in RA patients and correlate with disease severity 
(4-6).
Previous studies indicated that a gain of function mutation of RAGE correlates with 
RA. Linkage of RAGE with the HLA-DRB1-DQ region, a region known to associate with 
RA susceptibility and severity, could account for this correlation. To dissect the possible 
confounding effects of the HLA-DRB1 region for the possible association of RAGE with 
RA, we investigated the correlation of a gain of function mutation in RAGE, to HLA-DRB1 
alleles and RA.
377 consecutive RA patients of the Leiden Early Arthritis Clinic, an inception cohort 
for patients with recent onset arthritis (7) (mean age 48 ± 17 years SD, 55% female) and 
535 non-RA controls of the same cohort (mean age 57 ± 16 SD, 67% female) were in-
cluded in the analysis. All RA patients fulfi lled the 1987 criteria of the American College 
of Rheumatology. The study was approved by the local Ethics Committee and written 
informed consents were obtained from all patients and controls according the declaration 
of Helsinki. HLA genotyping was available for all patients and controls and in addition for 
typing of the RAGE G82S polymorphism a PCR was performed, followed by an overnight 
digestion with Alu I. The 82S polymorphism resulted in the formation of an extra AluI 
restriction site. 
A previous report by Hoffman et al (2) described that the RAGE 82S polymorphism cor-
related with susceptibility for rheumatoid arthritis. However, RAGE is in strong linkage 
disequilibrium with HLA-DR4 (8), particularly HLA-alleles encoding a common ‘shared 
epitope’ within the HLA-DRB1 allele. In the population studied by Hoffman et al, a link-
age was found with DR1*0401 and after correction for this allele, the correlation between 
the RAGE 82S polymorphism and susceptibility for RA was lost. These data were not 
conclusive, since the number of patients and controls positive for the RAGE 82S polymor-
phism were very low (5 out of 95 and 2 out of 134 respectively). Here, we identifi ed 46 out 
of 377 RA patients and 36 out of 535 controls harbouring the RAGE 82S polymorphism. 
We found an association between the RAGE 82S polymorphism and RA without correc-
tion for HLA alleles. However, in patients, RAGE 82S was in linkage (defi ned as P<0.01) 
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with DRB1*0401 (OR 4.43, P<0.00001) and *0901 (OR 5.05, P=0.002). Correction for pres-
ence or absence of these HLA alleles was done by the Svejgaard method (9). When the 
association of RAGE 82S with RA was corrected for the absence or presence of DRB1*0901, 
the association between RAGE and RA remained present. Conversely, after correction 
for the presence/absence of HLA DRB1*0401 the association between RAGE 82S and RA 
was lost (Table 1), indicating that RAGE is not associated with RA independently of HLA 
DRB1*0401 in this cohort. Also in logistic regression analysis with DRB1*0401 and RAGE 
as possible explanatory variables and the presence of RA as dependent variable, only 
DRB1*0401 was independently associated with RA (OR 2.5, P<0.001). 
In conclusion, considering the size of our study, it is unlikely that the RAGE 82S poly-
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Purpose of review. Identifi cation of the genetic variants that mediate risk for suscep-
tibility and severity of Rheumatoid Arthritis (RA) will allow development of new drug 
targets as well as increase the ability to predict disease course. Technical and methodologi-
cal progress has fuelled the progress in this fi eld.
Recent fi ndings. The second risk factor for RA was identifi ed, the PTPN22 polymor-
phism. This genetic variant regulates the threshold of T-cell activation. Intriguingly this 
variant is a risk factor for diabetes as well. Moreover it was shown that multiple genetic 
variants in one pathway (both in a transcription factor, RUNX-1 as in the transcription 
factor binding site of RUNX1 in the SLC22A4 gene) can each confer very small risks but 
by gene-gene interactions can confer a 9-fold risk to RA. Phenotype-genotype interactions 
were described by the enhanced prevalence of an RA-specifi c autoantibody (anti-CCP 
antibodies) in RA patients that harbour the RA-associated HLA class II genes, the shared 
epitope alleles. An environmental risk factor for RA, smoking was demonstrated to confer 
its risk especially in RA patients that have both the shared epitope alleles as the RA-spe-
cifi c anti-CCP antibodies.
Summary. Two new pathways (T-cell Receptor signalling and a haematopoietic-specifi c 
signal transduction pathway) have been discovered that allow future pharmacological 
interventions. The description of the new genetic risk factors and the interaction with en-
vironmental triggers as well as phenotypic features is gradually expanding our prognostic 
abilities to predict disease susceptibility and course.
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INTRODUCTION
The completion of human genome sequencing and the technological revolution in ge-
notyping is driving projects that aim to understand the genetic contribution to virtually 
every common disease by identifying sequence variants associated with these disorders. 
The motivation to study the genetic contribution is two-fold. First, identifi cation of new 
critical pathways in disease pathogenesis leads to the identifi cation of new drug targets 
leading to more optimal treatments. Second, the increased understanding of pathogenesis 
will lead to better and more focussed treatment protocols. The current clinical predic-
tion models have insuffi cient power to provide patients with individualized treatments. 
Given the fact that the effi cacy of treatments is proven at the group level by randomized 
controlled clinical trials, many patients are over- or under treated. It is hoped for that 
prediction of disease outcome by genetic risk factors may lead to more individualized 
treatment protocols.
For rheumatoid arthritis (RA) historically sound epidemiological data (the different preva-
lence of RA in various populations, migration studies, familial clustering and twin stud-
ies) demonstrated the genetic contribution to susceptibility of RA (1). The comparison 
between the concordance rates in monozygotic twins and the prevalence in the respective 
populations revealed that about 50% of the variation in occurrence of disease is caused by 
genetic factors (2). Moreover large initiatives from Japan, Europe, United Kingdom and 
the USA are present in which multicase families are available and genome wide searches 
are being performed. Finally, both the resources (large inception cohorts) and the tools 
(well developed disease activity measurements and outcome measurements) are available 
in the fi eld of arthritis to take maximum advantage of the automated genotyping tech-
nologies which enable the systematic ascertainment of sequence variants, in the form of 
single-nucleotide polymorphisms (SNPs), for the genomes of large numbers of individu-
als. During the last two years this has led to remarkable progress in understanding the 
genetic contribution to RA. This review is divided in four sections
• Progress following linkage data
• Progress from candidate genes from previously identifi ed linkage regions in RA
• Progress from candidate genes
• Progress on phenotypic-genotypic interactions
PROGRESS FOLLOWING LINKAGE DATA
For the pan-European, the Japanese, the North American Rheumatoid Arthritis and the 








spacing ranging from 10 to 12 centimorgans (cM). The French group published last year a 
scan with a mean marker spacing of 3.3 cM, resulting in an average distance between any 
RA susceptibility gene and its nearest marker of 0.8 cM (3). 19 non-HLA regions showed 
suggestive evidence for linkage (P < 0.05). Nine of these overlapped with regions sug-
gested in other published RA genome scans. In order to provide an estimate what the error 
rate of this approach is, an assessment of the signifi cance of the number of regions with 
suggestive evidence for linkage was obtained by using 10,000 computer simulations with 
the null hypothesis of absence of any true RA gene region. The probability of observing 
19 non-HLA peaks by chance was 3.7%, which provided convincing evidence that these 
peaks contained at least 1 true non-HLA RA gene region. Since a mean ± SD of about 11 ± 
4 false-positive peaks were expected, the number of true RA linkage peaks was estimated 
to be 8 ± 4.
The UK group explored the utility of SNPs for linkage analysis. A whole-genome screen 
of 157 families with multiple cases of RA was performed using 11,245 genomewide SNPs 
(4). The SNP analysis detected HLA*DRB1, the major RA susceptibility locus (P = .00004), 
with a linkage interval of 31 cM, compared with a 50-cM linkage interval detected by 
the previously published 10-cM microsatellite scan in the same cohort. Moreover, four 
additional loci were detected at a nominal signifi cance level (P < .05) in the SNP linkage 
analysis. The authors concluded that a dense SNP map was very suitable for performing 
linkage analysis in RA. This approach allowed loci to be defi ned more precisely.
PROGRESS FROM CANDIDATE GENES FROM PREVIOUSLY IDENTIFIED 
LINKAGE REGIONS IN RA
The Japanese consortium (5) set out by densely mapping candidate regions that were 
originally defi ned by whole genome scans. For the previously defi ned 1p36 region, the 
Japanese investigators reasoned that the unique specifi city of anti-CCP antibodies for RA 
might be caused by differential citrinullation caused by mutations in enzymes involved 
in citrinullation. The 1p36 gene region contained all the known genes that encode pep-
tidylarginine deiminases citrullinating (PAD) enzymes, the PAD genes (PAD types 1–4) 
in a region of 0.3 megabase (Mb). A case control study using in 830 RA patients and 736 
healthy Japanese controls identifi ed an association between haplotypes (combinations of 
SNPs on one chromosome that tend to inherit together) of the gene encoding PAD4 with 
increased susceptibility to RA. The difference between two haplotypic variants was four 
SNPs in exons, with three subsequent amino acid substitutions. The RA-susceptible PAD4 
variant was shown to produce a more stable transcript than the non-susceptible variant, 
implying an increased production of PAD4 by the RA-susceptible variant. Circumstantial 
evidence for a role of PAD4 in RA was the detection of PAD4 in synovial tissue. Although 
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this observation may provide insight in the generation of anti-CCP antibodies with the 
(not yet proven suggestion) that enhanced production of citrinullated antigens leads to a 
higher chance of developing anti-CCP antibodies, it is not known whether this is specifi c 
for the Japanese population. Data from both France Caucasians as well as Caucasians from 
the UK showed no association with PAD4 haplotypes and RA (6,7). More specifi c data 
on the PAD4 (8) gene revealed that this gene is extremely variable at least in the white 
Caucasian population. Therefore the jury is still out whether the observed association in 
the Japanese population is specifi c for this population or whether associations exist in 
other populations as well. This last option is important because this may indicate that the 
amount of citrinullated antigens can be a new target for therapy. 
With respect to the progress on the 1p36 region it is not yet known what proportion of 
this linkage peak can be explained by PAD4 gene variants. Another candidate gene in this 
region is the TNF-receptor type II gene that has a polymorphism causing the amino acid 
substitution M to R at position 196. Initially the UK group reported an association but in 
French families this association between different variants of the TNF-RII gene could only 
be replicated in a subset of multicase RA families (9,10). Finally by taking advantage of the 
spectrum of phenotypes in a large inception cohort from The Netherlands, it was found 
that either in RA patient that developed complete remission or in those with the worst 
progression to destructive disease and in healthy controls the genotype distribution was 
equal (11). Thus in conclusion it is most likely that variants in the TNF-RII gene are not 
relevant for susceptibility or severity of RA.
The HLA Class II molecules are the most powerful recognized genetic factors for RA that 
contributes to at least 30% of the total genetic effect. The HLA-DRB1 alleles *0101, *0102, 
*0401, *0404, *0405, *0408, *1001, *1402 share a conserved amino acid sequence (QKRAA, 
QRRAA or RRRAA) at position 70-74 in the third hypervariable region of the DRβ1 chain. 
These residues constitute an α-helical domain forming one side of the antigen presenting 
binding site. The Shared Epitope hypothesis postulates that the shared epitope motif itself 
is directly involved in the pathogenesis of RA by allowing the presentation of an arthrito-
genic peptide. Extensive evidence exists showing associations between the shared epitope 
encoding alleles and susceptibility to RA as well as severity of RA (12-14). Homozygosity 
for the shared epitope is associated with a higher risk to develop RA (15), and with more 
severe radiological destruction (13). Regional differences in HLA prevalence and associa-
tion with RA exist. Associations between HLA-DRB1*0401 and *0404 and RA were fi rst 
described in Western Americans and in the Northern Europe population. HLA-DRB1*1402 
was associated with RA in Native Americans (16) and associations with HLA-DRB1*0101 
and *1001 were reported in Indian and Mediterranean patients (17,18). On the other 
hand no associations were found in Greeks (19). Extra-articular manifestations of RA such 








tients (20). Homozygosity for HLA-DRB1*0401 as well as homozygosity for two different 
shared epitope encoding HLA-DRB1 alleles conferred a higher risk to develop extra-ar-
ticular manifestations than heterozygosity (20). A relationship of vasculitis with 3 geno-
types containing a double dose of the shared epitope, specifi cally HLA-DRB1*0401/*0401, 
*0401/*0404 and *0101/*0401 has been observed as well (21).
Although it is accepted that the shared epitope encoding HLA-DRB1 alleles are associated 
with RA, a more controversial issue is the question whether predisposition to RA is also 
conferred by HLA-DQ alleles. Support for a role for HLA-DQ comes from studies in mice 
(22,23) and humans (24,25). The concerning HLA-DQ alleles are the DQ3 and DQ5 het-
erodimers. As they both are in strong linkage with some shared epitope alleles, the indi-
vidual contribution of the HLA-DQ alleles is diffi cult to discern. Recently the HLA region 
has been fi ne-mapped (4). The highest linkage peak was located exactly at the DRB1 locus, 
however considering the wideness of the linkage peak haplotype associations cannot be 
excluded (4). Therefore, no defi nite evidence is available pinpointing RA susceptibility to 
either HLA-DR or HLA-DQ alleles.
Besides the above-mentioned predisposive effects of HLA-DRB1 alleles, there are also 
reports on protective effects by certain HLA-DRB1 haplotypes. These haplotypes contain, 
instead of the shared epitope, another common anchor-region consisting of the amino 
acids DERAA. The HLA-DRB1 alleles that express the DERAA sequence (DRB1*0103, 
*0402, *1102, *1103, *1301, *1302, *1304) have been shown to protect against RA (24-26). 
However, these studies have been performed with relatively few RA patients carrying the 
DERAA haplotype (24,25). There is also evidence that patients carrying the DERAA se-
quence have less erosive disease (27,28). It is not known whether the effect of the DERAA 
encoding HLA-DRB1 alleles is truly protective or is due to the effect of the concomitant 
absence of shared epitope encoding HLA-DRB1 alleles (non-predisposition). More clarity 
will come from currently performed studies in which a large number of patients with 
early RA have been followed for 4 years. As in this study subgroups of patients with the 
same amount of shared epitope alleles were compared, the effects of DERAA could be dif-
ferentiated from non-predisposition. It was observed that the DERAA haplotype conferred 
a lower risk to develop RA and was associated with a lower rate of joint destruction. 
PROGRESS FROM CANDIDATE GENES FROM PREVIOUSLY IDENTIFIED 
LINKAGE REGIONS IN AUTOIMMUNE DISEASE IN GENERAL
Linkage data to select candidate genes can be alternatively used by searching for genomic 
regions that overlap in the scans reported for several diseases such as arthritis, diabetes, 
asthma, atopic dermatitis, osteoporosis, and infl ammatory bowel disease (29). One of the 
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regions is the 5q31.1–q33.1 region. By very dense SNP mapping using a similar strategy 
as the PAD4 identifi cation in the Japanese population, the Japanese group performed 
linkage disequilibrium (LD) mapping using single nucleotide polymorphisms (SNPs) in a 
case-control approach (30). In 820 RA patients and 620 controls a risk for RA of 1.3 was 
identifi ed for a risk allele in the organic cation transporter gene SLC22A4. The expres-
sion of SLC22A4 is specifi c to haematological and immunological tissues and SLC22A4 
is highly expressed in the infl ammatory joints of mice with collagen-induced arthritis. 
Intriguingly the identifi ed SNP affects the transcriptional effi ciency of SLC22A4 in vitro 
by altering the binding affi nity of a haematopoietic transcription factor, called RUNX1. 
Next SNPs in this transcription factor were analysed as well. An association was observed 
with the minor allele in the RUNX1-gene conferring a small but signifi cant risk (1.3) in 
the comparison between 820 RA patients and 620 controls. Intriguingly, the biological 
data suggest that these two SNPs would have a cumulative effect given that a transcription 
factor with less binding capacity has to bind to a disrupted transcription factor binding 
site, thus resulting in overall loss of function. Indeed in the analysis of the data from 
individuals who were genotyped for both SNPs (719 cases and 441 controls), it was ob-
served that the genotype that was homozygous with respect to the susceptibility alleles 
of both genes showed a high odds ratio of 9 (95% confi dence interval 2–39), whereas the 
genotype that was homozygous with respect to the susceptible allele of SLC22A4 and het-
erozygous with respect to RUNX1 showed a moderately high odds ratio of 2.5 for disease. 
The data have been replicated in two other diseases (psoriasis and SLE) and studies are 
underway in cohorts of RA patients of different ethnic background. This is a nice example 
how gene-gene interactions may explain complex traits while at the same time the crude 
OR of the gene variant for the disease is quite low.
PROGRESS FROM CANDIDATE GENES
The methodology of searching genes can be divided in the unbiased approach of linkage 
analysis and subsequent fi ne mapping. In this method a linkage hot spot is covered with 
a grid of markers in order to search systematically for linkage disequilibrium (LD, the 
non-random association of genes across the genome) and haplotypes. Next the original 
region is narrowed and the disease gene is identifi ed. For multifactorial diseases like RA 
the power to detect a risk gene for a common disease with a relative risk of two by LD 
mapping necessitates data on transmission in 5000 affected and 5000 non-affected. Given 
the fact that these numbers are not available the choice of a candidate gene has subjec-
tive elements because the genes that are intuitively logical will be tested fi rst (see above-
mentioned examples of PAD4 and TNF-RII as candidate genes). A less biased approach 








more recombinations have taken place, leading too much smaller regions in which non-
random association of genes is present. Thus a positive result is less likely to be caused 
by linkage of recombining neighboring genes that explain the observed linkage pattern. 
The obvious curse is that selection of candidate genes is biased by limited knowledge. An 
interesting alternative was explored by Begovich et al. (31) who tested the association of 
SNPs with putative functional consequences in different sets of patients and controls. This 
yielded a large number of putative functional polymorphisms distributed differently in 
patients and controls. In a second set of 463 patients and 926 controls, all from Caucasian 
origin, a risk allele of a haematopoietic-specifi c protein tyrosine phosphatase, PTPN22 was 
identifi ed in 17% of the controls and 28% of the RA patients. The risk allele changed the 
function of the protein that functions as negative regulator of T-cell activation, leading to 
T-cells with a lower threshold for T-cell activation. This mutation is apparently leading to 
autoimmune disease in general since this mutation also conferred risk for diabetes in both 
an American and an Italian population (32). These data are a nice example of the power of 
the technique of whole genome SNP scanning but also emphasize the power of replication 
to diminish the number of false positives (33). Although this approach has considerable 
power to detect risk genes, real-positives may be falsely excluded if risk is only conferred 
in the context of gene-gene interactions such as the RUNX1 pathway genes. 
Progress from other candidate genes that were selected by presumed importance is still 
preliminary. On the telomeric portion of the HLA region is a gene located which is called 
“inhibitor of NF-kappa B-like gene” or I-kappa-BL. In spite of initial reports of a positive 
association of a SNP located at –62, a large Spanish study in two cohorts failed to detect 
any association (34).
Haplotypes as defi ned by microsatellites (the IL10R-CA repeat) of the IL10 gene has been 
previously associated with RA in several ethnic populations with severe RA (35). Using a 
SNP –A2849G that tags this haplotype, Lard et al were not able to fi nd this association in 
incident cases of RA, but observed that this haplotype was associated with higher rates 
of joint destruction in a cohort-followed overtime as well as with higher titers of autoan-
tibodies (36). Recent data indicate the importance of IL10 promoter haplotypes for the 
outcome of transplantation indicating it relevance for immune-mediated diseases (37). 
Moreover it has been demonstrated by a robust assay that haplotypes of the IL10 can be 
transcribed at a different rate implying a biological basis for the observed associations 
(38). However, currently the relation between the different haplotypes and susceptibility 
to RA is still unclear. For the association of IL10 haplotypes gene-gene interactions have 
been suggested by the observation that the association of IL10 genotypes is only present 
in female patients and not in male patients (39). Finally IL10 haplotypes were associated 
with treatment responses to TNF-blocking agents (40).
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For a large number of genes suggested to be relevant in the pathophysiology of RA 
association was observed in only one study without replication such as Beta-adrenergic 
receptor gene SNPs, RANKL, ICAM-1, VEGF, PDCD-1 and IL1-RA gene or data were pub-
lished of lack of association with RA such as CTLA-4, CCR5, Mannose-Binding-Lectin, 
Toll-like receptor 2 or 4 gene variants (41-50).
PROGRESS FROM PHENOTYPIC-GENOTYPIC INTERACTIONS 
Apart from the relevance of gene-gene interactions, progress has been made with respect 
to identifi cation of gene-environment interactions. The risk conferred by the HLA region 
has been put in a different perspective given the signifi cant interaction between smoking 
and presence of the shared epitope (SE) of HLA-DR as risk factors for seropositive RA, 
but not at all for seronegative RA (51). Thus the major genetic risk factor for RA is only 
active in a certain subgroup of RA (RF positive), and the magnitude of this genetic risk 
factor is to a large extent infl uenced by the presence of an environmental risk factor (here 
smoking). 
Another clear genotypic-phenotypic association was reported for the presence of CCP-
antibodies and SE-HLA alleles (52). This has put into functional perspective by the obser-
vation that immunity to citrinullated antigens is infl uenced by the better fi t of antigens 
after citrinullation in the HLA binding groove of the HLA-DR4 allele (one of the shared 
epitope alleles) (53).
CONCLUSION
The fi eld of genetics has shown remarkable progress. For the coming years it is expected 
that the technical breakthroughs with respect to rapid and massive genotyping in large 
cohorts will lead to the further elucidation of the risk genes. It has become clear that repli-
cation of results, preferably in independent cohorts is essential for reliable data. Given the 
extensive collaborations that have been formed, this is not foreseen to be a major prob-
lem. The major challenges will be to identify genetic variants that confer small risks by it 
selves but by affecting a pathway by a number of genetic variants are of great relevance in 
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Chapter 7
Refi ning the complex rheumatoid arthritis 
phenotype based on specifi city of the 


























Objective. The main genetic risk factor for rheumatoid arthritis (RA), the HLA region, has 
been known for 25 years. Previous research has demonstrated, within the RA population, 
an association between HLA-DRB1 alleles carrying the shared epitope (SE) and antibodies 
directed against cyclic citrullinated peptides (anti-CCP antibodies). We undertook this 
study to make the fi rst comparison of SE allele frequencies in the healthy population with 
those in RA patients who do or do not harbor anti-CCP antibodies.
Methods. HLA-DRB1 typing was performed in 408 RA patients from the Leiden Early 
Arthritis Clinic (the Leiden EAC; a Dutch population-based inception cohort in which 
disease course was followed up over time), in 423 healthy Dutch controls, and in 720 
affected members of 341 US multiplex (sibpair) families of Caucasian origin from the 
North American RA Consortium (NARAC) with well-established disease and fulfi lling the 
American College of Rheumatology classifi cation criteria for RA. The presence of anti-CCP 
antibodies was determined by enzyme-linked immunosorbent assay. 
Results. For the Leiden EAC, the odds ratio (OR) describing the association of 2 copies 
of the SE allele with anti-CCP positivity (using no copies of the SE allele in the healthy 
control group as the referent) was 11.8 (P < 0.0001), while the OR for 1 SE allele was 4.4 
(P < 0.0001). No association with the SE was observed in the Dutch anti-CCP-negative RA 
patients. For the NARAC families, linkage and association analysis revealed the SE to be 
associated only with anti-CCP-positive disease and not with anti-CCP-negative disease. 
Stratifi ed analyses indicated that anti-CCP antibodies primarily mediated association of 
the SE with joint damage or disease persistence. 
Conclusion. HLA-DRB1 alleles encoding the SE are specifi c for disease characterized by 
antibodies to citrullinated peptides, indicating that these alleles do not associate with RA 
as such, but rather with a particular phenotype.
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INTRODUCTION 
A defi nition of the rheumatoid arthritis (RA) phenotype has been developed through 
consensus procedures. The current RA classifi cation criteria were developed by expert 
clinicians who examined the features of “classic” RA cases and analyzed their sensitivity 
and specifi city using clinical judgment as the gold standard. As is the case with most 
complex disorders defi ned by consensus criteria, there is large variation in the phenotype. 
Despite the phenotypic heterogeneity encompassed by this disease defi nition, the genetic 
contribution is estimated to be 50-60% (1), with the HLA region having the largest impact 
on genetic risk. In particular, HLA-DRB1 alleles encoding a common amino acid sequence 
(the shared epitope SE) in the third hypervariable region of the DRB1 molecule have been 
identifi ed as risk alleles for RA (2). The functional signifi cance implied by the location of 
this SE sequence along the rim of the peptide-binding groove has stimulated efforts to 
search for the putative RA antigen.
A considerable proportion of RA patients have autoantibody responses, especially rheu-
matoid factor (RF). More recently, another autoantibody response has received much at-
tention. These antibodies are directed against cyclic citrullinated peptides (CCPs) and are 
highly specifi c for RA (3,4). Intriguingly, these antibodies may be detected years before 
disease onset (5,6), are stable over time (7), and are associated with joint destruction, the 
hallmark of RA (8,9).
The immune response to citrullinated antigens may occur in the context of the SE, 
because conversion of arginine to citrulline at the peptide side-chain position interact-
ing with the SE signifi cantly increases peptide-major histocompatibility complex affi nity 
and leads to the activation of CD4-positive T cells in mice transgenic for one of the SE 
alleles (10). Previous research has demonstrated, within the RA population, an associa-
tion between HLA alleles and anti-CCP antibodies, but no comparison has been made 
between the HLA profi le in the healthy population and that in RA patients who do or do 
not produce anti-CCP antibodies (8,9,11). Such a comparison may be important, since 




Four hundred eight Dutch RA patients were participants in the Leiden Early Arthritis 
Clinic (EAC), a population-based inception cohort described previously in detail (12). 
All RA patients fulfi lled the 1987 revised criteria of the American College of Rheumatol-








origin. The study protocol included collection of serologic, radiographic, and clinical data 
upon study entry and yearly thereafter. Informed patient consent was obtained, and the 
local medical ethics committee approved the study. Radiographs of the hands and feet 
were obtained for all EAC patients at baseline and at each subsequent annual visit and 
were scored for damage using the modifi ed Sharp/van der Heijde method (14). Controls 
consisted of a random panel of 423 healthy unrelated Dutch individuals.
Patients with RA who had clinical remission of disease were defi ned as follows: at co-
hort entry they had 1) symmetric arthritis of the small joints, 2) morning stiffness of 
at least 1 hour duration, 3) a diagnosis of defi nite or probable RA according to the ACR 
criteria, and 4) they had achieved long-term and complete remission of disease (no signs 
of arthritis in the absence of disease-modifying drugs). Patients were not included in the 
remission group when their disease had been in remission for <1 year without the use of 
disease-modifying drugs. All other patients were classifi ed as having persistent RA.
The US sample consisted of multiplex (sibpair) families of Caucasian origin from the 
North American RA Consortium (NARAC) with well-established disease and fulfi lling the 
ACR classifi cation criteria, as described previously (15). Radiographs of the hands and feet 
of all affected individuals were obtained at the time of study entry, unless fi lms obtained 
within 2 years prior to entry were available for review. To document the presence of 
erosive disease, all radiographs were read by a single radiologist who was blinded to the 
patients’ clinical and genetic information.
Serology and genotyping
Anti-CCP titers were determined based on a second-generation enzyme-linked immuno-
sorbent assay (ELISA) (either the Immunoscan RA Mark 2 [Euro-Diagnostica, Arnhem, The 
Netherlands], in the case of the Leiden EAC, or an ELISA manufactured by Inova Diagnos-
tics [San Diego, CA], in the case of the NARAC). HLA-DRB1 typing and subtyping were 
performed using polymerase chain reaction-based methods. The following alleles were 
classifi ed as SE positive: DRB1*0101, *0102, *0104, *0401, *0404, *0405, *0408, *0413, 
*0416, *1001, and *1402 (2). Genotyping of NARAC families for 27 microsatellite markers 
on chromosome 6 was performed using markers from the Marshfi eld set8A combo list 
(available online at http://www.marshfi eldclinic.org/research/genetics/sets/combo.html) 
with additional markers in the HLA complex, as described previously (15).
Statistical analysis
Nonparametric linkage analysis was performed using the Multipoint Engine for Rapid 
Likelihood INference (MERLIN) statistical package (16). Analysis of the anti-CCP-positive 
families (575 affected members in 271 families comprising 317 sibpairs) was restricted to 
anti-CCP-positive siblings (i.e., anti-CCP-negative siblings were excluded). Analysis of the 
anti-CCP-negative families (145 affected members in 70 families comprising 75 sibpairs) 
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was restricted to anti-CCP-negative patients and their siblings with negative or low titers 
of anti-CCP antibodies (<49), provided that at least 1 sibling in the family had anti-CCP-
negative disease. Chi-square tests and odds ratios (ORs) were used to assess the statistical 
signifi cance and magnitude of associations for categorical outcomes.
With regard to the issue of multiple testing, statistical signifi cance levels accounted 
for the fact that we examined the following 4 hypotheses in this study: 1) whether the 
SE and anti-CCP antibodies are associated, 2) whether the SE and anti-CCP antibodies 
are associated differently in RA patients and in controls, 3) whether the SE and anti-CCP 
antibodies are associated with remission, and 4) whether the SE and anti-CCP antibodies 
are associated with joint destruction. Although one may argue that these 4 hypotheses are 
probably not completely independent based on previous data, we considered results to be 
statistically signifi cant if the P values were less than or equal to 0.01.
RESULTS
As shown in Table 1, the presence of the SE allele was strongly associated with anti-CCP 
positivity. There was also evidence of a dose effect, with increasing copies of the SE allele 
being associated with increasing risk for RA. For the Leiden EAC, the OR describing the 
association of 2 copies of the SE allele with anti-CCP positivity (using no copies of the SE 
allele in the healthy control group as the referent) was 11.8 (P < 0.0001), while the OR for 
1 SE allele was 4.4 (P < 0.0001). When no copies of the SE allele in the EAC was used as 
the referent, the OR describing the association of 2 copies of the SE allele with anti-CCP 
positivity was 8.6 (P < 0.0001), while the OR for 1 SE allele was 3.4 (P < 0.0001). Interest-
ingly, however, no association with the SE was observed in the Dutch anti-CCP-negative 
RA patients (for 2 copies of the SE allele versus healthy Dutch controls, OR 1.4, P = 0.3; for 
1 copy of the SE allele versus healthy Dutch controls, OR 1.3, P = 0.2), indicating that the 
SE does not associate with RA as such, but rather with a defi ned anti-CCP phenotype. 
Table 1. Distribution of SE and anti-CCP positivity*
Dutch EAC RA patients
Anti-CCP positive (n=195) Anti-CCP negative (n=213)
SE Dutch controls 
(n=423), no (%)
No (%) OR (95% CI) No (%) OR (95% CI)
+/+ 26 (6) 49 (25) 11.79 (6.58-21.13) 16 (8) 1.38 (0.71-2.67)
+/– 153 (36) 107 (55) 4.37 (2.88-6.65) 88 (41) 1.29 (0.91-1.82)
–/– 244 (58) 39 (20) 1.0 109 (51) 1.0
* The following alleles were classifi ed as shared epitope (SE) positive: DRB1*0101, *0102, *0104, 
*0401, *0404, *0405, *0408, *0413, *0416, *1001, and *1402 (4). EAC = Early Arthritis Clinic; RA = 









Other autoantibodies such as IgM RF have been reported to be associated with the SE 
as well. However, a comparison of the distribution of copies of the SE allele among RA 
patients who were RF negative and anti-CCP positive (10 SE+/+ patients, 21 SE+/- patients, 
4 SE-/- patients) with the distribution among those who were RF positive and anti-CCP 
negative (4 SE+/+ patients, 11 SE+/- patients, 22 SE-/- patients) yielded a strikingly signifi -
cant difference (P < 0.0001). Thus, the SE appears to be associated primarily with anti-CCP 
autoantibodies, but not with RF autoantibodies.
Analysis of NARAC families revealed a strong association between the SE and anti-CCP 
positivity. Specifi cally, the OR describing the association of 2 copies of the SE allele with 
anti-CCP positivity was 7.7 (P < 0.0001), and the OR for 1 SE allele was 3.5 (P < 0.0001), 
both relative to NARAC patients with no copies of the SE allele.
Results of nonparametric linkage analysis in NARAC families highlighted the strong 
relationship between the HLA region and anti-CCP positivity. Figure 1 shows the linkage 
analysis for 27 microsatellite markers on chromosome 6 among 720 affected members 
of 341 families. Among the 271 anti-CCP-positive families, the maximum logarithm of 
odds (LOD) score in the region was 10.63, in contrast to the maximum LOD score of 
1.12 among the 70 anti-CCP-negative families. Anti-CCP-negative families were defi ned 
by anti-CCP-negative patients and their siblings with negative or low titers of anti-CCP 
antibodies (<49), provided that at least 1 sibling in the family had anti-CCP-negative dis-
ease. Therefore, sensitivity analyses employing stricter defi nitions of anti-CCP-negative 
families (e.g., all affected individuals within a family must be anti-CCP negative) were 
performed, and these revealed a similar pattern (data not shown). The level of 49 was 
chosen due to the fact that titers in the range of 25-49 are considered intermediate based 
on analyses of sensitivity versus specifi city (3,17). 
Figure 1. Results of nonparametric linkage analysis of chromosome 6 in anti-CCP-
positive and anti-CCP-negative Caucasian multiplex families with well-established 
rheumatoid arthritis. The 2 curves correspond to anti-CCP-positive families (575 affected 
members of 271 families) and anti-CCP-negative families (145 affected members of 70 families). 
LOD = logarithm of odds.
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The prospective design of the EAC cohort allowed us to examine the relative contribu-
tions of anti-CCP status and the SE to the rate of joint destruction (Figure 2). Large differ-
ences were observed between anti-CCP-positive and anti-CCP-negative patients. No ap-
parent association was observed between SE positivity and progression of joint damage in 
anti-CCP-negative patients. In contrast, radiographic severity scores were higher among 
anti-CCP-positive patients who were SE positive than among those who were SE negative. 
Similar results were observed for the second hallmark of RA, chronic infl ammation. The 
presence of anti-CCP antibodies yielded an OR of 9.5 (P < 0.0001) for persistent disease 
compared with RA patients who had clinical remission of their disease. In stratifi ed analy-
ses of the NARAC population, the number of copies of the SE allele was associated with 
the presence of erosive disease among patients with anti-CCP-positive disease (P < 0.02), 
but not among those with anti-CCP-negative disease. 
DISCUSSION
Defi ning the phenotype for multifactorial diseases often occurs through consensus pro-
cedures. The current RA classifi cation criteria were developed by expert clinicians who 
examined the features of “classic” RA cases and analyzed their sensitivity and specifi city 
using clinical judgment as the gold standard. It is anticipated that phenotype defi nitions 
Figure 2. Progression of joint damage (in Sharp/van der Heijde units) according to 
the presence of the SE and anti-CCP antibodies. 74 patients were anti-CCP positive and SE 
positive, 18 were anti-CCP positive and SE negative, 30 were anti-CCP negative and SE positive, and 
34 were anti-CCP negative and SE negative. Radiographs of the hands and feet were obtained at 
baseline and at each subsequent annual visit and were scored for damage using the modifi ed Sharp/








based on specifi c biologic characteristics such as anti-CCP antibody production will fa-
cilitate the search for genetic risk factors, leading to greater understanding of underlying 
disease mechanisms.
It has been previously reported that the SE correlates strongly with another autoantibody, 
RF (18). Given the fact that RF is less specifi c for RA than anti-CCP, it is not surprising that 
the SE was more strongly associated with anti-CCP than with RF. Indeed, comparison of 
the distribution of copies of the SE allele among RF-negative, anti-CCP-positive patients 
with the distribution of copies of the SE allele among RF-positive, anti-CCP-negative pa-
tients revealed a much stronger association of the SE with anti-CCP antibodies. Although 
anti-CCP autoantibody titers were not available for the healthy controls in the current 
study, many previous studies have documented the absence of anti-CCP antibody produc-
tion among healthy individuals (3-8,9). Further, previous research indicates that a double 
dose of the SE allele is relatively rare among controls. Finally, even among RA patients 
with a double dose of the SE allele, approximately one-third was anti-CCP negative. Thus, 
it is highly unlikely that anti-CCP antibodies are present in healthy controls.
Another intriguing observation is that the proportion of anti-CCP-positive RA patients 
is clearly less in inception cohorts with incident cases of arthritis than in groups of RA 
patients who have been selected for chronic, well-established disease (2,5,8), as was true 
for NARAC patients. Our analysis demonstrated differences in disease course for anti-
CCP-positive disease compared with anti-CCP-negative disease. The strong tendency to 
achieve longstanding remission in anti-CCP-negative disease is compatible with the fact 
that cohorts of patients with longstanding disease are selected for anti-CCP positivity. 
The phenotypic data on joint destruction are compatible with the hypothesis that the 
presence of the SE is not only a risk factor for anti-CCP-positive disease but is also associ-
ated with more destructive disease. Although the current study had insuffi cient statistical 
power to examine associations of the SE with the rate of joint destruction among sub-
groups defi ned according to anti-CCP antibody production, this was due in part to the 
low rate of joint destruction in anti-CCP-negative patients. Thus, additional studies will 
be required to more defi nitively address this question.
Prior to this study, we defi ned 4 hypotheses to be tested and conservatively considered 
them as independent tests, and we therefore used a threshold for statistical signifi cance of 
P ≤ 0.01. Although one may argue that this threshold is too conservative, this decision did 
not alter the main fi ndings in this study, since most of the results were associated with P
values that were either much smaller than 0.01 or much larger than 0.05.
A strength of the current study was the demonstration of an association between the 
SE and anti-CCP-positive RA in 2 independent cohorts and using 2 analytic methods, 
association and linkage. Moreover, a recent study of juvenile RA demonstrated that anti-
CCP-positive patients were 5 times more likely to be DR4 positive compared with anti-
CCP-negative patients. Intriguingly, a strong association was observed between HLA-DR4 
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and the presence of anti-CCP antibodies in healthy children as well (4 of 688 children 
tested positive for anti-CCP antibodies, and all 4 children carried the DR4 allele) (19). 
Unfortunately, HLA typing in that study did not allow for determination of SE status, but 
those data also support the theory that a better fi t in the SE of citrullinated antigens can 
give rise to the anti-CCP antibody response.
In summary, we propose that refi nement of the RA phenotype (as defi ned by the ACR 
criteria) to “disease characterized by the presence of antibodies to citrullinated peptides” 
will facilitate the search for the mechanisms underlying the pathophysiology of the dis-
ease. Indeed, despite the fact that the most prominent genetic risk factor for RA has been 
known for 25 years, our current data illustrate that the SE is not associated with disease 
in a substantial proportion of RA patients, but rather that it is associated with disease in 
RA patients who have anti-CCP antibodies. Thus, our data suggest the presence of distinct 
pathways underlying disease induction/progression in anti-CCP-positive and anti-CCP-
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Objectives. Recent data have shown that the most prominent and longest known ge-
netic risk factors for rheumatoid arthritis (RA), HLA-DRB1 shared epitope alleles, are only 
associated with RA that is characterized by the presence of antibodies against cyclic citrul-
linated peptide (anti-CCP antibodies) and not with anti-CCP-negative RA. We undertook 
this study to investigate whether anti-CCP-negative RA is associated with other HLA-
DRB1 alleles. 
Methods. HLA typing was performed for 377 patients from the Leiden Early Arthritis 
Clinic who were diagnosed as having RA within the fi rst year of followup (206 anti-CCP-
positive patients and 171 anti-CCP-negative patients), 235 patients who, after 1 year, had 
undifferentiated arthritis (UA) (28 anti-CCP-positive patients and 207 anti-CCP-negative 
patients), and 423 healthy control subjects. Odds ratios (ORs) with 95% confi dence in-
tervals (95% CIs) for HLA-DRB1 allele frequencies were determined for all patient groups 
compared with the healthy control group. 
Results. HLA-DR3 was more frequently present in the anti-CCP-negative RA group than 
in the control group (OR 1.84, 95% CI 1.26-2.67). This was not the case for anti-CCP-
positive RA (OR 0.92, 95% CI 0.60-1.40). HLA-DR3 was also more frequently present in 
anti-CCP-negative UA patients (OR 1.59, 95% CI 1.10-2.28), but not in anti-CCP-positive 
UA patients (OR 0.68, 95% CI 0.17-1.92). 
Conclusions. HLA-DR3 is associated with anti-CCP-negative arthritis and not with anti-
CCP-positive arthritis. These data show that distinct genetic risk factors are associated 
with the presence of anti-CCP antibodies in RA and indicate that different pathogenetic 
mechanisms underlie anti-CCP-positive and anti-CCP-negative RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease with a complex genetic 
background. As in other autoimmune diseases, an association between RA and the HLA 
complex has long been observed in many different populations and is thought to account 
for approximately one-third of the genetic component of RA susceptibility (1). There is 
extensive evidence for the association between certain frequently occurring HLA-DRB1 
alleles, the so-called “shared epitope” (SE)-encoding alleles (DRB1*0101, *0102, *0104, 
*0401, *0404, *0405, *0408, *0413, *0416, and *1001), and susceptibility to RA (2). These 
SE alleles encode for a common amino acid sequence in the third hypervariable region of 
the DRB1 molecule (QKRAA, QRRAA, or RRRAA).
In recent years, many studies on antibodies against cyclic citrullinated peptide (CCP) 
showed that these antibodies are highly specifi c and predictive for RA (3), that they can 
be detected years before onset (4), and that they are associated with joint destruction 
(5). Furthermore, the presence or absence of these antibodies seems to be a stable trait 
(6). Anti-CCP antibodies are detected in SE-positive as well as in SE-negative RA patients. 
Carriership of SE alleles in RA is associated with the presence of anti-CCP antibodies (7). 
Interestingly, when we recently compared anti-CCP-positive and anti-CCP-negative RA 
patients with healthy controls, we found that HLA-DRB1 alleles encoding the SE were 
only associated with RA in the presence of anti-CCP antibodies and were not associated 
with anti-CCP-negative RA (8). These data indicate that the SE-encoding alleles are not 
associated with RA as such, but rather with anti-CCP-positive RA. These observations 
indicate that distinct phenotypic manifestations of the disease are associated with distinct 
genetic risk factors. They also raise the question of whether anti-CCP-negative RA is as-
sociated with HLA-DRB1 alleles other than SE-encoding alleles. We therefore investigated 
the possible associations of particular HLA-DRB1 alleles with anti-CCP-positive RA and 
anti-CCP-negative RA. To verify the results and to study whether the results were specifi c 




In 1993 an Early Arthritis Clinic (EAC) was started at the Department of Rheumatology of 
the Leiden University Medical Center, as described previously (9). The population studied 
here consisted of 377 patients who, within the fi rst year of follow-up, fulfi lled the Ameri-
can College of Rheumatology (ACR; formerly, the American Rheumatism Association) 








not be properly classifi ed according to one of the ACR criteria sets and were therefore cat-
egorized as having UA. For every patient within the cohort, routine diagnostic laboratory 
screening was performed, including measurements of IgM-rheumatoid factor (IgM-RF). 
Informed patient consent was obtained, and the study was approved by the local medical 
ethics committee. Four hundred twenty-three healthy Dutch individuals served as con-
trols. The control subjects were normal healthy donors of both sexes who were randomly 
selected and were ages 55 years and younger.
HLA genotyping
HLA class II alleles were determined in all patients and controls. The HLA-DRB1 (sub)typing 
was performed by polymerase chain reaction using specifi c primers and hybridization 
with sequence-specifi c oligonucleotides.
Anti-CCP autoantibodies
Serum antibodies directed against CCP were assessed with a commercial enzyme-linked 
immunosorbent assay (Immunoscan RA, Mark 2; Euro-Diagnostica, Arnhem, The Neth-
erlands). Anti-CCP antibodies were measured in serum collected within 4 months after 
the fi rst visit (94%) or, when serum was not available within this time period, in the fi rst 
stored serum sample available thereafter.
Statistical analysis
Odds ratios (ORs) were calculated using the Epi Info Statcalc computer program (Centers 
for Disease Control and Prevention, Atlanta, GA) to compare HLA-DR allele frequencies 
between the patient groups and the control population. ORs were reported with 95% 
confi dence intervals (95% CIs), which excluded the value of 1 in case of statistical signifi -
cance. Exact confi dence limits were used as described by Mehta et al (11). For HLA-DR3, 
both allele frequencies and genotype frequencies were compared between the patient 
groups and the control population using the same methods described above.
RESULTS
To fi nd possible associations of HLA-DRB1 alleles with anti-CCP-positive or anti-CCP-
negative RA, we analyzed HLA-DRB1 allele frequencies and the presence of anti-CCP 
antibodies in 377 RA patients of the Leiden EAC. Two hundred six of the RA patients 
had anti-CCP antibodies and 171 were anti-CCP negative. Other patient characteristics 
are presented in Table 1. After we determined HLA-DRB1 allele frequencies, we calculated 
ORs and 95% CIs for both patient groups compared with a control group of 423 healthy 
individuals (see Table 4). 
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As described previously, the SE alleles DRB1*0401, *0404, *0405, and *0408 were associ-
ated with predisposition for anti-CCP-positive RA, as were DR9 and DR10. Interestingly, 
HLA-DR3 was associated only with predisposition for anti-CCP-negative RA (OR 1.84, 
95% CI 1.26-2.67) (Table 2). This association was not found for anti-CCP-positive RA, in-
dicating that HLA-DR3 is only associated with RA in the absence of anti-CCP antibodies. 
To confi rm these fi ndings in another group of patients and to address the question of 
whether the association is only found in anti-CCP-negative RA or whether it is also pres-
ent in another form of arthritis, we also analyzed the association of HLA-DR3 with UA. 
In a group of 235 patients who, 1 year after their fi rst visit, were categorized as having 
Table 1. Baseline characteristics of the 377 rheumatoid arthritis (RA) patients and 235 
undifferentiated arthritis (UA) patients within the study.
RA UA
Age, mean (range) years 57 (14-92) 48 (16-88)
Female, % 66 58
IgM rheumatoid factor positive, % 55 14
Anti-CCP* antibody positive, % 55 12
Presence of erosions on radiographs of hands and feet**, % 35 18
Duration of symptoms, median (range) weeks 19 (0.6–104) 23 (0.14-104)
* CCP = cyclic citrullinated peptide
** radiological data were available for 58% of the 377 RA patients and for 51% of the 235 UA 
patients
Table 2. Association of HLA-DR3 alleles with anti-CCP positive or negative rheumatoid arthritis 








































































































RA= rheumatoid arthritis; UA= undifferentiated arthritis; Co=controls; CCP= cyclic citrullinated 
peptide; OR= odds ratio; 95% CI= 95% confi dence interval.
ORs were calculated comparing double-dose DR3 carriers (DR3/DR3), single-dose DR3 carriers (DR3/x) 
or at least single-dose DR3 carriers with carriers of no DR3 alleles (x/x) in patients versus controls and 








UA (Table 2), HLA-DR3 was more frequently present in anti-CCP-negative patients (n = 
207) than in healthy controls (OR 1.59, 95% CI 1.10-2.28), suggesting that HLA-DR3 is 
not specifi cally associated with anti-CCP-negative RA, but rather with anti-CCP-negative 
arthritis. No association was observed between HLA-DR3 and anti-CCP-positive UA (n = 
28) (OR 0.68, 95% CI 0.17-1.92) (Table 2). Analysis of HLA-DR3 allele frequencies in UA 
patients thus confi rmed the results found in RA patients and indicated that association 
with HLA-DR3 also occurs in anti-CCP-negative UA. Analysis of whether HLA-DR3 is asso-
ciated with development of RA in patients who presented initially with anti-CCP-negative 
UA did not show that HLA-DR3 increased the risk for developing RA (data not shown), 
indicating that HLA-DR3 is not a prognostic risk factor for the development of RA in this 
group of patients.
Since the presence of anti-CCP antibodies is linked to the presence of RF and since RF 
is associated with the SE (12), we next compared the frequencies of HLA-DR3 in IgM-RF-
positive and IgM-RF-negative RA patients with that in controls. Indeed, HLA-DR3 was also 
associated with RF-negative RA (OR 1.66, 95% CI 1.13-2.43). However, after dividing the 
study population into those with and without anti-CCP antibodies, the association was 
lost for the anti-CCP-positive group (Table 3). Anti-CCP-negative, RF-positive RA patients 
and anti-CCP-negative, RF-negative RA patients both harboured HLA-DR3 signifi cantly 
more frequently than did control subjects (OR 2.44, 95% CI 1.25-4.53 and OR 1.69, 95% 
CI 1.11-2.54, respectively). In contrast, anti-CCP-positive, RF-positive RA patients and 
anti-CCP-positive, RF-negative RA patients did not (OR 0.91, 95% CI 0.58-1.42 and OR 
0.98, 95% CI 0.37-2.24, respectively) (Table 3). These data indicate that anti-CCP status, 
rather than RF status, is the predominant disease trait associated with HLA-DR3. 
Table 3. HLA-DR3 allele frequencies in rheumatoid arthritis with and without anti-CCP antibodies 
and IgM-RF.
Population HLA-DR3 allele frequency
N 
(DR3 alleles/ total alleles)
% OR (95% CI)
RA
anti-CCP + ; RF + 32 / 342 9.4 0.91 (0.58-1.42)
anti-CCP + ; RF - 7 / 70 10.0 0.98 (0.37-2.24)
anti-CCP – ; RF + 16 / 74 21.6 2.44 (1.25-4.53)
anti-CCP – ; RF – 43 / 268 16.0 1.69 (1.11-2.54)
Controls 86 / 846 10.2 1.0
RA= rheumatoid arthritis; CCP= cyclic citrullinated peptide; RF= rheumatoid factor; OR= odds ratio; 
95% CI= 95% confi dence interval
ORs were calculated comparing allele frequency of the diseased group with allele frequency in the 
healthy control group
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Table 4. HLA-DRB1 allele frequencies in 206 anti-CCP positive RA patients, 171 anti-CCP negative 
RA patients and 423 healthy controls.
DRB1 anti-CCP positive RA 
(N=412)




N % OR (95% CI) N % OR (95% CI) N %
DR1
01(00) 33 8.0 31 9.1 6 0.7
0101 28 6.8 13 3.8 92 10.9
0102 0 0 3 0.9 2 0.2
0103 0 0 1 0.3 1 0.1
Total 61 14.8 1.28 (0.89-1.83) 48 14.0 1.20 (0.81-1.76) 101 11.9
DR3
03(00) 0 0 0 0 2 0.2
0301/ a 9 2.2 5 1.5 0 0
0301 30 7.3 53 15.5 84 9.9
0302/ b 0 0 1 0.3 0 0
Total 39 9.5 0.92 (0.60-1.40) 59 17.3 1.84 (1.26-2.67) 86 10.2
DR4
04(00) 9 2.2 2 0.6 0 0
0401 84 20.4 2.56 (1.80-3.63) 33 9.6 1.07 (0.67-1.66) 77 9.1






0403/ c 0 0 0 0 8 0.9





0404 25 6.1 12 3.5 2 0.2
0408 7 1.7 3 0.9 3 0.4
0405 5 1.2 10.4 (1.15-492) 0 0 - 1 0.1
0406 1 0.2 0 0 0 0
0407 1 0.2 4 1.2 8 0.9
Total 134 32.5 2.83 (2.12-3.79) 57 16.7 1.18 (0.82-1.67) 123 14.5
DR7
07(00) 6 1.5 5 1.5 91 10.8
0701 28 6.8 27 7.9 0 0
Total 34 8.3 0.75 (0.48-1.14) 32 9.4 0.86 (0.54-1.33) 91 10.8
DR8
08(00) 2 0.5 2 0.6 16 1.9
0801 3 0.7 1 0.3 10 1.2
0803 0 0 0 0 1 0.1
Total 5 1.2 0.37 (0.11-0.99) 3 0.9 0.27 (0.05-0.88) 27 3.2
DR9
09(00) 2 0.5 1 0.3 10 1.2
0901 11 2.7 5 1.5 0 0
Total 13 3.2 2.72 (1.09-7.00) 6 1.8 1.49 (0.44-4.57) 10 1.2
DR10
10(00) 8 1.9 2 0.6 4 0.5
1001 12 2.9 1 0.3 0 0








DRB1 anti-CCP positive RA 
(N=412)




N % OR (95% CI) N % OR (95% CI) N %
DR11
11(00) 8 1.9 6 1.8 5 0.6





1101 8 1.9 6 1.8 0 0
1104 2 0.5 2 0.6 0 0





1102 1 0.2 2 0.6 0 0
Total 21 5.1 0.45 (0.26-0.75) 23 6.7 0.61 (0.36-0.99) 90 10.6
DR12
12(00) 6 1.5 4 1.2 7 0.8
1201 1 0.2 1 0.3 16 1.9
1202 0 0 1 0.3 4 0.5
Total 7 1.7 0.52 (0.19-1.25) 6 1.8 0.54 (0.18-1.36) 27 3.2
DR13
13(00) 0 0 3 0.9 6 0.7
1301/ g 2 0.5 9 2.6 116 13.7
1301 4 1.0 13 3.8 0 0
1302 13 3.2 14 4.1 1 0.1
1303 2 0.5 4 1.2 3 0.4
Total 21 5.1 0.31 (0.18-0.50) 43 12.6 0.82 (0.55-1.20) 126 14.9
DR14
14(00) 6 1.5 9 2.6 0 0
1401 0 0 1 0.3 27 3.2
1404 1 0.2 0 0 0 0
Total 7 1.7 0.52 (0.19-1.25) 10 2.9 0.91 (0.39-1.97) 27 3.2
DR15
15(00) 33 8.0 33 9.6 128 15.1
1501 16 3.9 17 5.0 1 0.1
Total 49 11.9 0.75 (0.52-1.08) 50 14.6 0.95 (0.65-1.37) 129 15.2
DR16
16(00) 1 0.2 2 0.6 5 0.6
Total 1 0.2 0.41 (0.01-3.68) 2 0.6 0.99 (0.09-6.08) 5 0.6
Total 
alleles
412 100 342 100 846 100
RA= rheumatoid arthritis; UA= undifferentiated arthritis; CCP= cyclic citrullinated peptide; OR= odds 
ratio; 95% CI= 95% confi dence interval.
ORs were calculated comparing allele frequencies of the diseased group with allele frequencies in the 
healthy control group. HLA typings without subtyping are presented as x(00). Subtypings without 
conclusive result are presented as 
a 0301/ for subtyping HLA-DRB1*0301, *0304 or *0305; b 0302/ for subtyping HLA-DRB1 *0302 or 
*0303 or *0307; c 0403/ for subtyping HLA-DRB1*0403, *0406 or *0407; d 0404/ for subtyping HLA-
DRB1*0404, *0408 or *0419; e 1101/ for subtyping HLA-DRB1*1101 or *1104; f 1102/ for subtyping 
HLA-DRB1*1102 or *1103; g 1301/ for subtyping HLA-DRB1*1301 or *1302.
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DISCUSSION
The data presented herein show that distinct genetic risk factors are associated with 
distinct subtypes of RA as defi ned by the presence of anti-CCP antibodies. SE-encoding 
alleles are associated with anti-CCP-positive RA and not with anti-CCP-negative disease. 
In contrast, anti-CCP-negative disease is associated with HLA-DR3, while this associa-
tion is not found in anti-CCP-positive RA. Although HLA-DR3 or SE expression is not 
required for the development of anti-CCP-negative or anti-CCP-positive RA, respectively, 
our fi ndings are important because they indicate that distinct pathogenic mechanisms 
may underlie anti-CCP-positive and anti-CCP-negative RA. 
In a previous study of a relatively small number of patients (n = 44), it was found that 
HLA-DR3 frequencies in RA patients differ from the frequencies observed in controls (13). 
Likewise, in a group of 85 Arab RA patients, HLA-DR3 conferred a risk for RA susceptibility 
(14), and a more recent study showed a signifi cantly increased frequency of HLA-DR3 in 
patients with synovitis of recent onset (15). In a Caucasian population of 167 RA patients, 
an association with HLA-DR3 was observed after excluding SE alleles from the analysis 
(16). Our fi ndings represent an extension of those fi ndings by establishing that HLA-
DR3 is associated only with a particular subset of RA. Our analysis also confi rmed that 
particular HLA-DRB1 alleles, such as DR8, DR11, and DR13, protect against RA (17). We 
now show that these alleles tend to be associated with protection against both anti-CCP-
positive and anti-CCP-negative disease. Therefore, our data indicate that the HLA alleles 
conferring protection do so independently of the anti-CCP status, while the alleles that 
predispose to RA are associated with distinct RA phenotypes (anti-CCP-positive or anti-
CCP-negative RA).
It is debatable, however, whether the association of HLA-DR3 with anti-CCP-negative 
RA (and UA) is attributable to the HLA-DR3 gene itself. Other genetic factors in high link-
age disequilibrium with HLA-DR3 may also underlie the observed association. HLA-DR3 is 
known to be part of a conserved ancestral haplotype (A1;B8;DRB1*03, also known as the 
8.1 haplotype (18) that occurs frequently in Caucasian individuals and has been reported 
to be associated with RA (19). Jawaheer et al described an additional genetic risk factor 
present within the major histocompatibility complex (MHC) that is part of this conserved 
haplotype (20). Their fi nding concerned a certain allelic combination of tumor necrosis 
factor (TNF) polymorphisms and another polymorphism on the HLA class III region of 
chromosome 6. Likewise, the class III MHC TNF-lymphotoxin region was described as 
appearing to infl uence susceptibility to RA separately from the HLA-DR region (21), and a 
microsatellite marker (MIB*350) that is also part of an ancestral haplotype associated with 
DRB1*0301 was described as a risk factor for RA independently of DRB1*0301 (22).
In summary, HLA-DR3 is associated with anti-CCP-negative RA and UA and not with 








factors are associated with different phenotypes, which suggests that various pathogenetic 
mechanisms underlie anti-CCP-positive and anti-CCP-negative disease.
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Chapter 9
Smoking is a risk factor for anti-CCP 
antibodies only in rheumatoid arthritis 
patients that carry HLA-DRB1 shared 
epitope alleles
S.P. Linn-Rasker

















Objectives. To study the gene-environment interaction between tobacco-exposure (TE) 
and shared-epitope (SE) alleles on autoantibodies in rheumatoid arthritis (RA) and undif-
ferentiated arthritis (UA).
Methods. From incident cases of arthritis (n=1305), patients that did not fulfi ll any clas-
sifi cation criteria at the two weeks visit, UA (n=486), as well as patients that fulfi lled 
the ACR criteria for RA (n=407) were identifi ed. IgM Rheumatoid Factor (RF), anti-cyclic-
citrullinated peptide (CCP) antibodies and HLA-DRB1 alleles were determined. 
Results. In RA an interaction was found between TE and SE for the presence of anti-CCP 
antibodies, as the odds ratio (OR) for anti-CCP antibodies of patients having both TE and 
SE was higher than the summed ORs of patients having only TE or SE (OR TE+SE- 1.07, 
TE-SE+ 2.49, and TE+SE+ 5.27, all relative to TE-SE-). A similar effect was found for RF, but 
stratifi cation revealed that the interaction primarily associates with the anti-CCP anti-
body response. In patients with UA at two weeks or with persistent UA after one year no 
interaction between TE and SE was observed for the presence of autoantibodies.
Conclusions. TE increases the risk factor for anti-CCP antibodies only in SE-positive 
RA-patients. The gene-environment interaction between smoking and SE leading to auto-
antibodies is specifi c for RA and is not observed in UA.
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INTRODUCTION 
In the search for the etiology of Rheumatoid arthritis (RA) genetic predisposition, envi-
ronmental- and dietary risk factors may present clues for pathogenesis (1-7). The most 
important genetic risk factor for the development of RA is the presence of HLA Class II 
alleles that share the conserved amino acid sequence called the Shared Epitope (SE) (8). 
These SE-residues constitute a part of the antigen presenting binding site. The Shared 
Epitope hypothesis postulates that the shared epitope motif itself is directly involved in 
the pathogenesis of RA by allowing the presentation of a peptide to arthritogenic T-cells. 
The most prominent environmental risk factor for RA is smoking; smokers have increased 
levels of Rheumatoid Factor (RF) (9-11), are more prone to develop RA (11-14) and de-
velop more severe disease (15-17). Interaction between environmental and genetic risk 
factors points to the existence of disease-specifi c pathogenic pathways involved in disease 
induction or progression.
For RA Padyukov et al recently described a gene-environment-interaction between smok-
ing and SE that provides risk (OR 2.8; 95% CI 1.6-4.8) for RF-positive but not RF-negative 
RA in a large cohort of 858 RF-positive and 1048 RF-negative patients with RA (18). Re-
cently, we identifi ed in two large cohorts from both the USA and from Europe by differ-
ent genetic-epidemiological methods (association and linkage) that HLA-DRB1 alleles are 
only a risk factor for RA patients that have anti-CCP antibodies and not in the absence of 
anti-CCP antibodies, suggesting different pathogenic pathways for anti-CCP positive and 
negative RA (19). 
This study investigates whether the gene-environment interaction smoking-shared epi-
tope is also present for the anti-CCP antibody response and whether this interaction was 
more pronounced for the development of RF compared to the development of anti-CCP 
antibodies. Secondly, this study aimed to assess whether the interaction smoking and SE 
is specifi c for patients with RA or is also present in undifferentiated arthritis (UA). To this 
end patients with arthritis that did not fulfi ll any classifi cation criteria at presentation and 
patients with persistent UA at one-year follow-up were used. These patients have a spon-
taneous remission rate of about 50% (20) and might have differences in the underlying 
pathogenesis. If the interaction between smoking and SE that leads to autoantibody for-
mation is specifi c for the pathogenesis of RA, it is hypothesized that such an interaction 
will not be seen in patients with an undifferentiated arthritis of which clinical follow-up 










For this study, the Leiden Early Arthritis Clinic (EAC), a population-based inception co-
hort of patients with newly diagnosed early arthritis was used (for further reading see 
(21)). RA was diagnosed according to the American College of Rheumatology (ACR) cri-
teria of 1987(22). Patients who could not be properly classifi ed according to one of the 
ACR-criteria at 2 weeks follow-up were categorized as having UA (20). This population 
of UA patients was further divided in patients that (1) had developed RA, (2) remained 
unclassifi ed (persistent UA) or (3) had developed other rheumatic diseases such as spon-
dylarthropathies, osteoarthritis, gout, reactive arthritis at one year follow-up (Figure 1). 
At inclusion in the EAC-cohort, for each patient the smoking status (cigarettes, cigars) 
was registered as past, current or never smokers. Current and past smokers were classifi ed 
as tobacco exposure positive (TE+) and never smokers as tobacco exposure negative (TE-
)(11). Baseline laboratory parameters included C-reactive protein (CRP), IgM rheumatoid 
factor (ELISA as previously described 23), anti-CCP antibodies (ELISA, Immunoscan RA 
Mark 2, Euro-Diagnostica, Arnhem, The Netherlands and Axis-Shield, Dundee, UK) and 
HLA-Class II alleles. The HLA-DRB1 (sub-)typing was performed by polymerase chain re-
action using specifi c primers and hybridisation with sequence-specifi c oligonucleotides. 
Shared epitope alleles were: DRB1 *0101, *0102, *0401, *0404, *0405, *0408, *0410 and 
*1001 (24). Patients homozygous and heterozygous for shared epitope were both classifi ed 
as SE positive. Missing data for the whole cohort of 1305 patients ranged for several items 
Baseline
2 weeks
1 year 1 year
UA=Undifferentiated Arthritis
RA= Rheumatoid Arthritis














Figure 1. Flow chart early arthritis patients.
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SE, TE anti-CCP and RF between 0%-20%. An analysis of the baseline values of patients 
with missing data-points revealed no differences to those patients without. 
Statistical analysis
Odds ratios were calculated for the primary outcome measures RF and anti-CCP antibod-
ies. Stratifi ed analysis was performed for both anti-CCP-positive and anti-CCP negative 




Between 1993 and 2003, 1305 patients were included in the EAC-cohort. At two weeks 
follow-up, 486 patients did not fulfi ll any classifi cation criteria and were thus classifi ed 
as UA. At this time 276 patients fulfi lled the ACR criteria for RA. Of the 486 UA patients, 
after one year follow-up 131 patients were diagnosed as having RA. In 203 patients the 
diagnosis remained UA (persistent UA) and in the other 152 patients another rheumatic 
disorder such as spondylarthropathy, osteoarthritis, psoriatic arthritis, etc was identifi ed 
(Figure 1). The total number of patients from the cohort that was identifi ed as having 
RA at one year was 407. From the patients classifi ed as persistent UA at one year, 15% 
developed RA during further follow-up (K.Verpoort, unpublished data). 
Baseline patient characteristics of patients that at two weeks presented with RA or UA 
are given in Table 1; the data on the UA patients are presented for both the UA patients 
Table 1. Patient characteristics at baseline of patients that presented with RA, patients that 
presented with UA and developed RA after 1 year and patients that presented with UA and had 
other diagnoses than RA after one year follow-up.







Age yr (mean) 58 56 48 <0.001
Female (%) 66 64 51 n.s.
CRP (mg/l, mean) 35 29 21 0.036
IgM RF + (%) 65 52 13 <0.001
Anti-CCP + (%) 54 51 7 < 0.01
Shared Epitope + (%) 68 63 49 0.046
Tobacco exposure + (%) 47 52 50 n.s.
Shared Epitope + means presence of 1 or 2 shared epitope alleles. 
Tobacco exposure + means current and past smokers as indicated in the medical history. 
*P values were determined for UA→RA versus UA→non RA. 








that developed RA, as the UA patients that had persistent UA after one-year follow-up. 
UA patients that did not develop RA were younger at presentation than the patients that 
developed RA (mean 48 years, vs. 56 years, p<0.001). The UA patients that developed RA 
after one year had at baseline higher levels of CRP, RF and anti-CCP antibodies and were 
more often SE-positive compared to the UA-patients that had persistent UA or developed 
other rheumatologic diagnosis (Table 1). No differences were observed between the 131 
RA patients that developed RA after 1 year and the 276 patients with RA that were diag-
nosed at the two weeks visit.
Interaction tobacco exposure and shared epitope in RA
In RA and UA patients the interaction between SE and TE was analyzed. Outcome param-
eters were RF and anti-CCP antibodies. 
In all RA patients, no effect of TE on the RF status was seen in SE negative patients in 
contrast to a clear effect in SE positive patients. The OR for positive RF was 1.47 for TE+ 
SE- patients, 1.35 for TE- SE+ patients and 3.23 for TE+SE+ patients all relative to TE-SE- 
patients (Table 2), showing an interaction between TE and SE for the development of RF. 
In SE negative RA patients, no effect of TE was seen for positive anti-CCP antibodies in 
contrast to a clear effect in the SE positive group. The OR for positive anti-CCP antibodies 
was 1.07 for TE+ SE- patients, 2.49 for TE+ SE- patients and 5.27 for TE+SE+ patients, again 
all relative to TE-SE- patients. As the odds ratio for anti-CCP antibodies of patients having 
both TE and SE was higher than the summed OR’s of patients having only TE or SE, an 
interaction was found between TE and SE for the presence of anti-CCP antibodies. The 
difference between the TE- SE+ patients and the TE+ SE+ patients was signifi cant both for 
IgM-RF and for anti-CCP (Table 2). 
Presuming that RF-positive and anti-CCP positive patients partly overlap each other, a 
stratifi ed analysis was done for both RF-positive and RF-negative and anti-CCP positive 
and negative patients. The results, shown in Table 2, demonstrate that when stratifi ed for 
the presence/absence of anti-CCP antibodies, no signifi cant interaction is found between 
TE and SE in relation to the presence of RF. When stratifi ed for RF, in the RF negative 
group an interaction between TE and SE was observed for the development of anti-CCP 
antibodies. These data suggest that the interaction between TE and SE primarily associates 
with positive anti-CCP antibodies and not with positive RF.
Interaction tobacco exposure and shared epitope in UA
In the whole group of patients who presented with UA, the combination of TE and SE 
did not signifi cantly increase the risk for the presence of positive RF or anti-CCP antibod-
ies (Table 3). The OR for positive anti-CCP antibodies in TE- SE+ patients with UA was 
increased compared to TE-SE- (OR 3.83: 95% CI 1.33-12.53), but addition of TE to the 
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Table 2. Odds ratios for developing RF and anti-CCP antibodies in the presence of Tobacco 
Exposure (TE) and/or shared epitope alleles (SE) in all Rheumatoid Arthritis patients at 1 year.
TE SE RF + RF- OR 95% CI p
– – 23 31 1.00 - -
+ – 25 23 1.47 0.62-3.45 0.33
– + 54 54 1.35 0.66-2.75 0.37 *
+ + 72 30 3.23 1.54-6.81 <0.001 *
 0.002 π
TE SE anti-CCP 
+
anti-CCP - OR p
– – 18 34 1.00 - -
+ – 17 30 1.07 0.43-2.65 0.87
– + 58 44 2.49 1.18-5.31 0.01 #
+ + 67 24 5.27 2.37-11.80 <0.001 #
<0.001 π
anti-CCP TE SE RF + RF- OR 95% CI p
+ – – 14 4 1.00 - -
+ + – 17 0 ∞ ∞ 0.10
+ – + 46 12 1.10 0.22-4.42 0.88 ¶
+ + + 54 13 1.19 0.24-4.68 0.79 ¶
0.23
– – – 7 27 1.00 - -
– + – 8 22 1.40 0.38-5.32 0.57
– – + 6 38 0.61 0.12-2.40 0.41 ¶
– + + 7 17 1.59 0.39-6.34 0.45 ¶
0.39 π
RF TE SE anti-CCP 
+ 
anti-CCP - OR 95% CI p
+ – – 14 7 1.00 - -
+ + – 17 8 1.06 0.26-4.34 0.92
+ – + 46 6 3.83 0.91-16.07 0.03 ¶
+ + + 54 7 3.86 0.96-15.11 0.02 ¶
0.02 π
– – – 4 27 1.00 - -
– + – 1 22 0.31 0.01-3.47 0.28
– – + 12 38 2.13 0.56-9.97 0.22 ¶
– + + 13 17 5.16 1.28-24.71 0.01 ¶
0.04 π
* TE-SE+ versus TE+SE+: OR 2.4 (95%CI 1.3-4.4, p=0.002)
# TE-SE+ versus TE+SE+: OR 2.1 (95%CI 1.1-4.1, p=0.02)
¶ Comparison TE-SE+ versus TE+SE+ not signifi cant








Table 3. Odds ratios for developing RF and anti-CCP antibodies in the presence of Tobacco 
Exposure (TE) and/or shared epitope alleles (SE) in patients with Undifferentiated Arthritis (UA).
3A. All UA patients at two weeks
TE SE IgM RF + IgM RF – OR 95% CI p
– – 12 55 1.00 - -
+ – 13 48 1.24 0.47-3.29 0.63
– + 19 60 1.45 4.60-3.59 0.34 ¶
+ + 18 54 1.53 0.62-3.82 0.31 ¶
0.75 π
TE SE anti-CCP + anti-CCP – OR 95% CI p
– – 6 54 1.00 - -
+ – 9 48 1.69 0.49-6.19 0.35
– + 20 47 3.83 1.33-12.53 0.01 ¶ 
+ + 21 47 4.02 1.40-13.09 0.01 ¶ 
<0.01 π
3B. Subgroup of UA patients who develop RA within one year 
TE SE IgM RF + IgM RF – OR 95% CI p
– – 6 12 1.00
+ – 8 14 1.14 0.26-5.24 0.84
– + 15 22 1.36 0.37-5.44 0.61 ¶
+ + 19 13 2.92 0.76-11.90 0.08 ¶
0.87 π
TE SE anti-CCP + anti-CCP – OR 95% CI p
– – 8 10 1.00
+ – 8 13 0.77 0.18-3.33 0.69
– + 19 16 1.48 0.41-5.46 0.50 ¶
+ + 21 9 2.92 0.74-11.66 0.08 ¶
0.12 π
3C. Subgroup of persistent UA patients at one year
TE SE IgM RF + IgM RF – OR 95% CI p
– – 6 37 1.00
+ – 5 32 0.96 0.21-4.20 0.95
– + 9 34 1.63 0.46-6.17 0.39 ¶
+ + 4 33 0.75 0.14-3.48 0.67 ¶
0.62 π
TE SE anti-CCP + anti-CCP – OR 95% CI p
– – 1 36 1.00
+ – 2 34 2.12 0.10-128 0.54
– + 8 27 10.67 1.26-486 0.01 ¶
+ + 4 32 4.50 0.41-227 0.16 ¶
0.03 π
¶ Comparison TE-SE+ versus TE+SE+ not signifi cant
π P-value of Chi-square analysis of 2 by 4 table
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presence of SE did not signifi cantly increase the risk of having anti-CCP antibodies (OR 
4.02 relative to OR of 3.83, table 3A). 
Subsequently, we assessed whether in the subgroup UA patients that developed RA 
(n=131) smoking combined with presence of SE increased the risk of having anti-CCP 
antibodies. Therefore the non-smoking SE negative UA patients that developed RA were 
compared to smoking SE negative UA patients that developed RA patients (OR 0.77), as 
well as to non-smoking SE-positive patients with UA that developed RA (OR 1.48) and 
fi nally to smoking, SE-positive patients with UA that developed RA (OR 2.92). In this 
smaller group of RA patients a trend for the interaction of SE and TE to increase the risk 
of having anti-CCP antibodies was observed. Calculations for outcome RF showed similar 
results (Table 3B).
The same calculations were repeated for patients with persistent UA (n=203). Although 
the number of anti-CCP positive UA patients is low, no effect of tobacco exposure com-
bined with SE on the risk of having anti-CCP antibodies or RF was observed (Table 3C). 
Thus, the interaction of SE and tobacco exposure was found for the presence of RF and for 
anti-CCP antibodies in patients with RA and in those UA patients that develop RA within 
one year but not in patients with persistent UA. 
DISCUSSION
A strong gene-environment interaction between TE and SE for the presence of autoanti-
bodies was observed. Intriguingly, this gene-environmental interaction was only present 
in patients with RA and not observed in patients with (persistent) UA. Stratifi ed analysis 
for the different autoantibody responses IgM RF and anti-CCP showed that the interac-
tion is primarily for the anti-CCP response. 
A recent Swedish study demonstrated that a gene-environment interaction between SE 
and smoking results in an elevated risk specifi cally for RF-positive RA (18). These data 
were replicated as well as extended in the present study. Replication by a separate group 
in a separate cohort minimizes the risk that the current fi ndings are false positive (25). 
Both the Swedish and the current data demonstrate the lack of a relation between smok-
ing and autoantibodies in SE-negative RA, indicating that this interaction is preferential 
for a given pathogenetic pathway in SE-positive RA. To specify this pathogenetic pathway 
with regard to the specifi city of the autoantibody response, the stratifi ed analysis for anti-
CCP positivity yielded no additional effect of smoking on risk to develop RF. In contrast 
the stratifi ed analysis for RF indicated that smoking more than doubled the risk in the 
SE-positive patients to develop anti-CCP antibodies. These data suggest that the gene-








associated with the anti-CCP response. Apart from the specifi city of this gene-environ-
ment interaction, our group has recently described that SE is only a risk factor for anti-
CCP positive RA and not for anti-CCP negative RA (19). The current data do not allow 
the analysis of smoking as a risk factor for anti-CCP positive RA versus anti-CCP negative 
RA because no data of smoking in a matched group of the general population are known. 
However given the fact that SE alone is not a risk factor for anti-CCP negative RA (19), the 
gene-environment interaction between smoking and SE leading to anti-CCP antibodies 
seems characteristic for anti-CCP positive RA. Indeed no effect of smoking was observed 
in the SE-negative patients (see Table 2). These data are in line with our previously re-
ported hypothesis that different pathogenetic pathways operate in anti-CCP negative RA 
as compared to anti-CCP positive RA. The demonstration of these pathogenetic pathways 
is diffi cult because it is not known which proteins are citrinullated as a result of smoking, 
nor is it known if or how smoking breaks normal tolerance to citrinullated self-proteins.
In this study the diagnosis persistent RA was defi ned as the presence of arthritis that did 
not fulfi ll any of the classifi cation criteria after one-year follow-up. This may lead to some 
misclassifi cation because a small proportion of UA patients only develop RA after a longer 
time period. However, in previous analysis of this cohort this concerned only less than 
15% of the patients with persistent UA at one year. More importantly, no interaction 
between smoking and shared epitope was observed at all in the persistent UA group. 
A weakness of the current study is that the information on TE is limited to patient history 
taking and patients were not asked about the number of pack-years smoking. Therefore 
no conclusion on the minimal exposure can be drawn. 
In summary, smoking was confi rmed to be a risk factor for anti-CCP antibodies in the 
presence of shared epitope alleles in patients with RA. In UA no interaction between TE 
and SE was demonstrated for the presence of autoantibodies.
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Chapter 10
The HLA-DRB1 shared epitope alleles 
are primarily a risk factor for anti-CCP 
antibodies and are not an independent 
risk factor to develop rheumatoid 
arthritis















Objectives. The Shared-Epitope (SE)-containing HLA-DRB1-alleles represent the most 
signifi cant genetic risk factor for rheumatoid arthritis (RA). Recent studies showed that 
the SE-alleles only associate with RA that is characterized by the presence of anti-Cyclic 
Citrullinated Peptide (CCP)-antibodies, and not with anti-CCP-negative disease. Here we 
studied whether the SE-alleles contribute to the development of anti-CCP-positive RA, 
or rather associates with the presence of anti-CCP-antibodies. Therefore the infl uence of 
SE-alleles and anti-CCP-antibodies on the progression from recent onset undifferentiated 
arthritis (UA) to RA is investigated. 
Methods. From the Leiden Early Arthritis Cohort, an inception cohort of patients with 
recent onset arthritis, the patients with UA at the 2-week visit were selected (n=570). 
SE-alleles, rheumatoid factor (RF) and anti-CCP-antibody levels were determined. Progres-
sion to RA or other diagnoses was monitored.
Results. 177 UA patients developed RA during 1-year follow-up, whereas 393 patients re-
mained unclassifi ed or developed other diagnoses. The SE-alleles correlated with the pres-
ence of anti-CCP-antibodies, but, after stratifi cation for anti-CCP-antibodies, not with the 
presence of RF. Both in SE-positive and SE-negative UA-patients, the presence of anti-CCP-
antibodies was signifi cantly associated with the development of RA. More intriguingly 
however, no apparent contribution of the SE-alleles was found on the progression to RA 
when stratifi ed for the presence of anti-CCP-antibodies. In anti-CCP-positive patients the 
presence of SE-alleles was associated with signifi cantly higher levels of anti-CCP-antibod-
ies, suggesting that the SE-alleles act as classical immune response genes.
Conclusions. The SE-alleles do not independently contribute to the development of RA 
from UA, but rather to the development of anti-CCP-antibodies.
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INTRODUCTION
The most important genetic risk factor for rheumatoid arthritis (RA) are the HLA-Class 
II alleles. Especially the HLA-DRB1 alleles encoding for the shared epitope (SE) confer a 
higher risk to develop RA (1). The shared epitope hypothesis postulates that the shared 
epitope motif (a conserved amino acid sequence in the peptide binding pocket of the 
DRB1 molecule) is directly involved in the pathogenesis of RA by allowing the presenta-
tion of an arthritogenic peptide to T cells (2). Recently, it was observed by two different 
methods (linkage and association analysis) that the SE-alleles are only a risk factor for 
RA that is characterised by the presence of anti-cyclic citrullinated peptide (anti-CCP) 
antibodies and that the SE-alleles are not associated with anti-CCP-negative RA (3). Anti-
CCP antibodies are highly specifi c for RA, can be detected years before the fi rst clinical 
manifestation of RA (4) and are reported to be a good predictor for the development of RA 
(5). Because the contribution of the SE-containing HLA-alleles to the pathogenesis of RA 
is not well understood, the novel information on the association of SE-alleles with anti-
CCP-positive disease (3) led us to evaluate the hypothesis that the SE-alleles are mainly 
a risk factor for anti-CCP-antibodies, rather than for (anti-CCP-positive) RA. To this end, 
we took advantage of a well-characterized inception cohort and studied the patients with 
an early arthritis that at presentation could not be classifi ed according to the ACR-criteria 
(undifferentiated arthritis). Analysis of the clinical evolution, in combination with ge-
netic and serological risk factors, of these patients prone to develop RA allows insight in 
the factors that are associated with progression towards RA. Accordingly this permits the 




For this study, the Leiden Early Arthritis Clinic (EAC) was used (see for description ref 6). 
In short, the EAC was started in 1993. Patients were referred to the EAC when arthritis 
was suspected and were included in the cohort when arthritis was found at physical ex-
amination. At baseline blood samples were taken. At present more than 1900 patients are 
included. Two weeks after inclusion, 313 patients had the diagnosis RA according to the 
1987 ACR criteria and 570 patients had an arthritis that could not be classifi ed according 
to one of the ACR criteria and were therefore called undifferentiated arthritis (UA). After 
one year of follow-up, the disease status of all UA patients was examined in order to deter-
mine whether they had developed RA according to the ACR-criteria. It might be possible 








later time point. Inherent to the design of an inception cohort the duration of follow-up 
differs within the study population. However, at the moment of analysis the majority of 
patients (94%) has been followed for more than one year (mean follow-up 8 years, SD 3 
years) and only 9% of the patients that did not classify as RA at one year developed RA 
later on in the disease course. 
Laboratory investigations
Baseline laboratory parameters (determined using blood samples that were taken at inclu-
sion) included IgM rheumatoid factor (RF, ELISA) and anti-CCP2 antibodies (ELISA, Im-
munoscan RA Mark 2, Euro-Diagnostica, Arnhem, The Netherlands). The cut-off level for 
anti-CCP antibody positivity was according to the manufacturers instruction set at a level 
of 25 arbitrary units. The HLA-DRB1 (sub)typing was performed by polymerase chain 
reaction using specifi c primers and hybridisaton with sequence specifi c oligonucleotides. 
The shared epitope alleles were HLA-DRB1*0101, *0102, *0401, *0404, *0405, *0408,*0410 
and *1001. Of 438 from the 570 UA patients both data on SE-alleles and anti-CCP anti-
bodies were available.
Statistical analysis
Odds ratios were calculated and proportions were compared by the chi-square test. Differ-
ences in means between groups were analysed using the Mann Whitney test or t-test when 
appropriate. The question whether SE-alleles and anti-CCP antibodies both independently 
contribute to progression of RA was investigated with a stratifi cation procedure, as well 
as with logistic regression analysis. In this logistic regression analysis the disease outcome 
was entered as dependent variable and anti-CCP antibodies and SE-alleles as possibly 
explanatory variables; with a backward selection procedure the signifi cant independent 
variables were selected. For all tests, p-values of < 0.05 were considered signifi cant. 
RESULTS AND DISCUSSION
Outcome of UA
Of 570 patients with UA at the two weeks visit, 177 developed RA during the fi rst year of 
follow-up, 99 patients developed other rheumatologic diseases (reactive arthritis, psoriatic 
arthritis, SLE, etc) and 294 patients remained unclassifi ed (persistent UA). For further 
analysis the patients with persistent UA and with other rheumatologic diagnosis were 
described as the non-RA group. Characteristics of the patients that developed RA and the 
non-RA group are depicted in Table 1. In univariate analysis, the presence of SE-alleles, 
RF and anti-CCP antibodies were all associated with signifi cantly higher odds ratio’s to 
develop RA (OR 1.8, 6.3 and 8.5 respectively, Table 1). 
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Association between SE-alleles and presence of auto-antibodies
To determine whether the SE-alleles correlate with RF, with anti-CCP antibodies or with 
both auto-antibodies, the associations between SE-alleles and anti-CCP and the associa-
tions between SE-alleles and RF were investigated in the 570 UA patients. In univariate 
analysis, the SE-alleles were associated with both RF and anti-CCP antibodies (OR 1.7, 
95%CI 1.1-2.7, p=0.01 and OR 3.1, 95%CI 2.1-5.3, p<0.001 respectively). As anti-CCP 
positivity is correlated with RF positivity, the association between SE-alleles and anti-CCP 
antibodies was assessed in both the RF-positive and RF-negative patients. In RF-negative 
patients the presence of SE-alleles was associated with a higher odds ratio to develop 
anti-CCP antibodies (OR 2.9, 95%CI 1.2-6.9, p<0.01). Similarly, in RF-positive patients 
the presence of SE-alleles conferred a higher odds ratio to have anti-CCP antibodies (OR 
5.6, 95% CI 2.1-14.6, p<0.001). These data indicate that the SE-alleles are associated with 
the presence of anti-CCP antibodies independent of the presence or absence of RF. Next 
it was assessed whether the SE-alleles are associated with RF, independent of the anti-CCP 
antibodies. In both the anti-CCP positive and anti-CCP negative patient groups, the SE-
alleles were not associated with the presence of RF (p=0.9 and 0.2 respectively), indicating 
that after correction for the presence or absence of anti-CCP antibodies the SE-alleles do 
not confer risk to RF positivity. In conclusion, the SE-alleles are primarily correlated with 
the presence of anti-CCP antibodies but not with the presence of RF.
SE-alleles and anti-CCP antibodies in progression from UA to RA
Subsequently, the infl uence of SE-alleles on the progression from UA to RA was examined. 
Univariate analysis assessing the association between patient characteristics and disease 
outcome revealed that the presence of SE-alleles and anti-CCP antibodies at baseline were 
both associated with the development of RA (see Table 1). However, as the presence of 
SE-alleles and anti-CCP antibodies are correlated, the individual effect of SE-alleles on the 
development of RA was determined by stratifi cation for anti-CCP antibodies. Both in the 
anti-CCP positive and in the anti-CCP negative UA-patients, the presence of SE-alleles was 
not associated with the development of RA (Table 2). These data are important as they 
Table 1. Baseline characteristics of patients with undifferentiated arthritis at two weeks that did 
and did not develop RA during the fi rst year of follow-up
RA (n=177) non-RA (n=393) P OR (95%CI)
Age (yr, mean ± SD) 56.3 ± 15.3 48.6 ± 16.9 <0.001 –
Gender F/M 121/56 208/185 0.001 1.9 (1.3-2.8)
SE positive* 100 (63%) 158 (49%) 0.005 1.8 (1.2-2.6)
Anti-CCP positive# 83 (51%) 38 (11%) <0.001 8.5 (5.2-13.7)
RF positive 84 (47%) 56 (14%) <0.001 6.3 (4.1-9.7)
* SE data was missing in 17 of the UA-RA patients and in 68 of the UA-non-RA patients









indicate that the SE-alleles do not correlate with RA development in patients with UA 
when stratifi ed for the presence/absence of anti-CCP antibodies.
To assess the effect of the anti-CCP antibodies independent of SE alleles, the risk to 
develop RA was determined in SE-positive and SE-negative UA-patients separately (Table 
2). This analysis showed that in the SE-positive as well as in the SE-negative UA patients 
the presence of anti-CCP antibodies was signifi cantly associated with the development of 
RA (OR 8.7 and 10.1 respectively).
In a logistic regression analysis with a backward selection procedure entering the dis-
ease outcome (RA versus non-RA) as dependent variable and the SE-alleles and anti-CCP 
antibodies as possibly explanatory variables, the anti-CCP antibodies were the only in-
dependent factor that signifi cantly associated with the development of RA with an odds 
ratio of 9.2 (p<0.001). This odds ratio resulting from multivariate analysis is not impor-
tantly different from the odds ratio for anti-CCP antibodies on the development of RA as 
observed in univariate analysis (OR 8.5, see Table 1).
In conclusion, these data show that after stratifi cation for SE-alleles the anti-CCP anti-
bodies confer a high risk to develop RA, whereas after stratifi cation for anti-CCP antibod-
ies the SE-alleles are not associated with progression to RA. Together these data indicate 
that the SE-alleles primarily predispose to the presence of anti-CCP antibodies and are not 
an independent risk factor for the development of RA.
Association between SE-alleles and anti-CCP antibody level
In classic studies performed in mice on the genetical background associated with antibody 
production it has been shown that major histocompatibility alleles act as Immune Re-
sponse genes (Ir-genes) that control the magnitude and specifi city of antibody production 
in a dominant fashion (7). In these mice the magnitude of the antibody response of the 
fi rst generation offspring was comparable to the magnitude of the high responding parent, 
denoting that in mice homozygositiy for MHC-genes did not improve the level of antibody 
Table 2. Number of UA-patients that during one year of follow-up did not and did develop RA, 
stratifi ed for baseline anti-CCP antibodies and SE-alleles
non-RA n (%) RA n (%) P OR (95%CI)
Stratifi cation for anti-CCP antibodies
anti-CCP – SE – 142 (55) 37 (53)
0.8 1.1 (0.6-1.9)SE + 118 (45) 33 (47)
anti-CCP+ SE – 8  (26) 21 (27)
0.9 0.9 (0.3-2.6)SE + 23  (74) 56 (73)
Stratifi cation for SE-alleles
SE – anti-CCP – 142 (95) 37 (64)
<0.001 10.1 (3.9-27.1)anti-CCP + 8  (5) 21 (36)
SE + anti-CCP – 118 (84) 33 (39)
<0.001 8.7 (4.5-17.0)anti-CCP + 23 (6) 56 (61)
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production compared to heterozygosity (7). As the current data revealed that the SE-alleles 
are associated with anti-CCP antibodies, we wished to investigate whether the character-
istics of the SE-alleles resemble such a classic Ir-gene. Thus we wished to analyse whether 
the level of anti-CCP antibodies present in serum was correlated to the presence of SE-al-
leles. To this end the correlation between the presence of SE-alleles and level of anti-CCP 
antibodies was assessed in all anti-CCP positive patients that at one-year follow-up had the 
diagnosis RA. Of a total number of 490 RA patients (313 RA diagnosed at two weeks fol-
low-up and 177 patients that progressed from UA to RA during the fi rst year of follow-up), 
233 patients had anti-CCP antibodies of which 73% harboured SE-alleles. The anti-CCP 
antibody levels of anti-CCP-positive SE-positive and anti-CCP-positive SE-negative patients 
are depicted in Figure 1. SE-positive patients had a signifi cantly higher level of anti-CCP 
antibodies (n= 169, mean 1032, SEM 72 arbitrary units) than SE-negative patients (n= 46, 
mean 652, SEM 86 arbitrary units, p=0.001). Patients carrying one SE-allele displayed a 
signifi cantly higher level of anti-CCP antibodies (n=123, mean 1029; SEM 86 arbitrary 
units) compared to patients without SE-alleles (p=0.002). Patients with two SE-alleles did 
not have a signifi cantly higher anti-CCP level (n=46, mean 1041, SEM 134 arbitrary units) 
compared to patients carrying one SE-allele (p=0.94). Thus, the current data show that in 
anti-CCP-positive patients the presence of SE-alleles is associated with higher levels of anti-
CCP antibodies and indicate that the presence of one or two SE-alleles does not result in 
an apparent difference in anti-CCP antibody level. This observation is compatible with the 
notion that the SE-alleles are Ir-genes for the development of anti-CCP antibodies. 
Figure 1. Levels of anti-CCP antibodies (arbitrary units) in anti-CCP positive RA 
patients without and with SE-alleles. The median anti-CCP antibody level is depicted. 
The mean anti-CCP antibody levels for the anti-CCP positive RA patients were: mean 1041 (SEM 134, 
n=46) for carrying two SE-alleles, 1029 (SEM 86, n=123) for carrying 1 SE-allele and 652 (SEM 86, n= 
46) for carrying no SE-alleles. The median anti-CCP antibody levels for the subgroup anti-CCP positive 
UA patients that progressed to RA were: 699 (IQR 278-1282, n=13) for carrying 2 SE-alleles, 927 (IQR 









Recently, we reported that the SE-alleles were only associated with anti-CCP-positive RA 
and not with anti-CCP-negative disease, indicating that the SE-alleles are not associated 
with RA as such but rather with a distinct phenotype of the disease. We now extend these 
fi ndings by showing that the SE-alleles are not an independent risk factor for the develop-
ment of RA after correction for anti-CCP-antibody status. The SE-alleles were however 
associated with the presence of anti-CCP antibodies. Moreover, the presence/ absence 
of SE-alleles was correlated with the levels of anti-CCP antibodies, suggesting that the 
SE-alleles act as classic Ir-genes for the development of anti-CCP antibodies. Although 
no formal conclusions on causality can be drawn from this association study, these fi nd-
ings suggest that anti-CCP antibodies mediate the association between SE-alleles and RA. 
It would be of interest to replicate the fi ndings of the present study by following the 
development of anti-CCP antibodies and RA in healthy asymptomatic persons with and 
without SE-alleles. Nevertheless, the present data constitute an important refi nement of 
the long-known association between HLA and RA by indicating that the SE-alleles do not 
primarily associate with RA, but rather with anti-CCP-positivity.
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Antibodies to citrullinated proteins (anti-CCP) are highly specifi c for rheumatoid arthritis 
(RA) and precede the onset of disease symptoms, indicating a pathogenetic role for these 
antibodies in RA. Recently we showed that distinct genetic risk factors are associated 
with either anti-CCP positive and anti-CCP-negative disease. These data are important as 
they indicate that distinct pathogenic mechanisms are underlying anti-CCP positive and 
negative disease. Likewise, these observations raise the question whether anti-CCP posi-
tive and negative RA are clinically different disease entities. Therefore, we investigated 
whether RA patients with anti-CCP antibodies have a different clinical presentation and 
disease course compared to patients without these auto-antibodies. In a cohort of 454 
incident patients with RA, 228 patients were anti-CCP positive and 226 patients anti-CCP 
negative. The early symptoms, tender and swollen joint count and C-reactive protein 
level at inclusion, as well as the swollen joint count and radiological destruction during 
4 years follow-up were compared for the 2 groups. There were no differences in morning 
stiffness, type, location and distribution of early symptoms, patients’ rated disease acti-
vity and C-reactive protein at inclusion between RA patients with and without anti-CCP 
antibodies. The mean tender and swollen joint count for the different joints at inclusion 
was similar. At follow-up, patients with anti-CCP antibodies had more swollen joints and 
more severe radiological destruction. Nevertheless, the distribution of affected joints, for 
swelling, bone erosions and joint space narrowing, was similar. In conclusion, the pheno-
type of RA patients with or without anti-CCP antibodies is similar with respect to clinical 
presentation but differs with respect to disease course.
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INTRODUCTION
Autoantibodies directed to citrullinated proteins (e.g. anti-cyclic-citrullinated peptide, 
anti-CCP antibodies) are highly specifi c serological markers for rheumatoid arthritis (RA) 
that are thought to be directly involved in the disease pathogenesis (1). Citrullinated pro-
teins are not exclusively located in synovial tissue of RA patients, but can also be found in 
synovium samples of patients with other infl ammatory joint diseases (2), suggesting that 
the specifi city of anti-CCP antibodies for RA is not due to the expression of citrullinated 
proteins but might be the result of an abnormal humoral response. Intriguingly this anti-
body response may occur years before any clinical symptoms, as shown by the presence of 
anti-CCP antibodies several years before the clinical onset of arthritis (3,4). Furthermore, 
a proportion of RA patients do not harbour anti-CCP antibodies, suggesting that the pres-
ence of anti-CCP antibodies is not obligatory for the development of arthritis or that the 
pathogenic mechanisms underlying anti-CCP positive and negative RA are different.
These observations inspired subsequent research addressing the question whether RA pa-
tients with anti-CCP antibodies are different from those who are anti-CCP negative. Very 
recently, we demonstrated in two independent Caucasian populations that the shared 
epitope encoding HLA-DBR1 alleles associate with RA in patients with anti-CCP antibod-
ies but not in patients without these antibodies (unpublished data, 5). These fi ndings are 
important as they indicate that the shared epitope alleles are not associated with RA as 
such, but rather with a particular phenotype of the disease.
Given the fi ndings suggesting a pathophysiological role for anti-CCP antibodies in RA 
and the reported immunogenetical differences between anti-CCP positive and negative 
patients, it is conceivable that anti-CCP positive and negative RA are different disease 
entities and have thus different phenotypical properties. Anti-CCP antibodies have been 
suggested to be associated with more severe radiological outcome (5,6). However, to our 
knowledge a detailed description of the distribution and degree of early symptoms and 
signs in both patient groups has not been published. Nevertheless, such an analysis is 
relevant as it might provide novel insight into the putative pathogenic role of anti-CCP 
antibodies in the aetiology of the disease. Therefore, in this study we set out to determine 
whether anti-CCP antibody positive and negative RA patients differ in different aspects 
of their phenotype, either the early symptoms of disease, the fi ndings at physical ex-
amination at initial presentation or the acute phase reactant C-reactive protein at initial 
presentation. Moreover, we expanded the data on the infl uence of anti-CCP antibodies 
on disease course during 4-year follow-up for the distribution and extend of both infl am-








of RA patients with or without anti-CCP antibodies is similar with respect to clinical 
presentation but differs with respect to disease course.
PATIENTS AND METHODS
Patients
In 1993 an Early Arthritis Clinic (EAC) was started at the department of Rheumatology 
of the Leiden University Medical Center, the only referral center for Rheumatology in a 
health care region of about 400 000 inhabitants in the western part of the Netherlands 
(7). General practitioners were encouraged to refer patients directly when arthritis was 
suspected. Patients referred could be seen within two weeks and were included in the pro-
gram when the physician’s examination of the patients revealed arthritis and the symp-
toms had lasted less than 2 years. At the fi rst visit the rheumatologist answered a form 
with questions about the initial symptoms as reported by the patient (type of initial joint 
symptoms, localization and distribution of initial joint symptoms, presence of morning 
stiffness). Patients rated their global assessment of disease activity on a visual analogue 
scale (0-100). The Health Assessment Questionnaire, a self-assessed questionnaire asking 
about the ability of the patient to perform several daily activities over the past week, was 
used to obtain an index of disability. A tender joint count and swollen joint count (8,9) 
was performed on entering the study and yearly thereafter. For the tender joint count, 
each joint was scored on a 0-3 scale with 3 being maximal tenderness (0= no tenderness, 
1= pain on pressure, 2= pain and winced and 3= winced and withdrew). For the swollen 
joint count the individual joints were scored on a 0-1 scale (0 = no swelling, 1= swelling). 
At inclusion from every patient blood samples were taken for routine diagnostic labora-
tory screening including C-reactive protein and were stored to determine antibodies to 
CCP2 at a later time point. The anti-CCP2 antibody ELISA (Immunoscan RA Mark 2; Euro-
diagnostica, Arnhem, The Netherlands) was performed according to the manufacturer’s 
instructions with a cut off value of 25 units. At present more than 1600 early arthritis 
patients are included in the EAC-cohort and have a follow-up of at least one year. 454 
patients fulfi lled the diagnosis of RA according to criteria of the 1987 American College of 
Rheumatology one year after inclusion in the study. The treatment of the patients in our 
longitudinal cohort study is characterized by a secular trend. The 122 RA patients (61 anti-
CCP negative and 61 anti-CCP positive) included between 1993 and 1995, were treated 
initially with analgesics and subsequently with chloroquine or salazopyrine if they had 
persistent active disease (delayed treatment); the 135 (70 anti-CCP negative and 65 anti-
CCP positive) RA patients included between 1996 and 1998, were promptly treated with 
either chloroquine or salazopyrine (early treatment) (for further description see 10). The 
197 RA patients (97 anti-CCP negative and 100 anti-CCP positive) included after 1998 
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were promptly treated with either methotrexate or salazopyrine (early treatment). The 
rheumatologists that treated the patients were not aware of the anti-CCP status of their 
patients because anti-CCP antibodies were not routinely determined at inclusion but were 
assessed for research purposes years after inclusion using stored serum samples. Patients 
gave their informed consent and the local Ethical Committee approved the protocol. 
Radiograpic progression
Radiographs of hands and feet were made at baseline, at one year and yearly thereafter. 
For 138 patients a complete radiological follow-up was available for 4 years. Inherent to 
an inception cohort, not all included patients had already completed 4 years of follow-up. 
Radiographs were scored using the Sharp-van der Heijde method (11). The rheumatologist 
that scored the radiographs was blinded to the clinical data and unaware of the study 
question. The distribution of radiological destruction of the small joints was studied by 
comparing the erosion score and joint space narrowing score of the metacarpophalangeal 
(MCP) and proximal interphalangeal (PIP) joints of the hands. 
Statistical analysis
Differences in means between groups were analysed with the Mann-Whitney test or t-test 
when appropriate. Proportions were compared using the chi square test. In the analysis 
of the tender joint count and the swollen joint count, for each joint location, the scores 
for the left and right joints were summed. Furthermore, the scores for the individual 
metacarpophalangeal joints were summed, as well as the scores for the metatarsophalan-
geal joints and the interphalangeal joints of the hands and feet. For the 138 RA patients 
with complete 4 year radiological follow-up, the swollen joint count, erosion score and 
joint space narrowing score were determined for the individual metacarpophalangeal and 
proximal interphalangeal joints of the hands at inclusion and 2 and 4 years follow-up, 
and expressed in mean with 95% confi dence interval (95% CI). The distribution and 
degree of radiological destruction and swelling of these joints was studied by comparing 
the variance of these scores for the individual joints. The 95% CI was used as a measure 
of variance; as the number of observations in this study is constant (138 patients at all 
time points during 4 years follow-up), the extent of the confi dence interval refl ects the 
degree of variance. Correlations between joint swelling and erosion score or joint space 
narrowing score were determined for each MCP and PIP joint of the hands using the 
Spearman correlation test. The statistical Package for Social Sciences (SPSS) version 12.0 










Early symptoms of disease
In total 454 patients fulfi lled the ACR-criteria for RA; 228 of these patients had anti-CCP 
antibodies and 226 patients had no anti-CCP antibodies at inclusion. Patient character-
istics and the type, localization and distribution of initial disease symptoms are depicted 
in Table 1. In both groups, 13% of patients reported to have no morning stiffness. In the 
patients that experienced morning stiffness the mean duration in the anti-CCP negative 
and anti-CCP positive patients was similar: 118 minutes and 123 minutes respectively. In 
both groups symptoms started with pain and swelling, predominantly symmetrical and 
in the small joints of the hands and feet. In the statistical analysis without correction 
for multiple testing, one difference in initial presentation between the two groups was 
observed: in anti-CCP positive patients symptoms started more often at both upper and 
lower extremities than in anti-CCP negative patients (20% vs. 11% respectively, p<0.05). 
Table 1. Characteristics of the early symptoms in rheumatoid arthritis patients with and without 
anti-CCP antibodies.
Anti-CCP– (N=228) Anti-CCP+ (N=226)
Female n (%) 147 (64%) 150 (66%)
Age at inclusion Mean ± SD 57 ± 17 55 ± 16
Morning stiffness No n (%)




123 ± 128 
















Localization of initial joint symptoms: n (%)
- small joints of hands and/or feet
- large joints










Localization of initial joint symptoms: n (%)
- upper limbs
- lower limbs




















VAS patients’ rated global disease activity (0-100) 51.3 ± 39.9 46.7 ± 28.2
HAQ-score (mean ± SD) 1.0 ± 0.7 1.0 ± 0.7
# Patients can have both swelling and pain at the start of the symptoms and therefore total can add 
to more than 100%. * P< 0.05, anti-CCP+ vs. anti-CCP–
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Given the marginal p-value, that was not signifi cant after correction for multiple testing, 
this fi nding was not considered a relevant difference. The mean patients’ rated global 
disease activity on a VAS was not signifi cantly different between the two groups. Likewise, 
the functional ability measured by a HAQ-score was similar in both groups. In conclusion, 
there are no fundamental differences in the early symptoms of disease between anti-CCP 
positive and anti-CCP negative RA patients.
Findings at physical examination at initial presentation
In each of the 454 patients a tender joint count and swollen joint count was performed 
at inclusion. The mean tender joint count per joint is presented in Table 2. There were 
no signifi cant differences between RA patients with and without anti-CCP antibodies. 
Table 3 reveals the mean scores for joint swelling for both anti-CCP positive and anti-CCP 
negative patients, showing no statistical signifi cant differences between the two groups. 
Thus, anti-CCP positive or negative RA patients cannot be distinguished at presentation 
by physical examination.
Table 2. Tender joint count (mean ± SD) at inclusion in rheumatoid arthritis patients with and 
without anti-CCP antibodies.
Anti-CCP- (N=228) Anti-CCP+ (N=226)
Temporomandibular joints 0.01 ± 0.41 0.08 ± 0.36
Sternoclavicular joints 0.23 ± 0.76 0.12 ± 0.47
Acromioclavicular joints 0.31± 0.63 0.55 ± 0.79
Shoulder joints 0.85 ± 1.5 0.86 ± 1.4
Elbow joints 0.42 ± 0.99 0.35 ± 0.81
Wrist joints 0.94 ± 0.94 0.80 ± 0.93
Metacarpophalangeal joints 4.3 ± 4.3 3.5 ± 3.4
Proximal interphalangeal joints of the hands 3.2 ± 3.6 3.3 ± 3.4
Distal interphalangeal joints of the hands 1.3 ± 2.4 1.2 ± 2.2
Hip joints 0.18 ± 0.73 0.11 ± 0.54
Knee joints 0.54 ± 0.88 0.59 ± 0.90
Ankle joints 0.41 ± 0.92 0.53 ± 1.1
Subtalar joints 0.31 ± 0.72 0.52 ± 0.76 
Midtarsal joints 0.21 ± 0.40 0.18 ± 0.58
Metatarsophalangeal joints 4.2 ± 3.4 4.1 ± 3.7
Interphalangeal joints of the feet 0.91 ± 1.8 1.4 ± 3.2
Total Ritchie articular index score 10.4 ± 8.2 10.2 ± 8.0
Tenderness was scored per joint on a 0-3 scale; 0 = no tenderness, 1 = pain at pressure, 2 = pain and 
winced and 3 = winced and withdrew. The scores for the metacarpophalangeal joints were summed, 
as the scores for metatarsophalangeal joints and the interphalangeal joins of the hands and feet. 
The scores for the left and right joints were summed. The summed scores were divided by the total 
numbers of patients; the resulting means (± SD) are presented. There were no statistical differences 








Acute phase reactant at initial presentation
The mean C-reactive protein level was 29.5 mg/L (SD 31.5) in the anti-CCP negative RA 
patients and 35.6 mg/L (SD 37.8) in the anti-CCP positive patients, and was not signifi -
cantly different between the two groups (p=0.08).
Swollen joints at follow-up
In the 138 early arthritis patients with complete radiological follow-up for 4 years the 
swollen joint count was assessed yearly. These patients had a mean age at inclusion of 
53.7 ± 13.9 years, 67% (93 patients) were women and 74 patients (54%) were anti-CCP 
positive. The total number of swollen joints decreased during follow-up. At inclusion, in 
the anti-CCP negative patients the mean (±SD) number swollen joint was 10.0 ± 7.2; at 
2 and 4 years follow-up the mean (±SD) number swollen joints was respectively 4.1 ± 6.7 
and 3.1 ± 4.2. The mean (±SD) number swollen joints in the anti-CCP positive group was 
at inclusion 8.6 ± 5.5; this decreased to 5.2 ± 7.5 and 5.3 ± 6.8 at 2 and 4 years follow-up 
respectively. At 4 years follow-up the total number of swollen joints was signifi cantly 
higher in the RA patients with anti-CCP antibodies (p=0.01).






Temporomandibular joints 0.01 ± 0.10 0.02 ± 0.18
Sternoclavicular joints 0.08 ± 0.34 0.04 ± 0.22 
Acromioclavicular joints 0.06 ± 0.24 0.03 ± 0.17
Shoulder joints 0.08 ± 0.30 0.12 ± 0.40
Elbow joints 0.22 ± 0.54 0.20 ± 0.49
Wrist joints 1.0 ± 0.89 1.0 ± 0.90
Metacarpophalangeal jointss 3.2 ± 3.0 2.2 ± 2.2
Poximal interphalangeal joins of the hands 2.6 ± 3.1 2.0 ± 1.8
Distal interphalangeal joints of the hands 0.32 ± 0.60 0.21 ± 0.60
Knee joints 0.46 ± 0.74 0.49 ± 0.74
Ankle joints 0.31 ± 0.67 0.34 ± 0.63
Subtalar joints 0.24 ± 0.61 0.21 ± 0.55
Metatarsophalangeal joints 1.6 ± 2.2 1.8 ± 2.4
Interphalangeal joints of the feet 0.06 ± 0.24 0.18 ± 0.58
Total number of swollen joints 10.0 ± 7.2 8.6 ± 5.5
Swelling was scored for each joint on a 0-1 scale, 0 = no swelling, 1 = swelling. The scores for the 
metacarpophalangeal joints were summed, as the scores for metatarsophalangeal joints and the 
interphalangeal joins of the hands and feet. The scores for the left and right joints were summed. The 
summed scores were divided by the total numbers of patients; the resulting means (± SD) are presented. 
There were no statistical differences between patients with and without anti-CCP antibodies. 
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In addition, the scores for the individual MCP and PIP joints of the hands were com-
pared. Overall the pattern of infl ammation of the individual small joints is similar in CCP-
negative and CCP-positive RA as is depicted by the means and 95% CI of the swollen joint 
count in Figure 1. Several individual joints had signifi cant higher scores in the anti-CCP 
positive patients compared to the anti-CCP negative patients; this concerned at inclusion 
the 1st MCP joint at the right side, at 2 years follow-up the 5th PIP joint at the left side and 
at 4 years follow-up the 1st MCP, 3rd PIP, 4th PIP and 5th PIP joints at the left side and 3th
PIP, 4th PIP and 5th PIP joints at the right side (p<0.05). Furthermore Figure 1 shows that in 
both anti-CCP positive and negative RA patients, the second and third MCP joints were 
more frequently swollen than other MCP joints. Likewise, in both groups the second and 
third PIP joints were more frequently affected than the other PIP joints. In conclusion, the 
pattern of infl ammation of the individual small joints of the hand seems similar in anti-
CCP positive and negative patients, however, particular at 4 years follow-up some MCP 
and PIP joints are signifi cantly less frequently swollen in anti-CCP negative RA patients.
Radiographic progression
In the 138 RA patients with complete 4 years radiological follow-up, the total Sharp-van 
der Heijde scores between the RA patients with and without anti-CCP antibodies were 
compared (Figure 2). At 2 and 4 years follow-up anti-CCP positive patients had signifi -
cantly higher radiological scores than anti-CCP negative patients (p<0.001). 
The distribution of the radiological destruction in the MCP and PIP joints of the hands 
was further investigated. The erosion scores and joint space narrowing scores of the MCP 
and PIP joints are depicted in Figure 3. As the most pronounced radiological destruction 
was present in anti-CCP positive patients, the erosion scores and joint space narrowing 
scores are shown for the RA patients with anti-CCP antibodies. Figure 3 shows that at 
all time points, of all MCP joints, the second MCP joints had the highest erosion score, 
followed by the third MCP joints. Concerning the PIP joints, the highest erosion scores 
were present in the third and fourth PIP joints. Figure 3 further reveals that the second 
and third MCP joints are the MCP joints with the highest joint space narrowing scores 
at all time points during follow-up. The joint space narrowing scores of the PIP joints 
differ less, but there are slightly higher scores for the third and fourth PIP joints. The ero-
sion scores and joint space narrowing scores for the patients without anti-CCP antibodies 
revealed the same distribution as for the anti-CCP positive RA patients (data not shown). 
In the anti-CCP negative patients the values for the mean and 95%CI were lower than in 
the anti-CCP positive patients, which is in concordance with the fi nding of lower total 
Sharp-van der Heijde scores in anti-CCP negative RA patients. Correlations between joint 
swelling and erosion score and between joint swelling and joint space narrowing score 








Figure 1. Joint swelling (mean and 95%CI) of the metacarpophalangeal and 
proximal interphalangeal joints of the hands at inclusion, 2 and 4 years follow-up in 
rheumatoid arthritis patients with and without anti-CCP antibodies.
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for all MCP joints, except the fourth MCP joints, the erosion score was signifi cantly cor-
related with joint swelling (p<0.05). The joint space narrowing scores were signifi cantly 
correlated with joint swelling in all MCP joints except the fourth MCP joint (p<0.05). This 
implies that at that time point the joints that were the most swollen were also the joints 
with the most severe radiological destruction. 
DISCUSSION
This study shows that the phenotype of RA patients with or without anti-CCP antibodies 
does not differ at clinical presentation. In a large prospective early arthritis cohort we 
observed neither a signifi cant difference in the reported fi rst symptoms nor in the signs 
found at the physical examination at initial presentation between anti-CCP positive and 
negative patients. However, during follow-up anti-CCP positive RA patients have more 
swollen joints and show more radiological destruction than anti-CCP negative RA pa-
tients. Remarkable is that at follow-up, in spite of the difference in magnitude of disease 
characteristics, the distribution of swollen joints and the distribution of radiological joint 
space narrowing and bone erosions remains similar for RA patients with and without 
anti-CCP antibodies. This implies that, although different associations with known risk 
factors are reported for anti-CCP positive and negative RA patients, the presence or ab-
sence of anti-CCP antibodies is not associated with a distinguishable clinical phenotype 
at presentation of disease. 
Figure 2. Total Sharp-van der Heijde scores (mean ± SEM) at inclusion, 2 and 4 years 








Figure 3. Erosion and joint space narrowing scores of the metacarpophalangeal and 
proximal interphalangeal joints of the hands (means and 95%CI) at inclusion, 2 and 4 
years follow-up in rheumatoid arthritis patients with anti-CCP antibodies.
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Pathophysiologically, this may have implications. It was recently observed that the 
prominent genetic risk factor HLA-Class II alleles only associate with susceptibility to RA 
in the presence of anti-CCP antibodies but not with RA in the absence of these antibodies 
(unpublished data, 5). In mice it has been shown that citrullination of arginine in a pep-
tide can lead to a higher binding affi nity of that peptide for HLA-DRB*0401, an important 
shared epitope allele (12), allowing peptide-specifi c T-cell induction. It can be speculated 
that also in humans citrullination may improve antigen presentation to CD4 positive 
T-cells and that the genetical background (presence of shared epitope alleles) provide 
the basis for a citrulline-specifi c immune reaction. It was demonstrated that anti-CCP 
antibodies occur years before disease onset (3,4). This last observation suggests that in 
anti-CCP positive RA patients the induction of disease occurs years before presentation, 
however the current study shows that the age of onset of clinical disease is similar in 
RA patients with and without anti-CCP antibodies. The risk factors such as HLA-alleles 
differ between anti-CCP negative RA and anti-CCP positive RA (5). Although differences 
in risk factors presume different pathophysiological pathways for anti-CCP positive and 
negative RA, the initial phenotypical presentation of both patient groups is similar and 
characterised by a symmetric poly-arthritis of the same small joints. At follow-up the 
clinical phenotype remains comparable with regard to joint distribution, but the anti-
CCP positive patients have more infl amed joints and once there is infl ammation also 
more rapid joint destruction. This leads to a pathophysiological model in which one or 
more triggers lead to arthritis in similar joints in anti-CCP positive and negative patients. 
Subsequently during infl ammation antigens are citrullinated and in the presence of anti-
CCP antibodies infl ammation is aggravated, resulting in more severe radiological destruc-
tion. Further studies are needed to add insight into the pathogenic role of circulating 
anti-CCP antibodies in anti-CCP positive RA and to unravel risk factors associated with 
anti-CCP negative RA.
In a study by Kastbom et al (13) several baseline disease characteristics of anti-CCP positive 
and negative RA patients were compared. This study observed no signifi cant differences 
in baseline total swollen joint count, C-reactive protein levels or DAS28 score between 
RA patients with and without anti-CCP antibodies, but showed a positive correlation be-
tween the number of fulfi lled ACR-criteria and the frequency of anti-CCP positivity (13). 
Furthermore, in this study anti-CCP positive individuals were more often treated with 
disease modifying antirheumatic drugs than anti-CCP negative patients (13). Although in 
the present study secular trends in the initial treatment strategies with disease modifying 
antirheumatic drugs were present, these trends yielded the same effect for the anti-CCP 
positive and negative RA patients. Furthermore, the rheumatologists that treated the pa-
tients were not aware of the anti-CCP status of their patients. Therefore, the more severe 








more delayed treatment of these patients or confounding by treatment adapted to the 
anti-CCP status. We cannot exclude that during follow-up the anti-CCP positive patients 
that had more infl amed joints received more aggressive treatment. However, in case of 
a more aggressive treatment during follow-up in anti-CCP positive patients, this did not 
prevent the development of more severe radiological destruction in the RA patients with 
anti-CCP antibodies. The fi nding that the swollen joint count decreased during follow-up 
is probably due to the fact that at inclusion patients were not treated with disease modify-
ing antirheumatic drugs.
The sensitivity of anti-CCP2 antibodies for RA is reported to vary between 39% and 80% 
(14,15). The present study measured anti-CCP2 levels at inclusion (a very early stage of 
the disease) and reports a relatively low percentage (50%) of RA patients with anti-CCP 
antibodies. As CCP measurements were not repeated during follow-up, we cannot exclude 
that some RA patients that were anti-CCP negative at inclusion have become anti-CCP 
positive on a later stage in the disease. A relatively low prevalence of anti-CCP antibodies 
in early arthritis patients has been described before (14).
The present study shows that the second and third MCP joints have the highest erosion 
scores, as well as the highest joint space narrowing scores and are, of all MCP joints, most 
frequently swollen. Although the present study was not designed to study the correlation 
between infl ammation and destruction, the observed similarity in joints that are affected 
by swelling, erosions and joint space narrowing supports the concept that in general the 
mechanisms leading to clinical infl ammation and radiological destruction are related. 
This study includes a detailed description on the distribution of affected joints in RA and 
shows that the MCP joints of the second and the third digits are most frequently infl amed 
and destructed. Although to our experience rheumatologists generally feel that the joints 
of the second and third digits are more frequently infl amed than other joints of the hands, 
to our knowledge this phenotypic characterisation has not been frequently described. 
CONCLUSION
The present study shows that, although separate risk factors for anti-CCP positive and 
negative RA were recently described, the clinical presentation of RA patients with or with-
out anti-CCP antibodies is not different. Patients with anti-CCP antibodies develop a 
more severe disease course with more radiological destruction compared to RA patients 
without these auto-antibodies. Nonetheless, also at follow-up the distribution of affected 
joints is similar.
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Chapter 12
The invasiveness of fi broblast-like 
synoviocytes is an individual patient 
characteristic associated with the rate 
of joint destruction in patients with 
rheumatoid arthritis
















Objectives. Rheumatoid arthritis (RA) is characterized by infl ammation and destruction 
of synovial joints. Fibroblast-like synoviocytes (FLS) harvested from synovial tissue from 
patients with RA can invade normal human cartilage in severe combined immunodefi -
ciency disease (SCID) mice and matrigel in vitro. This study was undertaken to investigate 
the association of these in-vitro characteristics with disease characteristics in patients 
with RA.
Methods. Synovial tissue samples of 72 RA and 50 OA patients were obtained; from 
7 patients with RA samples of different joints were collected. The FLS invasiveness in 
Matrigel matrix was studied; the intra-individual and inter-individual differences were 
compared. Of the patients with the FLS that exhibit the most extreme differences in in-
vitro ingrowth (most and least invasive FLS) the X-rays of hand and feet were collected 
and read according to the Sharp-van der Heijde method to determine the relationship 
between in vitro invasion data and estimated yearly joint damage progression.
Results. FLS from patients with RA were more invasive than FLS from patients with OA 
(P < 0.001). The mean intra-individual variation in FLS invasion was much less than the 
mean inter-individual variation (mean ± SD 1067 ± 926 and 3845 ± 2367 for intra-indi-
vidual and inter-individual variation, respectively; P = 0.035), which shows that the level 
of FLS invasion is a patient characteristic. The mean ± SEM Sharp score on radiographs of 
the hands or feet divided by the disease duration was 4.4 ± 1.1 units per year of disease 
duration in patients with the least invasive FLS (n = 9), which was much lower compared 
with the 21.8 ± 3.1 units per year of disease duration in patients with the most invasive 
FLS (n = 9) (P < 0.001).
Conclusions. The ex vivo invasive behaviour of FLS from patients with RA is associated 
with rate of joint destruction and is a patient characteristic given the much smaller intra-
individual than inter-individual variation.
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease which predominantly targets the sy-
novial joints ultimately leading to joint destruction. The destructive process is suggested 
to be mediated, at least in part, by fi broblast-like synoviocytes (FLS) from the synovium, 
because in a severe combined immunodefi ciency disease (SCID) mouse co-implementa-
tion model it was demonstrated that FLS of patients with RA attach to and invade in 
normal cartilage (1). Moreover, many groups have observed that in RA, FLS show char-
acteristics of transformed cells like anchorage independent growth (2), insensitivity to 
apoptosis, and increased proliferation. Processes that are associated with the FLS-change 
from normal to aggressive behaviour are phosphorylation of the signal transducer and ac-
tivator of transcription (STAT3) protein and elevated levels of the pro-oncogene c-myc (3). 
Whether these features are non causal associations or a causal factor is not yet known. FLS 
in culture express large amounts of proteases which can degrade extracellular matrix com-
ponents such as collagens. One family of proteases that is expressed by FLS are the matrix 
metalloproteinases (MMPs). FLS express MMP-1, -3, -9 and -10 and expression of these 
MMPs correlate with invasion (4). Other protease families that are expressed in RA FLS are 
the cathepsins and ADAMs (a disintegrin and metalloproteinase). FLS from patients with 
RA express several oncogenes at higher levels than FLS from normal controls. Oncogenes 
that are upregulated in RA are c-myc (11), Ras (5) and p53 (6,7). These data have led to 
the suggestion that aspects of behaviour of FLS in RA resemble malignant tissue. However 
whether the transformed behaviour is of relevance for the disease characteristics of RA 
and if so for which characteristics has not been studied. The present study investigates the 
association of in vitro characteristics of FLS with disease characteristics in RA patients. We 
particular adressed the questions 1) whether the degree of FLS invasion is comparable in 
different joints of the same patient, i.e. is the FLS invasiveness a characteristic occurring at 
multiple joints of the same patient or rather a random process, and 2) whether the degree 
of in vitro invasion is correlated with the degree of radiological destruction.
MATERIALS AND METHODS
Patients and synovium
Synovial tissue was obtained from 122 patients (72 with RA and 49 with OA) at joint 
replacement surgery or synovectomy. 69% of the patients with RA were female and the 
mean age was 60 years ± 14. The samples were obtained from knee (53 patients), elbow 
(17 patients), shoulder (12 patients), hip (26 patients), ankle (7 patients), wrist (4 patients) 
and foot (1 patient). All patients with RA met the criteria of the American College of 








ile phosphate buffered saline (PBS). Connective tissue and fat were removed and tissue 
was digested with collagenase IA (1 mg/ml; Sigma, St Louis, MO, USA) for at least two 
hours at 37°C. Cells were separated from the tissue using a 200 mm fi lter (NPBI, Emmer-
Compascuum, The Netherlands) and cultured in 75 cm2 culture fl asks (Cellstar, Greiner, 
Alphen aan de Rijn, The Netherlands) with Iscove’s modifi ed Dulbecco’s medium (IMDM; 
Biowitthaker, Verviers, Belgium) supplemented with glutamax (GibcoBRL, Paisley, UK), 
penicillin and streptomycin (Boehringer Mannheim, Germany), and 10% fetal calf serum 
(FCS; GibcoBRL, Paisley, UK) at 37°C and 5% CO2. When the cells had grown to confl u-
ence they were detached with 0.25% trypsin and split in a 1:3 ratio. For invasive growth 
analysis passage 1 or 2 FLS were used. Light microscopy and Giemsa staining indicated 
that more than 95% of cells were FLS. As a control for the possible contamination of 
macrophages in the cell source, we reasoned that after several passages the macrophages 
will be gone. Thus the invasiveness of FLS from several patients was tested for several pas-
sages. This revealed stable invasiveness for several passages. Moreover, FACS staining of a 
randomly chosen subset of the samples revealed absence of CD14-positive cells.
In vitro invasion assay
Invasiveness of FLS was measured as described previously (4). Briefl y, Transwells (6.5 mm 
diameter, 8.0 mm pore width; Costar, Cambridge, NY, USA) were coated with paraffi n 
to avoid meniscus formation. Hereafter, the transwells were pre-incubated with 100 ml 
IMDM for 30 minutes at 37ºC. Transwells were coated overnight with 100 ml of 0.375 
mg/ml Matrigel (Matrigel basement membrane matrix; Becton Dickinson, USA) in IMDM 
under sterile conditions in a laminar fl ow cabinet. The next day the Matrigel-coated wells 
were incubated with 100 ml IMDM for 1 hour at 37ºC. Cells were harvested as described 
above and after removal of the medium, 200 ml of 100,000 FLS/ml in IMDM was seeded 
in the inner compartment of the transwell system. In the outer compartment, 900 ml 
IMDM/10% FCS/10% human serum was pipetted and the cells were incubated for 3 days 
at 37ºC and 5% CO2. After 3 days, the cells were fi xed with 2% glutaraldehyde in PBS for 
30 minutes at room temperature. After removal of the glutaraldehyde and subsequent 
washing with PBS, the cells were stained with a crystal violet solution for 30 minutes 
at room temperature. The cells were thoroughly washed with PBS and the cells that did 
not invade through the transwell membrane were removed together with the matrix by 
cleaning the inner wells of the transwell system with a cotton bud. The number of cells 
that had grown through the matrix and the transwell membrane were counted under a 
light microscope. All experiments were carried out in duplicate. 
Radiological destruction and FLS characteristics
To compare the association between the degree of FLS invasiveness and joint destruction, 
the radiographs of hands and feet of the patients with the most invasive FLS (9 patients) 
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and least invasive FLS (9 patients) were scored according to the Sharp/van der Heijde 
method (8). The person that scored the radiographs was unaware of the clinical data and 
study question. The total erosion and joint space narrowing scores, as well as the total 
Sharp-van der Heijde scores, were divided by the disease duration from date of diagnosis 
to determine the radiological progression per year (9).
Statistical analysis
Differences in invasiveness of FLS between patients, differences between intra-individual 
and inter-individual variation and the radiological scores of the patients with the most 
and less invasive disease were compared with the Mann-Whitney test.
RESULTS
FLS were isolated from these tissues and cultured. When the cells had grown to con-
fl uency, the cells were harvested and tested for invasiveness as described before (4). RA 
FLS were signifi cantly more invasive than OA FLS in this assay (p< 0.001 mean ± SD 
2884±2326 and 4573±2502 for OA and RA respectively; Figure 1). These results are in line 
with previous studies (1;4).
Then it was studied whether the invasiveness of FLS from different joints operated at 






































































Figure 1      Figure 2
Figure 1. In vitro invasiveness of FLS from patients with RA (72) and OA (50). Each dot 
represents one individual. Invasiveness was measured using a transwell system coated with matrigel. 
The number of invasive cells was determined by counting the number of cell under the fi lter.
Figure 2. In 7 RA patients in vitro invasiveness of FLS was obtained from two 
different joints. Synovial samples were obtained at different times, and invasiveness was 
measured using a transwell system coated with matrigel. The number of invasive cells was 
determined by counting the number of cell under the fi lter. Tissue samples were obtained from hip 








different samples were obtained from two different joints. The differences in invasive-
ness within the different samples of individual patients was signifi cantly less than the 
differences in invasiveness between patients (p= 0.035; median difference ± SD: 1067 ± 
926 and 3845± 2367 for intra- and inter-individual variation respectively). The results are 
shown in Figure 2. From the group of OA patients, three patients were operated twice. 
This group was too small to analyse the differences between intra-individual and inter-
individual variation. Thus, the variation within patients is smaller than the variation 
between patients.
Next it was adressed whether the in vitro invasiveness of FLS was correlated with radiologi-
cal joint destruction in RA. It has been published that the estimated yearly progression 
rate obtained by dividing the Sharp-van der Heijde score of radiographs of hands and feet 
by the disease duration correlated well with the observed destruction rate in observational 
studies with multiple measurements (9). Therefore, we assessed the association between 
invasiveness of FLS and radiological joint destruction. The Sharp-van der Heijde scores 
from the nine most invasive and the nine least invasive FLS were determined and the 
estimated yearly progression rates were compared (Figure 3). For the patients with the 
most invasive FLS the total Sharp-van der Heijde score per year disease duration is 21.8 
(SEM 3.1), with an erosion score of 13.3 (SEM 1.7) and a narrowing score of 8.5 (SEM 1.6). 
For the patients with the least invasive FLS, the total Sharp-van der Heijde score per year 
disease duration is 4.4 (SEM 1.1), with an erosion score of 2.5 (SEM 0.7) and a narrowing 
score of 1.9 (SEM 0.5). No difference in disease duration was observed between patients 
with most and least invasive FLS (15.9 ± 11.5 versus 15.0 ± 7.3 years respectively; p=0.85). 
These results show a strong association between invasiveness of FLS and radiologically 
estimated yearly rate of joint destruction (p<0.001).
Figure 3. Association between in vitro invasiveness of FLS and estimated yearly 
radiological progression. From the nine most invasive and the nine least invasive RA patients 
the radiographs of hand and feet were scored according to the Sharp-van der Heijde method. 
The total Sharp-van der Heijde scores were divided by disease duration to determine the yearly 
radiological progression.
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DISCUSSION
This study shows that in RA the intra-individual variation in FLS invasiveness is much 
less than the inter-individul variation, indicating that the invasive behaviour is a charac-
teristic of an individual RA patient. Furthermore, this study shows for the fi rst time that 
the in vitro FLS invasiveness is associated with radiological joint destruction. Patients 
with the least invasive FLS have signifi cantly lower Sharp-van der Heijde scores per year 
disease duration compared to the patients with the most invasive FLS. This suggests that 
the invasive behaviour of FLS is of relevance for the pathogenesis of RA.
The fi nding of a rather large variation in rate of invasion of FLS between patients implies 
that the mechanism or processes underlying invasive behaviour differs between individu-
als. The mechanism that leads to transformation of FLS is not fully understood.
Previous studies have shown a myriad of alterations in the behaviour of FLS in RA. One 
very striking change in FLS is the expression of oncogenes (10). Oncogenes that are 
upregulated in RA are c-myc (11 ;12), Ras (5), p53 etc. Inhibition of the Ras pathway 
reduced expression of MMP-1 and MMP-3. Inhibition of both Ras and c-myc pathways 
also reduced invasion into normal human cartilage in the SCID mouse coimplantation 
model (13). And it is demonstrated that down-regulation of p53 infl uences proliferation 
and invasion of RA FLS (14;15). Transformation of FLS is different in different individuals, 
suggesting that a genetic component plays a role. 
This study shows that the transformed behaviour of FLS in patients with RA is a pa-
tient characteristic and is strongly associated with clinical joint destruction. We used FLS 
from passages 1 and 2 in this study. Although no macrophages were detected in these 
samples by light microscopy and Giemsa staining, and no CD14-positive cells were de-
tected in a randomly chosen subset of the samples, we cannot exclude unambiguously 
that macrophages contaminated the cells. However, the experiments in which FLS from 
different passages and from different donors were compared yielded similar levels of in-
vasiveness, which is evidence against major artefacts from macrophages. Further research 
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Chapter 13
Variation in radiological joint destruction 
in rheumatoid arthritis differs between 
monozygotic and dizygotic twins and 
pairs of unrelated patients






Genetic contribution to RA severity 141
Currently, the research on genetic factors associated with rheumatoid arthritis (RA) fl our-
ishes and the number of genetic factors found to associate with RA susceptibility has 
expanded in the latest years. Besides the long-known HLA class II alleles, a R620W SNP 
in the PTPN22 gene has been identifi ed and replicated in several different populations 
(1). A number of other SNPs also confer risk to RA; some of them await replication or 
gave distinct results in different populations (2). The total genetic contribution to RA 
susceptibility is estimated by comparing monozygotic and dizygotic twins and is reported 
to account for 50-60% of the population liability to the disease (3). As the HLA-Class II 
alleles account for about one third of the genetic contribution, it is expected that in the 
nearby future more genetic factors will be identifi ed. Currently most attention is paid on 
the role of genetics in RA susceptibility. So far the contribution of genetics to RA severity 
is not known. The recognition of genetic factors associating with RA severity might be 
helpful in predicting the disease course and may lead to the identifi cation of pathways 
involved in joint destruction. To get more insight in the role of genetics in RA severity, 
the present report investigates the variability in radiological joint destruction between 
monozygotic and dizygotic twins and random pairs of unrelated RA patients.
This study includes the monozygotic (n=20) and dizygotic (n=8) twins with RA that were 
enrolled in the North American RA Consortium (NARAC). The unrelated RA patients were 
included in the Leiden Early Arthritis Cohort (EAC) (4). The median disease duration at 
the time of the radiograph was 9 years in dizygotic twins and 10 years in monozygotic 
twins. The monozygotic twins were all rheumatoid factor positive (see Table 1). To match 
for differences in era of disease onset and autoantibody status, the unrelated RA patients 
selected from the EAC cohort were rheumatoid factor positive and included in the cohort 
in the early or mid ‘90 years. This resulted in 40 persons with available radiographs made 
after 8 years of disease; these patients were by the computer assigned in 20 random pairs. 
All subjects were Caucasian and had radiographs of the hands scored according to the 
Sharp-Van der Heijde method (5) by a rheumatologist that was unaware of the clinical 
data (intraclass correlation coeffi cient for repeated readings 0.96, 95% confi dence interval 
0.83-0.99). To correct for differences in disease duration, for every subject the Sharp score 
was divided by the disease duration at the time of the radiograph, yielding the estimated 
radiological progression per year (6). To determine the variation in joint destruction, for 
every pair of RA patients, the difference in radiological progression per year was calcu-
lated. Subsequently, to evaluate the variation in joint destruction in the different groups 
of patients, the mean difference and variance in radiological progression per year were 
compared between monozygotic and dizygotic twins and unrelated patients with RA.
Patient characteristics and results on radiological joint destruction scores are presented in 








of unrelated patients (p< 0.001 Mann Whitney test). The mean estimated radiological 
progression per year was not signifi cantly different among the groups of monozygotic 
twins, dizygotic twins and unrelated RA patients. However, the variation in joint destruc-
tion was the highest within the pairs of unrelated RA patients (mean difference 4.3 Sharp 
points per year), followed by the dizygotic twins (mean difference 2.4 Sharp points per 
year) and the smallest difference was observed within the monozygotic twins (1.7 Sharp 
points per year), with a signifi cant difference between the monozygotic twins and unre-
lated RA patients (p=0.037, Mann Whitney test). The fi nding of an increasing variation 
in degree of joint destruction comparing respectively monozygotic twins, dizygotic twins 
and unrelated pairs of RA patients supports the notion of a role for genetic factors in RA 
severity. 
The current report indicates that genetic factors are associated with the severity of joint 
destruction during the disease course of RA. This study has some limitations. First, as the 
number of dizygotic twins was low, the heritability could not be properly calculated. Clas-
sic twin studies compare monozygotic and dizygotic twins and are based on the principle 
that the environmental factors within twin pairs are (mostly) comparable and that the 
contribution of genetic factors to covariance within dizygotic twins is half that of mono-
zygotic twins. Unrelated patients are not used for quantifying the genetic contribution, as 
these patients differ in genetic as well ass environmental factors. Nevertheless, as RA starts 
and progresses at adult age, environmental factors are presumably also different within 
twin pairs. Therefore, comparison of mono- with dizygotic twins as well as twins with 
unrelated patients may be relevant. The current report added data on unrelated pairs of 
Table 1. Patient characteristics and radiological joint destruction scores of monozygotic and 





Unrelated RA patients 
random pairs (n=40)
Gender, % female 70 63 65
Age at diagnosis, 
mean ± SD 
37.1 ± 11.4 31.5 ± 17.3 53.8 ± 12.3#
Disease duration at radiograph, 
median
10.5 9.0 8.0
Rheumatoid factor positivity, % 100 63 100
Estimated radiological progression 
per year ¶, mean ± SEM
2.8 ± 0.6 1.7 ± 0.8 3.3 ± 0.6
Difference in Sharp scores per year 
within pairs, mean 
1.7 2.4 4.3 *
variance 3.3 6.1 16.1
# p< 0.001 unrelated RA patients versus monozygotic as well as dizygotic twins
* p= 0.037 unrelated pairs of RA patients versus monozygotic twins
¶ Sharp score of the hands divided by the disease duration at the time of the radiograph
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RA patients to dizygotic and monozygotic twin data and observed an increase in variation 
in joint destruction parallel to a decrease in genetic similarity, indicating that genetics 
factors are important for the severity of joint destruction in RA.
It might be a concern that twins and unrelated RA patients, although both Cauca-
sian, came from different continents. However, comparison of Sharp scores of American 
and Dutch early RA patients not treated with disease-modifying antirheumatic drugs 
(DMARDs) revealed similar scores (7,8).
The most important risk factor for RA severity is the autoantibody status. The unrelated 
RA patients were matched for rheumatoid factor comparable to the monozygotic twins. 
Matching on anti-CCP status was not possible as anti-CCP antibodies were determined in 
only a part of the twins. As the presence of autoantibodies associates with the presence 
of HLA-shared epitope alleles (9), it is likely that by matching for autoantibodies patients 
were also partly corrected for differences in shared epitope status. This might have under-
estimated the difference in variation due to genetic factors.
Given the hypothetical effect of the difference in age of onset between the twins and 
unrelated RA patients on the rate of joint destruction, the Sharp scores of EAC patients 
<35 and >60 years were compared, showing no signifi cant difference during 4 years fol-
low-up.
The patients included in this study were diagnosed with RA in the ‘80 years or begin-
ning of the ‘90 years. We did not provide detailed descriptions of treatment history of 
all patients and cannot exclude differences in treatment. Nevertheless, in the mentioned 
time era’s therapy with DMARDs was started in a relatively late stage and medications 
of choice were among others antimalarials, of which is known that their ability to halt 
disease progression is limited. Therefore, we suspect that considering the relatively mild 
medications used in the ‘80 and begin ‘90, the natural disease course of the patients is 
only limited affected.
In conclusion, the present study observed after correction for differences in disease dura-
tion and autoantibody status an increase in variation of radiological joint destruction 
comparing respectively monozygotic twins, dizygotic twins and unrelated pairs of RA 
patients. This indicates to an important contribution of genetic factors to radiological 
joint damage in RA. More extensive twin studies are needed to quantify the genetic con-
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Chapter 14
Genetics and clinical characteristics to 
predict rheumatoid arthritis. Where are 
we now and what are the perspectives?











In medicine, the perspective of prediction contains three major issues: the variability 
of the host, the characteristics of the disease-causing agent and the interaction between 
these factors (the disease process itself). The current review focuses on the prediction of 
RA in patients with undifferentiated arthritis. Data from inception cohorts have revealed 
that in about a third of the patients presenting with recent onset arthritis to a rheuma-
tologist no diagnosis can be made, so-called undifferentiated arthritis. In a portion of 
these patients RA develops, whereas a substantial portion remits spontaneously. Current 
epidemiological data on RA incidence rates are compatible with host (genetic) factors be-
ing an independent predictor of susceptibility to RA. The majority of the genetic factors 
have still to be identifi ed but HLA-alleles and PTPN22-alleles have now been identifi ed as 
risk factors in a number of populations. Disease characteristics such as anti-CCP antibod-
ies and erosions on X-rays are identifi ed as being of high predictive value. In the future, 
models that take into account both genetic and clinical characteristics will have to be 
evaluated in patient groups with undifferentiated arthritis in order to establish the ac-
curacy of these models in predicting with an 80% probability the chance on progression 
to RA. Such prediction models will be of help in treatment decisions in these patients.
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INTRODUCTION
A number of different items are used in clinical prediction models. These items vary from 
variability of the host, the variability of the causing agent, and variability in the disease 
process and fi nally the dynamics of the interaction that takes time into account as well. 
Examples of the relevance of measuring pure host characteristics are e.g. the BRCA-1/2 
carriership in families with a history of breast/ovarian cancer. Examples of the relevance 
of the characteristics of the disease-causing agent in sensu strictu are the causing micro-or-
ganisms in infectious diseases such as in community-acquired pneumonia. An example in 
rheumatology when both host and causing agent determine susceptibility is that certain 
micro-organisms (e.g. Chlamydia) particularly cause disease (reactive arthritis) in hosts 
that are HLA-B27 positive. Examples to detect differences in prognosis by studying the 
mode of interaction of host and disease-inducing process are the study of characteristics 
of diseased tissue such as micro-array studies in breast cancer. An example when the evo-
lution of the disease over time is included in the determination of a response parameter 
is cervical abnormalities detected by a slightly abnormal cervical smear test. The value 
of such a test can be that the cervical smear test is advised to be repeated within three 
months to see whether natural regression of the abnormalities has occured or whether 
progression to abnormalities indicative of precancerous characteristics has occurred.
The outcome of a prediction model can be the development of a disease or disease sever-
ity. In rheumatology and particularly in rheumatoid arthritis (RA), physicians generally 
want to avoid morbidity and disability. Existing prediction models are therefore built to 
predict chronicity and erosiveness. Prediction models are of importance as they might 
help in treatment decisions. They may guide the choice in treatment options between 
wait and see, start with a relative mild treatment or initiate aggressive treatment di-
rectly. The current evidence on (early) treatment of RA is based on large trials with 
RA patients, in which RA is defi ned according to the ACR criteria. Inception cohorts 
include patients in who during the fi rst visits with the current methodology a diagnosis 
can directly be made (about 60% of patients). About forty percent of patients in incep-
tion cohorts have a form of arthritis in which no defi nite diagnosis can be made; these 
patients are identifi ed as undifferentiated arthritis (UA). These UA patients can go into 
remission, develop RA or develop other diagnosis (see Figure 1)(1). At present no data 
on the effects of treatment of UA patients are available. Early treatment of the patients 
with UA that will develop RA might be benefi cial, whereas treatment of the group that 
will remit spontaneously is potentially harmful. The spontaneous remission rate of UA 
patients is about 40% (1). As current knowledge on the effects of treatment in RA is 
based on patients with RA classifi cation according to the ACR-criteria it will be helpful 








in most cases synonymous with prediction of disease persistency as the remission rate 
of RA is about 10-18% (2,3). 
The current review is focussed on prediction of RA. The following sections will review 
the evidence that pure host characteristics are informative, pure disease characteristics 
are relevant and which evidence is available that a combination of disease characteristics, 
host characteristics and natural course allows prediction. The applicability of prediction 
models is also determined by basic epidemiological rules and the predictive value of a 
test/model is dependent on the prevalence of the disease in a given population. For the 
question on genetic testing “where we are now and what are the perspectives” this is rel-
evant because most current data on genetic factors describe the comparison between cases 
and healthy controls. These are relevant data to undrape pathogenesis, but are diffi cult to 
be interpreted with regard to relevance in diagnostic testing in individual patients. 
VARIABILITY IN THE HOST DETERMINES INCIDENCE OF RA
This hypothesis has a number of relevant implications for RA. First, it assumes that the 
trigger or triggering events for RA are common and therefore the opportunity to encoun-
ter these triggering events is not the limiting or determining factor. Second, it has implica-
tions on the thoughts whether RA is one disease or an assembly of truly different diseases 
and third it assumes that a number of DNA variants are associated with disease and that 















Figure 1. Flow diagram of inception cohort.
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Does RA have a common trigger?
The assumption that RA has a common or a combination of commonly available triggers 
imply that such triggers can be encountered in most populations. An argument in favour 
of this assumption is that RA is a worldwide condition indicating that the triggers lead-
ing to RA are worldwide available. The incidence of RA is age related, with a higher RA 
incidence with higher age. This age-related incidence of RA provides some evidence how 
many triggers are needed to get RA. Roberts-Thompson et al. studied population data 
obtained from the Australian Bureau of Statistics in order to assess the number of events 
necessary leading to RA (4). By computer modelling in which the age-specifi c incidence 
rates, the proportion of population at risk and the age at onset are included, the number 
of random events that must occur for the disease to manifest (given a stochastic model) 
was calculated. This number varied somewhere between 4 and 6 events. In inception 
cohorts, the patients with UA at inclusion that after 1 year of follow-up had persistent UA 
were signifi cantly younger than the UA patients that during the fi rst year developed RA 
(1). The difference in age between the groups that do and do not progress to RA might 
reveal a difference in time period and subsequent chance to acquire suffi cient numbers 
of triggering events.
RA has a variable incidence in different populations. In Pima Indians the incidence rates 
in the same time periods were 10 times higher than in the Caucasian US population and 
5 times higher than in the Japanese population (5). This implies that the frequency of the 
events leading to RA is different in the different populations and/or that the host factors 
in the different populations differ. The relative contribution of genetic or environmental 
factors is diffi cult to determine, but based on studies of populations that have migrated 
to different environments, it is likely that the majority of the difference in rates of RA in 
different populations can be explained by genetic factors (6). Moreover, the differences 
in the frequency of the identifi ed genetic risk factor for RA, the HLA-alleles encoding the 
shared epitope, associate with the frequency of RA in the respective populations (7). An 
additional argument that RA is caused by commonly available triggers is the absence of 
geographical clustering of RA incident cases (8). In the aggregate, these data suggest that 
in modern lifestyle a combination of triggers is common in a variety of cultures but that 
host characteristics determine whether these triggers can lead to RA. 
Further understanding can be achieved by studying populations among whom RA is 
not prevalent. A study in indigenous people (Aboriginals) in Australia found no paleo-
pathological or ethnographical evidence to support the existence of RA before white 
settlement (9). Similarly in a rural Nigerian population RA was not observed (10) indicat-
ing that either the common trigger was not present at that time or that these populations 
are genetically protected. Arguments for this last statement are the much lower frequency 
of HLA-DR alleles encoding RA risk alleles in these populations. Careful studies have now 








prior interracial marriage was found. This indicates that genetic admixture is necessary for 
development of RA. Yet, a contribution of changing lifestyles that is concomitant to racial 
admixtures cannot be easily excluded.
In a study from Minnesota that studied RA incidence rates from 1955 to 1995, the 
incidence rate fell progressively over the 4 decades of study, from 61.2/100,000 in 1955-
1964, to 32.7/100,000 in 1985-1994 (11). A Japanese study showed that the incidence 
rates fell in Japan as well and the falling incidence rates over time have occurred in diverse 
populations such as Indians and Finnish (12). There are several possible explanations 
for the decrease in RA incidence. As this decrease is apparent in various populations, an 
explanation is likely a factor that has an identical effect in all populations throughout 
the world in the birth cohorts from 1890 to 1950. It is proposed that this is caused by a 
change in the population genome (13). The explanation for this genetic drift is that in 
previous times, human reproductive success was very unevenly distributed, with a minor-
ity of fertile women who gave birth to the majority of newborns. For example, in the 1912 
Australian census, 50% of the children were the offspring of 1 in 7 of the women (14). 
However, in recent times this predominance steadily decreased since both fertile and less 
fertile women have equally contributed to the next generation. There are also other ex-
planations for the decrease in RA incidence rates over time. Besides a real time dependent 
decline in RA, changing methodology in classifi cation may be also important (15). In 
addition to a decrease in RA incidence, a decrease in RA severity over time is also reported. 
This decline seems to be contributable to earlier and more aggressive treatment (16).
In summary, the overview of the studies on incidence rates of RA are compatible with 
the notion that host characteristics are the major factors that drive whether a patient will 
develop RA. We suggest that most persons nowadays will encounter those 4-6 trigger-
ing events and that host factors are the driving force to explain differences in incidence 
rates. 
What is the evidence in support of the assumption that RA is one 
disease versus an assembly of different diseases? 
At present, RA is formally diagnosed when patients fulfi l the criteria that were formulated 
by the ACR in 1987. Whether the patients that have RA according to these criteria, all have 
the same disease -characterised by an identical pathogenesis-, is questionable. Recently it 
was observed in a European and American population that RA patients carrying anti-
bodies to citrullinated proteins (anti-CCP antibodies) have an association with different 
genetic risk factors than patients that lack these antibodies. The shared epitope encoding 
HLA-alleles only conferred risk to anti-CCP positive RA and not to anti-CCP negative RA 
(17). Anti-CCP antibodies are reported to have high disease specifi city and are often pres-
ent before the clinical presentation (18,19); anti-CCP antibodies are therefore thought to 
play a role in RA pathogenesis. The fi nding that the shared epitope alleles only correlate 
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with anti-CCP positive disease strongly suggests that RA patients that have anti-CCP anti-
bodies have differences in the pathophysiological pathway compared to RA patients that 
are anti-CCP negative. This consequently induces the question whether anti-CCP positive 
and negative RA are different disease entities with distinct clinical characteristics. In a re-
cent study RA patients with and without anti-CCP antibodies were extensively compared 
with regard to clinical characteristics. No differences were found in the characteristics on 
disease presentation between these two patient groups: among others the age of disease 
onset, the type of initial symptoms, the distribution of initial symptoms, the presence 
and duration of morning stiffness, and the number and distribution of painful or swollen 
joints was similar in anti-CCP positive and negative RA patients (20). From these data it 
can be concluded that different pathophysiological pathways end in one phenotypical 
presentation of the disease. Specifi c characteristics of the host such as the presence of 
anti-CCP antibodies subsequently associate with the course of the disease.
Which potential genetic risk factors for RA are known?
The HLA Class II molecules are the most powerful recognized genetic factors so far for 
RA, contributing to at least 30% of the total genetic effect. The HLA-DRB1 alleles *0101, 
*0102, *0401, *0404, *0405, *0408, *1001, *1402 share a conserved amino acid sequence 
at position 70-74 in the third hypervariable region of the DRβ1 chain. These residues 
constitute an α-helical domain forming one side of the antigen presenting binding site. 
The Shared Epitope hypothesis postulates that the shared epitope motif itself is directly 
involved in the pathogenesis of RA by allowing the presentation of an arthritogenic pep-
tide. Extensive evidence exists showing associations between the shared epitope encoding 
alleles and susceptibility to RA. The presence of shared epitope encoding alleles is associ-
ated with odds of 3-4 to develop RA (21,22). 
The second genetic risk factor is a risk allele of a haematopoietic-specifi c protein tyrosine 
phosphatase, PTPN22. This allele was identifi ed in 17% of the North American white con-
trols and 28% of the RA patients and confers odds of about 2 to develop RA (23-26). This 
allele changed the function of the protein that functions as negative regulator of T-cell 
activation, leading to T-cells with a lower threshold for T-cell activation. This mutation is 
apparently leading to several autoimmune diseases since this mutation also conferred risk 
for SLE, type 1 diabetes and Graves disease (27,28). The last years an increasing number of 
SNPs associated with RA have been identifi ed. Some of them have not been replicated and 
some show different results in different populations. A genetic risk factor that is currently 
under investigation and seems to be associated with RA, diabetes and myocardial infarc-
tion, is MHC2TA. This SNP associates with a lower expression of MHC molecules and in a 
Swedish cohort of 1288 RA patients and 709 controls; this SNP conferred a 1.3 higher risk 
to develop RA (29). The fi ndings on this SNP await replication. In Japanese patients and 








that tend to inherit together) of the gene encoding PADI4 with increased susceptibility 
to RA was observed (30). The RA-susceptible PADI4 variant was shown to produce a more 
stable transcript than the non-susceptible variant, implying an increased production of 
PADI4 and therefore higher level of citrullination by the RA-susceptible variant. Unless a 
higher level of citrullination, the described PADI4 haplotypes did not correlate with (the 
level of) anti-CCP antibodies (30). The association of PADI4 with RA is shown in the Japa-
nese population. Data from Caucasians from France and the UK showed no association 
with PADI4 haplotypes and RA (31,32). Susceptibility genes can interact such that the 
resulting predisposition of carrying both genes is larger than the summed odds ratios of 
the individual genes. The presence of such interaction is important with regard to predic-
tion. In 820 Japanese RA patients and 620 controls a risk for RA of 1.3 was identifi ed for a 
risk allele in the organic cation transporter gene SLC22A4 9(33). Intriguingly, the identi-
fi ed SNP affects the transcriptional effi ciency of SLC22A4 in vitro by altering the binding 
affi nity of a haematopoietic transcription factor, called RUNX1. A small but signifi cant 
association was observed with the minor allele in the RUNX1-gene. Importantly homo-
zygosity for both susceptibility alleles (SLC22A4 and RUNX1) showed a high odds ratio 
of 9, indicative for a gene-gene interaction (33). Recently the effects of this RUNX-1 SNP 
was not found in a Caucasian population. (34). A SNP in the promoter region of FCRL3 is 
recently shown to be associated with susceptibility to RA (35). For a large number of other 
genes suggested to be relevant in the pathophysiology of RA, association was observed 
in only one study without replication. These studies concerned Beta-adrenergic receptor 
gene SNPs, RANKL, ICAM-1, VEGF, PDCD-1 and IL1-RA gene (36-40).
Besides genetic risk factors that confer a higher risk to develop RA, there also a genetic 
risk factors that protects to RA. This concerns particularly the HLA-DRB1 alleles that en-
codes for the amino acids DERAA (DRB1*0103, *0402, *1102, *1103, *1301, *1302, *1304). 
Interestingly, the HLA-DRB1 alleles can encode for different alleles with an opposite effect 
on disease susceptibility. The protective effect of the DERAA-encoding alleles is indepen-
dent from the shared epitope encoding alleles with predisposing effects (22,41,42). Both 
in the presence and in the absence of shared epitope encoding alleles the DERAA-encod-
ing alleles confer signifi cant lower odds of 0.6 to develop RA (22). 
In summary, the current knowledge on well-validated genetic risk factors to be included 
in a DNA fi ngerprint is limited to HLA-DRB1 and PTPN22. HLA-DRB1 is estimated to 
account for ~30% of the genetic component of this autoimmune disease (43) while the 
contribution of PTPN22 is much smaller. This implies that a signifi cant part of the genetic 
contribution is still to be identifi ed. In a number of whole genome scans (44) a consider-
able number of peaks of linkage have been identifi ed. In a study to estimate the number 
of true RA gene regions that took into account both the heterogeneity of RA and the 
performance of a dense genome scan, it was found that 8 +/- 4 regions (mean +/- SD) were 
true-positives and evidence for 3 additional regions was provided from covariate-based 
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analysis (45). One of those regions is the HLA-DRB1 locus, meaning that at least 10 +/- 4 
additional genes will be identifi ed with each quite modest effect. Technical progress such 
as SNP-based linkage analysis has been demonstrated to allow loci to be defi ned more 
precisely (46). The chance that this will lead to the identifi cation of the majority of the 
genetic risk factors is larger when RA is caused by a dozen common genetic variants than 
when RA is the result of many rare mutations. Given the fact that HLA and PTPN22 
have already been identifi ed, we speculate that RA is caused by a dozen common genetic 
variants. The statistical methods to evaluate many gene variants with disease status, as in 
candidate-gene case-control studies are still in its infancy especially for the low effect sizes 
of the individual disease loci and the sometimes low frequencies of the disease allele(s). 
The standard methods to evaluate the association of multiple markers with disease sta-
tus are based on multimarker multivariate analyses. For such multimarker multivariate 
analyses, one typically uses logistic regression to test simultaneously the main effects (and 
possibly interactions) of multiple markers. For each marker, a covariate can be created, 
such as the number of rare alleles at each marker. When this type of coding is used in 
logistic regression, the resulting score statistic for each marker implies many degrees of 
freedom, implying that the overall model suffers from weak power. Moreover complex 
models tend to overfi t the data stressing the necessity for replication in independent co-
horts. Despite these diffi culties the outlook is that the genetic contribution to RA is about 
50-60% (47). This number is estimated by the comparison between the concordance rates 
in monozygotic twins and the prevalence in the respective populations (47). This high 
percentage implies that measurement of genetic host characteristics is likely to have a role 
in a predictive test. 
Which environmental risk factors for RA are known?
So far smoking has been shown the only plausible environmental risk factor for RA. An 
association with smoking in RA is particularly found for rheumatoid factor positive RA 
compared to rheumatoid factor negative disease (48,49). Current or ex-smokers have a 
risk for autoantibody positive RA with an odds ratio of 1.7-1.9. The risk increases with 
cumulative dose of smoking (48). A recent report investigated whether smoking is primar-
ily associated with the development of rheumatoid factor or anti-CCP antibodies. This 
study nicely revealed a gene-environment interaction by showing that in the presence 
of HLA-shared epitope alleles smoking signifi cantly contributes to the development of 
anti-CCP antibodies (50). 
A predictive effect of oral anticonceptives on RA has been claimed (51). This fi nding has 








Predictive value of a DNA fi ngerprint-test
A large problem in transferring the data on genetic risk factors to prediction models is 
that the most current studies compared patients and controls, revealing odds ratios that 
are determined on group levels. The value of these genetic risk factors for individual 
predictive testing may be limited. Compare for example the statistical models to predict 
the pre-test probability on BRCA-1/2 genes. BRCA1 or 2 carriers have a very strong risk 
for ovarian/breast cancer. The statistical models to predict the presence of a BRCA1/2 risk 
allele are only informative in a selected population with affected family members (53). 
This example underlines that fi ndings for a whole group cannot be automatically used for 
prediction in subgroups of patients or for individuals. Genes may confer risk to subgroups 
of RA patients. For example, the well-known HLA-shared epitope alleles predispose partic-
ularly to anti-CCP positive RA (17). The BRCA- example also elucidates that the predictive 
value of a test depends on the prevalence of a disease in a population. For UA, a number 
of inception cohorts of patients with recent onset arthritis have identifi ed patients with 
a form of arthritis that has the potential for a persistent course, without fulfi lling the 
classifi cation criteria of other rheumatic disorders (54). In nine cohorts, the proportion 
of patients with UA that evolved into RA within 1 year varied from 17% to 32%. Thus, 
in this group of UA patients the pre-test probability of developing RA varies between 17-
32%. Given the dynamics of development of UA to either remission or progression to RA, 
the evaluation of predictive models for this patient group is highly relevant.
CHARACTERISTICS OF THE DISEASE PROCESS AND PREDICTION
The theoretical background of this section is the assumption that the expression of the 
disease in an initial phase allows prediction of the outcome. The genomic revolution has 
fuelled much optimism that gene expression profi les allow such outcome measures. Gene 
expression profi les are currently used in breast cancer to select the patients that would 
benefi t from adjuvant therapy (55). However, others warned that the prognostic value of 
the published micro-array results in cancer studies should be considered with caution as 
the list of genes identifi ed as predictors of prognosis was highly unstable and the molecu-
lar signatures depended strongly on the selection of patients (56). The prognostic value of 
the several micro-arrays in oncology therefore needs replication. 
Disease characteristics present at the presentation of UA that predict 
progression to RA 
The most important and best-validated disease characteristics with regard to prediction 
are auto-antibodies (anti-CCP and rheumatoid factor, RF) and the presence of erosions 
on the radiographs of hands and feet at initial presentation. In univariate analysis, the 
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presence of anti-CCP antibodies in patients with a UA conferred an odds ratio of 38 to 
develop RA, compared to anti-CCP negative patients with UA (57). A logistic regression 
model showed odds of 16 for anti-CCP antibodies in the prediction of RA (58). Raza et 
al. followed 124 patients with synovitis for less than 3 months for 72 weeks and assessed 
the prognostic value of anti-CCP antibodies and RF (59). In this study the combination 
of anti-CCP antibodies and RF had a positive predictive value of 100% and a negative 
predictive value of 88% for a diagnosis of RA (59). 
Clinical disease characteristics of 329 UA patients that presented to the Leiden Early 
Arthritis Clinic differed between the UA patients that developed RA versus those who did 
not develop RA. Disease characteristics associated with RA development were a higher age 
(55 versus 46), female sex (66% versus 50%), duration of morning stiffness (60 minutes 
versus 15 minutes), longer duration of symptoms (131 versus 81 days) and a higher num-
ber of swollen joints (4 versus 2)(1). 
Visser et al. developed a clinical model for the prediction of three forms of arthritis 
outcome: self-limiting disease, persistent non-erosive disease and persistent erosive dis-
ease (60). For the development of this model the fi rst 524 consecutive patients referred 
to the Leiden Early Arthritis Clinic were studied and the arthritis outcome was recorded 
after two years of follow-up. The developed prediction model consisted of 7 variables: 
symptom duration at fi rst visit, morning stiffness for ≥ 1 hour, arthritis in ≥ 3 joints, 
bilateral compression pain in the metatarsophalangeal joints, RF positivity, anti-CCP 
positivity and the presence of erosions at study entry. The ROC area under the curve for 
discrimination between self-limiting and persistent non-erosive arthritis was 0.84 and 
for discrimination between persistent nonerosive and erosive arthritis 0.91 (60). After 
the addition of predisposing HLA-Class II alleles, the discriminative ability of the model 
was not signifi cantly improved (60). The model derived by Visser used all patients of the 
Leiden Early Arthritis Clinic instead of only the patients with UA. The advantage of the 
model of Visser is that it can be used for a “random” patient with arthritis that visited an 
outpatient clinic of a rheumatologist, the disadvantage is that it also predicts occurrence 
of RA in patients that already fulfi lled the classifi cation criteria for RA. Currently it is 
analyzed whether the clinical characteristics used in this model also have predictive value 
in patients with UA.
To what extent can clinical observation be used in prediction?
Clinical observation of the natural course is the best way of predicting what the subse-
quent course will be. From a retrospective viewpoint, the history of the patients can be 
used as illustrated in the model proposed by Visser in which a long duration of complaints 
was associated with higher odds for chronic and erosive disease (60). The policy to include 
a “wait and see” policy can only be taken in the context when the possible disadvantages 








phenotypic characteristics that form the ACR classifi cation criteria, including joint de-
struction with subsequent deformities, and extra-articular features such as nodules. Given 
the accumulating evidence that appropriate therapy might prevent the development of 
a detrimental RA phenotype, observation without treatment is in our view only justi-
fi ed when the patients doesnot fullfi ll the ACR criteria. Specifi c studies that compare the 
initiation of treatment as a function of disease duration are scarce. Valuable data were ob-
tained in a 5-year follow-up study by Egsmose et al. in which early treatment with intra-
muscular gold was compared with a delayed treatment strategy (61). The early treatment 
group showed improvement with respect to signs and symptoms, physical function and 
radiographic progression, thus supporting the hypothesis of a therapeutic ‘window of op-
portunity’. In another trial by van der Heide et al. immediate versus delayed introduction 
of disease-modifying anti-rheumatic drug (DMARD) therapy were compared in patients 
with recently diagnosed RA (62). Early introduction of DMARDs showed greater patient 
improvement with regards to signs and symptoms, physical function and radiographic 
progression. Van Aken et al. compared the conventional pyramid strategy, consisting of 
sequential institution of NSAIDs and subsequent DMARD therapy, with immediate ini-
tiation of DMARD therapy in an observational study: again, the early treatment group 
showed less radiographic progression (63). Finally, an observational study performed at 
the Norfolk Arthritis Register provided evidence that patients in whom DMARD therapy 
was initiated within 6 months of diagnosis of RA had a better 5-year radiographic out-
come than patients starting DMARD therapy 6 months after RA diagnosis (64). All the 
aforementioned studies have investigated the importance of timing of treatment with 
regard to diagnosis. 
In conclusion, a role for clinical observation in prediction for development of RA seems 
only justifi ed in UA patients with a low probability to develop RA.
CONCLUSION
In the search to predict RA, current data indicate that host characteristics are relevant 
to predict RA. The identifi cation of these host characteristics have yielded HLA alleles as 
risk and as protective alleles and identifi ed PTPN22 as the second risk gene. Progress to 
identify genetic risk factors is slow due to the fact that each gene most likely has a very 
small effect and the lack of good statistical models to analyse combinations of genetic risk 
factors. Clinical factors to be included in a predictive model are most likely the duration 
of morning stiffness, the presence of an anti-CCP response and the presence of erosive 
abnormalities on X-rays of hands and feet.
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SUMMARY AND FUTURE PERSPECTIVE
Prediction of the future is impossible but a model can provide a probability to an indi-
vidual patient. Such a prediction model should guarantee a clinician and patient enough 
certainty (e.g. 80%) that a patient is assigned to the correct category. In the context of 
UA were about a third will develop RA and two third will not develop RA, it is not exactly 
known what the minimum value of R2 has to be to get a valuable prediction model. The 
R2, the fraction of explained variation, is a measure for the model’s ability to predict. It 
compares the mean squared error of the prognostic model to the mean squared error 
of the model without any prognostic variables and does not have a dimension. Some 
indication for an acceptable R2 can be obtained from a similar problem, the prediction of 
the severity of joint destruction in RA. De Vries et al. recently determined the adequacy 
of clinical parameters in the prediction of joint destruction (64). This model had a R2 of 
0.36 and correctly classifi ed 62% of patients. Furthermore it was calculated that to get a 
correct classifi cation of 80% of the patients, such a hypothetical model should have a R2
of 0.9 (65). A model that predicts joint damage scores gives an estimate for a continuous 
variable and is therefore different from a model that predicts the absence or presence 
of development of RA. Nevertheless the data as presented by De Vries et al. indicate the 
requirements for a model to adequately predict disease development in patients with 
UA. Currently, to our knowledge there are no prediction models analysed that are able 
to determine with at least 80% certainty whether an individual patient will or will not 
develop RA. However, given that more genetic factors that associate with susceptibility 
to RA will most likely be identifi ed in the next decade, we expect that the results of the 
genetic variants will be included in future prediction models. The predictive value of 
disease characteristics such as anti-CCP antibodies has already been identifi ed and given 
its very large and very specifi c effect, this will be included in prediction models. Clini-
cal characteristics have not yet been defi ned in great detail but we expect that with the 
current inclusion of many patients in different early arthritis initiatives, these data will 
become available in the next decade. Given the expectation that genetic, serological and 
clinical data each contain independent information, it should be possible to combine 
these datasets to gain more accurate prognostic information. Hopefully the R2 of such a 
model will be suffi ciently large to allow prediction at the patient level. 
This review is focussed on prediction of the diagnosis of RA but not on prediction of 
the prognosis of RA. This is caused by the lack of epidemiological data whether severity 
of RA such as rate of joint destruction is caused by e.g. genetic factors. In the next decade 
we expect that these basic epidemiological data will become available leading to develop-









 1. Van Aken J, van Dongen H, LeCessie S, Allaart CF, Breedveld FC, Huizinga TWJ. Long-
term outcome of rheumatoid arthritis that presented with undifferentiated arthritis 
compared to rheumatoid arthritis at presentation - an observational cohort study. Ann 
Rheum Dis. 2006;65(1):20-5.
 2. Linn-Rasker SP, Allaart CF, Kloppenburg M, Breedveld FC, Huizinga TWJ. Sustained re-
mission in a cohort of patients with RA: association with absence of IgM-rheumatoid 
factor and absence of anti-CCP antibodies. Int J Advances Rheumatology. 2004:2(4): 
4-6.
 3. van der Helm-van Mil AH, Dieude P, Schonkeren JJ, Cornelis F, Huizinga TW. No as-
sociation between tumour necrosis factor receptor type 2 gene polymorphism and rheu-
matoid arthritis severity: a comparison of the extremes of phenotypes. Rheumatology 
(Oxford). 2004:43(10):1232-4. 
 4. Roberts-Thomson PJ, Jones ME, Walker JG, Macfarlane JG, Smith MD, Ahern MJ. Stochas-
tic processes in the causation of rheumatic disease. J Rheumatol. 2002;29(12): 2628-34.
 5. Del Puente A, Knowler WC, Pettitt DJ, Bennett PH. High incidence and prevalence of 
rheumatoid arthritis in Pima Indians. Am J Epidemiol. 1989;129(6):1170-8.
 6. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 
2002;4:S265-72.
 7. Ferucci ED, Templin DW, Lanier AP.Rheumatoid arthritis in American Indians and Alaska 
Natives: a review of the literature Semin Arthritis Rheum. 2005;34(4):662-7.
 8. Silman A, Harrison B, Barrett E, Symmons D. The existence of geographical clusters of 
cases of infl ammatory polyarthritis in a primary care based register. Ann Rheum Dis. 
2000;59:152-154.
 9. Rachel A Roberts-Thomson,a P J Roberts-Thomson Rheumatic disease and the Australian 
aborigine. Ann Rheum Dis. 1999;58:266-70.
 10. Silman AJ, Ollier W, Holligan S, Birrell F, Adebajo A, Asuzu MC, et al. Absence of rheu-
matoid arthritis in a rural Nigerian population. J Rheumatol. 1993;20: 618-622.
 11. Doran MF, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE. Trends in incidence 
and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. 
Arthritis Rheum. 2002;46(3):625-31.
 12. Shichikawa K, Inoue K, Hirota S, Maeda A, Ota H, Kimura M, Ushiyama T, Tsujimoto 
M. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, 
Wakayama, Japan, 1965-1996. Ann Rheum Dis. 1999;58(12):751-6.
 13. Huizinga TWJ, Linn-Rasker S, Lard RG, Westendorp RG. Genetic drift as an explanation 
for the reduced incidence of RA, Arthritis Rheum. 2002;46(11):3107.
 14. Cummins J. Evolutionary forces behind human infertility. Nature 397: 557-8 (1993).
 15. Uhlig T, Kvien TK. Is rheumatoid arthritis disappearing? Ann Rheum Dis. 2005:64(1): 
7-10.
 16. Welsing PMJ, Fransen J, Van Riels PLCM. Is the disease course of rheumatoid arthritis 
becoming milder?: Time trends since 1985 in an inception cohort of early rheumatoid 
arthritis. Arthritis Rheum. 2005;2(9):2616-24.
 17. Huizinga TWJ, Amos CI, Van der Helm- van Mil AH, et al. Refi ning the complex rheu-
matoid arthritis phenotype based on specifi city of the HLA-DRB1 shared epitope for 
antibodies to citrullinated proteins, Arthritis Rheum. 2005;52(11):3433-8. 
 18. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated 
peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. 
Arthritis Rheum. 2003;48:2741-2749.
Genetics and clinical characteristics to predict RA 159
 19. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specifi c autoantibodies precede 
the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. 
Arthritis Rheum. 2004;50:380-386.
 20. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated 
proteins and differences in clinical progression of rheumatoid arthritis Arthritis Res Ther 
2005;7(5):R949-58.
 21. MacGregor A. Ollier W, Thomson W, et al. HLA-DRB1*0401/0404 genotype and rheu-
matoid arthritis: increased association in men, young age at onset, and disease severity. 
J Rheumatol 1995;22:1032-1036.
 22. Van der Helm-van Mil AH, Huizinga TW, Schreuder GM, et al An independent role for 
protective HLA Class II alleles in rheumatoid arthritis severity and susceptibility, Arthri-
tis Rheum 2005;52(9):2637-44. 
 23. Begovich AB, Carlton VE, Honigberg LA, et al. A Missense Single-Nucleotide Polymor-
phism in a Gene Encoding a Protein Tyrosine Phosphatase (PTPN22) Is Associated with 
Rheumatoid Arthritis. Am J Hum Genet. 2004;75(2):330-337. 
 24. Van Oene M, Wintle RF, Liu X, et al. Association of the lymphoid tyrosine phosphatase 
R620W variant with rheumatoid arthritis, but not Crohn’s disease, in Canadian popula-
tions. Arthritis Rheum 2005;52(7):1993-8.
 25. Simkins HM, Merriman ME, Highton J, et al. Association of the PTPN22 locus with rheu-
matoid arthritis in a New Zealand Caucasian cohort. Arthritis Rheum 2005;52(7):2222-
2225.
 26. Wesoly J, Chokkalingam AP, Van der Helm-van Mil AH, et al. Association of the 
PTPN22 C1858T SNP with RA phenotypes in an inception cohort. Arthritis Rheum 
2005;52(9):2948-50.
 27. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phos-
phatase is associated with type I diabetes. Nat Genet. 2004;36(4):337-338.
 28. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begov-
ich AB, Carlton VE, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK. Analysis of 
families in the multiple autoimmune disease genetics consortium (MADGC) collection: 
the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum 
Genet 2005;76(4):561-71. 
 29. Swanberg M, Lidman O, Padyukov L, et al. MHC2TA is associated with differential MHC 
molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and 
myocardial infarction. Nat Genet. 2005;37(5):486-94.
 30. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrul-
linating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. 
Nat Genet. 2003;34(4):395-402.
 31. Caponi L, Petit-Teixeira E, Sebbag M, et al. A family-based study shows no association 
between rheumatoid arthritis and the PADI4 gene in a French Caucasian population. 
Ann Rheum Dis 2004;64(4):587-93.
 32. Barton A, Bowes J, Eyre S et al. A functional haplotype of the PADI4 gene associated with 
rheumatoid arthritis in a Japanese population is not associated in a United Kingdom 
population. Arthritis Rheum 2004;50(4):1117-1121.
 33. Tokuhiro S, Yamada R, Chang X, et al. An intronic SNP in a RUNX1 binding site of 
SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthri-
tis. Nat Genet 2003;35(4):341-348.
 34. Wesoly JZ, Toes REM, Slagboom PE, Huizinga TWJ. RUNX1 intronic SNP is not asso-









 35. Kochi Y, Yamada R, Suzuki A, Harley JB, Shirasawa S, Sawada T, Bae SC, Tokuhiro S, 
Chang X, Sekine A, Takahashi A, Tsunoda T, Ohnishi Y, Kaufman KM, Kang CP, Kang 
C, Otsubo S, Yumura W, Mimori A, Koike T, Nakamura Y, Sasazuki T, Yamamoto K. A 
functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid 
arthritis and several autoimmunities. Nat Genet. 2005;37(5):478-85.
 36. Wu H, Khanna D, Park G, et al. Interaction between RANKL and HLA-DRB1 genotypes 
may contribute to younger age at onset of seropositive rheumatoid arthritis in an incep-
tion cohort. Arthritis Rheum 2004;50(10):3093-3103.
 37. Lee EB, Kim JY, Kim EH, et al. Intercellular adhesion molecule-1 polymorphisms in Ko-
rean patients with rheumatoid arthritis. Tissue Antigens 2004;64:473-477.
 38. Han SW, Kim GW, Seo JS, et al. VEGF gene polymorphisms and susceptibility to rheuma-
toid arthritis. Rheumatology 2004;43(9):1173-1177.
 39. Prokunina L, Padyukov L, Bennet A, et al. Association of the PD-1.3A allele of the PDCD1 
gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared 
epitope Arthritis Rheum 2004;50(6):1770-1773.
 40. Lee YH, Kim HJ, Rho YH, et al. Interleukin-1 receptor antagonist gene polymorphism 
and rheumatoid arthritis. Rheumatol Int. 2004;24(3):133-136.
 41. Mattey DL, Dawes PT, Gonzalez-Gay MA, Garcia-Porrua C, Thomson W, Hajeer AH, et al. 
HLA-DRB1 alleles encoding an aspartic acid at position 70 protect against development 
of rheumatoid arthritis. J Rheumatol. 2001;28(2):232-9.
 42. Wagner U, Kaltenhäuser S, Pierer M, Seidel W, Trölzsch, Häntzschel, et al. Prospective 
analysis of the impact of HLA-DR and –DQ on joint destruction in recent-onset rheuma-
toid arthritis. Rheumatology 2003;42:553-62.
 43. Deighton CM, Walker DJ, Griffi ths ID, et al. The contribution of HLA to rheumatoid 
arthritis. Clin Genet 1989;36:178-82.
 44. Huizinga TW. Genetics in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 
2003;17(5):703-16.
 45. Osorio Y Fortea J, Bukulmez H, Petit-Teixeira E, Michou L, Pierlot C, Cailleau-Moindrault 
S, Lemaire I, Lasbleiz S, Alibert O, Quillet P, Bardin T, Prum B, Olson JM, Cornelis F. 
Dense genome-wide linkage analysis of rheumatoid arthritis, including covariates. Ar-
thritis Rheum. 2004;50(9):2757-65.
 46. John S, Shephard N, Liu G, Zeggini E, Cao M, Chen W, et al.. Whole-Genome Scan, in 
a Complex Disease, Using 11,245 Single-Nucleotide Polymorphisms: Comparison with 
Microsatellites. Am. J. Hum. Genet. 2004;75:54-64.
 47. MacGregor AJ, Snieder H, Rigby AS, et al. Characterising the quantitative genetic contri-
bution to rheumatoid arthritis using data from twins. Arthritis Rheum 2004;43:31-37. 
 48. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, Alfredsson L; 
EIRA study group. Quantifi cation of the infl uence of cigarette smoking on rheumatoid 
arthritis: results from a population based case-control study, using incident cases. Ann 
Rheum Dis.2003;62(9):835-41.
 49. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction 
between smoking and shared epitope genes in HLA-DR provides a high risk of seroposi-
tive rheumatoid arthritis. Arthritis Rheum. 2004;50(10):3085-92. 
 50. Linn-Rasker SP, van der Helm-van Mil AH, Van Gaalen FA, Kloppenburg M, de Vries R, 
le Cessie S, Breedveld FC, Toes RE, Huizinga TW. Smoking is a risk factor for anti-CCP 
antibodies only in RA patients that carry HLA-DRB1 Shared Epitope alleles. Ann Rheum 
Dis. 2006;65(3):366-71.
 51. Doran MF, Crowson CS, O’Fallon WM, Gabriel SE. The effect of oral contraceptives and 
estrogen replacement therapy on the risk of rheumatoid arthritis: a population based 
study. J Rheumatol. 2004;31(2):207-13.
Genetics and clinical characteristics to predict RA 161
 52. Karlson EW, Mandl LA, Hankinson SE, Grodstein F. Do breast-feeding and other repro-
ductive factors infl uence future risk of rheumatoid arthritis? Results from the Nurses’ 
Health Study. Arthritis Rheum. 2004;50(11):3458-67.
 53. de la Hoya M, Diez O, Perez-Segura P, et al Pre-test prediction models of BRCA1 or BRCA2 
mutation in breast/ovarian families attending familial cancer clinics. J Med Genet 
2003;40(7):503-10.
 54. Verpoort KN, van Dongen H, Allaart CF, Toes RE, Breedveld FC, Huizinga TW. Undif-
ferentiated arthritis--disease course assessed in several inception cohorts. Clin Exp Rheu-
matol. 2004;22(5 Suppl 35):S12-7.
 55. Van ‘t Veer LJ, Dai H, Van de Vijver MJ, et al. Gene expression profi ling predicts clinical 
outcome of breast cancer. Nature 2002;415:530 - 536.
 56. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a mul-
tiple random validation strategy. Lancet 2005;5;365(9458):488-92.
 57. Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrulli-
nated peptides predict progression to rheumatoid arthritis in patients with undifferenti-
ated arthritis: a prospective cohort study. Arthritis Rheum 2004;50(3):709-15.
 58. Berglin E, Padyukov L, Sundin U, et al. A combination of autoantibodies to cyclic citrul-
linated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future 
onset of rheumatoid arthritis. Arthritis Res Ther 2004;6(4):R303-8.
 59. Raza K, Breese M, Nightingale P, et al. Predictive value of antibodies to cyclic citrullinat-
ed peptide in patients with very early infl ammatory arthritis. J Rheumatol 2005;32(2): 
231-8.
 60. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a predic-
tion model for persistent (erosive) arthritis. Arthritis Rheum 2002;46(2):357-65. 
 61. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefi t from early 
2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. 
J Rheumatol 1995;22: 2208–2213.
 62. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with 
“second-line” antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 
1996;124: 699–707.
 63. van Aken J, Lard LR, le Cessie S, et al Radiological outcome after four years of early ver-
sus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann 
Rheum Dis 2004;63: 274–279.
 64. Bukhari MA, Wiles NJ, Lunt M, et al. Infl uence of disease-modifying therapy on radio-
graphic outcome in infl ammatory polyarthritis at fi ve years: results from a large observa-
tional inception study. Arthritis Rheum 2003;48: 46–53.
 65. de Vries-Bouwstra JK, Le Cessie S, Allaart CF, Breedveld FC, Huizinga TWJ. Using pre-




Arthritis of the large joints, in particular 
the knee, at fi rst presentation is predictive 
for a high level of radiological destruction 
of the small joints in rheumatoid arthritis
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Objectives. To investigate the predictive value of the distribution of infl amed joints at 
fi rst presentation for the severity of the disease course in RA.
Methods. From 1009 consecutive patients included in the Leiden Early Arthritis Clinic, 
285 patients fulfi lled the ACR-criteria for RA within 1-year of follow-up. Of these, 28 
patients achieved remission. Radiographs of hands and feet were scored according to 
the Sharp-van der Heijde method and the 28 patients with the most destructive disease 
were selected. The distribution of infl amed joints of the patients with the extreme disease 
courses was compared. The association between the distribution of infl amed joints and 
the level of destruction of the joints of hands and feet in the whole group of RA-patients 
was assessed using regression analysis. 
Results. Comparison of the patients with extreme disease courses using univariate and 
logistic regression analyses revealed that arthritis of the large joints, in particular the 
knee, was associated with severe RA. In the whole group of RA-patients, the total number 
of swollen joints and the presence of knee arthritis associated independently with the 
level of destruction of the small joints. RA-patients with knee arthritis had higher C-reac-
tive protein levels than patients without knee arthritis and investigating the distribution 
of infl amed joints together with other variables yielded the number of swollen joints, 
C-reactive protein level, presence of anti-CCP antibodies and symptom duration as pre-
dictors for RA severity. 
Conclusions. Arthritis of large joints, in particular the knee, at fi rst presentation is as-
sociated with a destructive course of RA.
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INTRODUCTION 
The initial clinical presentation of rheumatoid arthritis (RA) is variable and the number 
as well as the distribution of infl amed joints may vary between a monoarthritis and an 
extensive polyarthritis. In general, RA is considered to be a chronic potentially destruc-
tive disease, but the severity of the disease course for an individual patient is diffi cult to 
predict at baseline. RA patients that present with an extensive polyarthritis may have a 
mild disease course or remit spontaneously, while patients that initially present with a 
monoarthritis may experience a severe destructive course of the disease. The implication 
of being able to predict the disease course in RA is obvious, given the value of early treat-
ment and the common use of aggressive treatment strategies (1-3). Several studies have 
assessed associations between clinical variables and RA severity (4-17). In these studies 
the presence of morning stiffness, symptom duration >6 months, rheumatoid factor (RF), 
antibodies against cyclic-citrullinated peptides (CCP), early radiological erosions and an 
elevated C-reactive protein (CRP) were correlated with a more severe outcome of the dis-
ease (4-17). So far, it is not known whether the distribution of infl amed joints is associated 
with the disease outcome in RA. Therefore, the present study aimed to investigate the 
predictive value of the distribution of infl amed joints at fi rst presentation for the severity 
of the disease course in RA. In order to identify the joints that are associated with a severe 
disease outcome, the distribution of swollen joints of RA-patients with extreme disease 
courses, sustained remission and progressive erosive disease, were compared. The com-
parison of the extremes of phenotypes may reduce the risk of missing risk factors caused 
by regression to the mean and this approach, in addition to studying the whole group of 
patients, may lead to the detection of additional prognostic factors. Subsequently, in the 
whole group of RA-patients the association between the distribution of infl amed joints 
at baseline and the level of radiological destruction of the small joints of the hands and 
feet during follow-up was determined and the ability of the identifi ed joints to predict RA 
severity in relation with other clinical parameters was assessed. 
PATIENTS AND METHODS
Patients
For this study, patients from the Leiden Early Arthritis Clinic, a population-based incep-
tion cohort of patients with newly diagnosed early arthritis were selected This cohort 
started in 1993 at the department of Rheumatology of the Leiden University Medical Cen-
ter, the only referral center for rheumatology in a health care region of ~400,000 inhabit-
ants in the Netherlands. General practitioners were encouraged to refer patients directly 








arthritis (for further reading see 18). In the study period (1993-1999), 1009 patients with 
early arthritis were included. After one year follow-up, 285 patients had fulfi lled the 1987 
ACR-criteria for RA (19). From these RA patients, two categories of patients with extreme 
disease courses were selected: those who entered sustained remission (remitting RA) and 
those had progressed to the most destructive disease (severe RA). Remission was defi ned 
as satisfying the proposed American Rheumatism Association (ARA) criteria for clinical 
remission (20) after having discontinued the use of Disease Modifying Antirheumatic 
Drugs (DMARDs) for at least one year. After one additional year of follow-up the presence 
of sustained remission was confi rmed. 28 patients had achieved sustained remission after 
mean disease duration of 3.7 years (range 210-3159 days SD 852 days). For more details 
on these patients see (21). The remitting patients are further referred to as “remitting 
RA”. Radiographs of the hands and feet were taken at baseline and yearly thereafter and 
the level of radiological joint destruction was scored according to the Sharp-van der Hei-
jde method (22-23). The rheumatologist that scored the radiographs was unaware of the 
study question. The patients with the most destructive disease course were identifi ed by 
selecting the 28 patients that had the highest Sharp-van der Heijde scores after one year 
of follow-up. This corresponded with a Sharp-van der Heijde score >34 (mean 59). These 
patients are further referred to as “most severe RA”.
Methods
At inclusion the rheumatologist questioned the patient about the initial symptoms as 
well as the presence of morning stiffness and the symptom duration. Physical examina-
tion at baseline included a swollen joint count, scaling each joint on a 0-1 scale (0 denotes 
no swelling and 1 indicates the presence of swelling). Subsequently, the joints or joint 
groups were categorized (e.g. all metacarpophalangeal joints on one side were counted as 
one joint). The following joint(groups) were studied: shoulders, elbows, wrists, metacar-
pophalangeal joints, proximal and distal interphalangeal joints, knees, ankles and meta-
tarsophalangeal joints. For the analysis a dichotomous approach was used that indicated 
the presence or absence of swelling per joint group. 
Baseline laboratory parameters included ESR, CRP, IgM rheumatoid factor ELISA as pre-
viously described (24) and anti-CCP2 antibodies (ELISA, Immunoscan RA Mark 2, Euro-
Diagnostica, Arnhem, The Netherlands). According to the instruction of the manufacturer 
a level > 25 arbitrary units was considered positive. 
Statistical analysis
The baseline parameters of the patients with remitting and severe RA were compared us-
ing the Mann-Whitney test for continuous variables and the chi-square test for nominal 
variables. Subsequently, a logistic regression analysis with backward selection procedure 
(p>0.10 as removal criteria, using likelihood ratio test) was performed with the presence 
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of remitting RA or most severe RA as dependent variable and the individual joint groups 
that were signifi cantly associated with the disease outcome in the univariate analysis and 
the total number of swollen joints as possible explanatory variables. 
To validate the fi ndings, the association between the joint groups and radiological joint 
destruction was assessed in the total group of RA patients. The Sharp-van der Heijde scores 
at 1 year follow-up were entered as a dependent variable in a linear regression analysis 
(backward selection procedure, p>0.10 as removal criteria) with the total number of swol-
len joints and the joint count for the individual joint groups as possible explanatory 
variables. To assess the association between the distribution of swollen joints and the 
level of radiological joint destruction in relation to other clinical variables that might be 
associated with RA severity, an other linear regression analysis (backward selection proce-
dure, p>0.10 as removal criteria) was performed. In this analysis the Sharp-van der Heijde 
score at one year follow-up was entered as a dependent variable and the total number of 
swollen joints, the swollen joint count for the individual joint groups, gender, age, the 
presence of anti-CCP antibodies, RF, morning stiffness, the CRP-level and symptom dura-
tion and as possible explanatory variables.
The statistical package for the social sciences (SPSS) version 11.0 (SPSS, Chicago, IL) was 
used to analyse the data. A p-value ≤0.05 was considered signifi cant.
RESULTS
Univariate comparison of patient characteristics at fi rst presentation of 
RA patients with extreme disease courses
The patients in the remitting and most severe RA group had no signifi cant differences in 
the distribution of gender, age and morning stiffness. The patients with the most severe 
disease course harboured more frequently RF and anti-CCP antibodies, had higher levels 
of CRP and had higher Sharp-van der Heijde scores at inclusion compared to patients 
with remitting RA (Table 1). The patients with the most severe disease course also had a 
signifi cantly higher number of swollen joints at fi rst presentation than the patients with 
remitting RA. The distribution of swollen joints was different between the two groups: the 
patients with the most severe RA had signifi cantly more often arthritis of the shoulders, 
elbows, proximal interphalangeal joints, knees and ankles (Table 2). There were no differ-
ences in the prevalences of swollen metacarpophalangeal and metatarsophalangeal joints 
between the two groups of RA-patients.
Regression analysis in the RA patients with extreme disease courses
To investigate which joint (groups) were independently associated with the disease out-








with the presence of remitting RA or most severe RA as dependent variable and the in-
dividual joint groups that were signifi cantly associated with the disease outcome in the 
univariate analysis (shoulder, elbow, proximal interphalangeal, knee, ankle) and the total 
number of swollen joints as possible explanatory variables. In this analysis only the pres-
ence of a swollen knee (odds ratio 7.0, P=0.004) was signifi cantly associated with the 
disease outcome (Table 3).






Female, n (%) 18 (64) 17 (61) 0.7
Age, years, median (IQR) 59 (48-71) 59 (50-72) 1.0
Morning stiffness, minutes, median (IQR) 138 (30-180) 137 (30-180) 1.0
Symptom duration, days median (IQR) 127 (57-207) 152 (87-281) 0.1
C-reactive protein mg/l, median (IQR) 29 (7-46) 56 (26-75) 0.01
IgM RF positive, n (%) 6 (21) 23 (82) <0.05
Anti-CCP 2 positive, n (%) 3 (11) 21 (75) <0.05
Total number of swollen joints, median (IQR) 5.3 (3-7) 7.3 (5-9) <0.05
Sharp-van der Heijde score, median (IQR) 0 (0-2) 10 (1-17) <0.05










Shoulder 1 (3%) 6 (21%) 6.4 2.0-26.4 <0.05
Elbow 4 (14%) 8 (29%) 2.5 1.2-5.5 <0.05
Wrist 19 (68%) 21 (75%) 1.4 0.7-2.8 0.3
Metacarpophalangeal 23 (82%) 23 (82%) 1.0 0.5-2.2 1.0
Proximal interphalangeal 17 (61%) 23 (82%) 2.9 1.5-5.9 <0.05
Distal interphalangeal 1 (4%) 1(4%) 1.0 0.2-4.1 1.0
Knee 7 (25%) 17 (61%) 4.7 2.5-9.0 <0.05
Ankle 4 (14%) 9 (32%) 2.9 1.4-6.3 <0.05
Metatarsophalangeal 8 (29%) 9 (32%) 1.2 0.6-2.7 0.6
* The numbers (percentages) indicate the number (percentage) of patients with swelling of (at least 
one of) the joints of the specifi c joint groups.
Table 3. Results of logistic regression analysis with backward selection procedure and remitting 
or severe RA as dependent variable and the total number of swollen joints and the joints with a 
signifi cant result in univariate analysis as possible explanatory variables
Joint group P Odds ratio 95% CI
Shoulder 0.07 8.7 0.8-90.1
Elbow 0.08 4.1 0.9-19.4
Knee 0.004 7.0 1.9-25.9
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Regression analysis in all 285 RA patients 
To validate the fi ndings, the association between the distribution of swollen joints and ra-
diological joint destruction was assessed in the total group of RA patients. The Sharp-van 
der Heijde score at 1 year follow-up was entered as a dependent variable in a linear regres-
sion analysis with a backward selection procedure and the total number of swollen joints 
and all evaluated joint groups as possible explanatory variables. This analysis revealed 
that in the total group of RA-patients the total number of swollen joints (p=0.004) and 
swelling of the knee (p=0.03) were independently associated with the level of radiological 
joint destruction of hands and feet (Table 4). A similar analysis was performed with the 
Sharp-van der Heijde scores at 2 and 3 year follow-up as dependent variable (X-rays were 
available of respectively 202 and 162 patients). In these analyses only swelling of the knee 
associated independently with the level of radiological joint destruction (B=7.2, SE=3.9, 
P=0.05 for the 2-year time point and B=3.5, SE=4.7, P=0.005 for the 3-year time point). 
Table 4. Results of linear regression analysis with backward selection procedure in the 285 RA-
patients with Sharp-van der Heijde score at 1-year follow-up as dependent variable and distribution 
and total number of swollen joints as possible explanatory variables.
Joint group B SE P
Knee 1.4 0.5 0.004
Total number of swollen joints 6.1 2.9 0.03
B indicates regression coeffi cient
Figure 1. The level of radiological destruction of the small joints of hands and feet 
during three years of follow-up of RA-patients with and without arthritis of the knee 
at fi rst presentation. *P<0.05 (Mann-Whitney test). At the 2 and 3 year time point radiographs 








Figure 1 displays the level of radiological destruction of the small joints of the hands and 
feet during three years of follow-up of the RA-patients that at fi rst presentation did have 
and did not have arthritis of the knee (Figure 1). 
In conclusion, regression analyses in both the whole group of RA-patients and using the 
approach of the extremes of the disease courses yielded the total number of swollen joints 
and particularly the presence of arthritis of the knee as independently associated with the 
level of joint destruction of the small joints of hands and feet during follow-up.
Predictive ability of distribution of swollen joints in relation with 
other clinical characteristics for RA severity
Next, we investigated the predictive ability of the presence of arthritis of the knee and the 
total number of swollen joints in relation to other clinical variables that are observed or 
described to be associated with a severe disease outcome: CRP, RF, anti-CCP antibodies, 
morning stiffness and symptom duration (4-17, Table 1). A linear regression analysis with 
a backward selection procedure revealed that the total number of swollen joints (B=0.9, 
SE=0.4, P=0.03), the presence of anti-CCP antibodies (B=8.4, SE=2.4, P<0.001), the CRP-
level (B=0.02, SE=0.007, P<0.01) and the symptom duration (B=0.2, SE=0.04, P<0.001) 
were independently associated with the level of joint destruction after 1 year of follow-up. 
In this analysis the presence of arthritis of the knee was not an independent predictor for 
disease severity. The fraction of explained variation of this model was 0.2. As after correc-
tion for clinical variables in a regression analysis the presence of arthritis of the knee was 
not independently associated with RA severity, in contrast to the CRP-level, the presence 
of anti-CCP antibodies and the symptom duration, we hypothesized that these variables 
might be distributed differently among the RA-patients with and without arthritis of the 
knee. Arthritis of the knee was present in 106 (39%) patients at fi rst presentation. The 
presence of anti-CCP antibodies and the symptom duration, but also the variables age, 
gender, RF and morning stiffness were not signifi cantly different between the RA patients 
with and without arthritis of the knee. However, there was a signifi cant difference in the 
level of CRP: RA-patients with arthritis of the knee at fi rst presentation had higher CRP-
levels (mean 48 mg/l, SD 35 mg/l) compared to RA-patients without involvement of the 
knee (mean 22 mg/l, SD 24 mg/l, P<0.001). 
DISCUSSION
The present study aimed to investigate the predictive value of the distribution of infl amed 
joints at fi rst presentation for the severity of the disease course in RA and demonstrated 
using two different approaches that the presence of arthritis of large joints, and arthritis 
of the knee in particular, is independently associated with the level of joint destruction. 
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In regression analysis both arthritis of the knee and the total number of swollen joints at 
baseline were signifi cantly associated with a severe disease outcome. Since all RA-patients 
fulfi lled the ACR-criteria and per defi nition had involvement of the small joints and as 
the presence/absence of arthritis was evaluated as a dichotomous variable per joint group, 
in the present study a difference in the total number of swollen joints refl ects a difference 
in the number of swollen large joint groups. From all joints the presence of arthritis of the 
knee at baseline was the strongest predictor for a higher level of radiological destruction 
of the small joints of the hands and feet. 
After the identifi cation of the knee and the total number of swollen joints as predictors 
for severe radiological destruction of small joints, we were interested whether these pa-
rameters were of additional value to established parameters for disease severity (anti-CCP 
antibodies, RF, C-reactive protein, morning stiffness, symptom duration). Therefore, a lin-
ear regression analysis was performed that included not only the distribution and number 
of swollen joints but also other clinical variables. This analysis revealed a signifi cant as-
sociation between with the level of radiological joint destruction and the total number 
of swollen joints, C-reactive protein, anti-CCP antibodies and symptom duration. The 
presence of knee arthritis was not signifi cantly associated with RA severity in this analysis. 
A post-hoc analysis demonstrated that patients with arthritis of the knee had higher levels 
of CRP compared to the patients without arthritis of the knee. Apparently the CRP-level 
is a stronger predictor for the level of joint destruction than the presence of an infl amed 
knee. Interestingly, the presence of anti-CCP antibodies was not different between patients 
with and without knee arthritis. These data suggest that infl ammation of large synovial 
joints, like the knee, induces a higher amount of pro-infl ammatory cytokines (among 
others Il-6) that subsequently triggers an increased production of CRP by the liver. Holt 
et al previously showed that in patients with infl ammatory arthritis the concentration 
of synovial Il-6 in knee joints was associated with the plasma level of Il-6 and also with 
plasma level of CRP (25). Although having arthritis of the knee was also correlated with a 
high level of CRP in the present study and the CRP-level appeared to be a better predictor 
for disease severity compared to knee arthritis, in clinical practice a physician establishes 
the presence of arthritis of large joints as the knee directly during the fi rst visit, whereas 
laboratory results are not immediately available. Furthermore, the presence of an elevated 
CRP-level can also be caused by non-rheumatologic factors such as a transient infection. 
Since the present study aimed to investigate the predictive value of the distribution of 
infl amed joints for the disease outcome in RA, the fi nding that the presence of arthritis of 
large joints and the knee in particular is associated with a more destructive disease might 








Studies that investigate the natural disease course in RA are nowadays hampered by the 
fact that aggressive and effective disease modifying antirheumatic drugs including bio-
logicals are used. The effective reduction of the disease activity diminishes the level of 
joint destruction. Despite the indisputable benefi t for RA patients, the natural course of 
the disease is altered and the patients that are currently treated for RA are less suitable 
for studies that aim to identify variables that predict the disease outcome. The patients 
included in the present study were treated for RA between 1993 and 1999. In this time 
era, therapy with DMARDs was started in a relatively late stage and medications of choice 
were among others antimalarials, of which is known that their ability to halt disease 
progression is limited. None of the included patients were treated with biologicals. From 
the 28 patients that achieved sustained remission 16 patients had received no DMARD 
therapy, 6 were treated with antimalarials and the remaining 7 were prescribed metho-
trexate or sulphasalazine. The patients included in the present study are more suitable for 
a study assessing risk factors for RA severity, than the patients that are nowadays included 
in our Early Arthritis Clinic.
In conclusion, early recognition of patients with RA with a potentially severe disease 
course is important since these patients in particular may benefi t from the therapeutic 
options that are currently available. It is already known that the presence of anti-CCP 
antibodies, symptom duration and CRP are associated with RA severity. This study reveals 
that also the presence of arthritis of large joints and particularly arthritis of the knee are 
predictive for a destructive disease course.
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Chapter 16
A rule to predict disease outcome 
in patients with recent-onset 
undifferentiated arthritis to guide 
individual treatment decisions















Objectives. In patients with undifferentiated arthritis (UA) methotrexate is an effec-
tive drug to inhibit symptoms, structural damage, and progression towards rheumatoid 
arthritis (RA). However 40-50% of UA-patients remit spontaneously. Thus adequate treat-
ment decision-making in early undifferentiated arthritis necessitates identifi cation of the 
UA-patients that will develop RA. 
Methods. A prediction rule was developed using data from the Leiden Early Arthritis 
Clinic, an inception cohort of patients with recent onset arthritis (n=1700). The patients 
that presented with UA were selected (n=570); progression to RA or other diagnosis was 
monitored after one-year follow-up. The clinical characteristics with independent pre-
dictive value for RA development were selected using logistic regression analysis. The 
diagnostic performance of the prediction rule was evaluated using the area under receiver 
operating characteristic curve (AUC). Cross-validation controlled for over-fi tting of the 
data (internal validation). For external validation, an independent cohort of UA-patients 
was used.
Results. The prediction rule consists of nine clinical variables: gender, age, localization 
of symptoms, morning stiffness, tender and swollen joint count, C- reactive protein, 
rheumatoid factor and anti-CCP antibodies. Each prediction score varies between 0 and 
14 and corresponds to a chance (percentage) RA development. For several cut-off values 
the positive and negative predictive values were determined. The AUC of the prediction 
rule, the prediction model after cross-validation and the external validation cohort were 
0.89, 0.87 and 0.97 respectively.
Conclusions. In early undifferentiated arthritis the risk to develop RA can be predicted, 
thereby allowing individualized treatment decisions to initiate disease-modifying anti-
rheumatic drugs in patients who present with UA.
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INTRODUCTION
Individualized treatment decision-making is one of the most important challenges of 
medicine. To this end a number of studies have appeared that associated clinical variables 
or gene-expression profi les with disease outcome, thereby providing help for clinicians in 
treatment decisions in several diseases (e.g. breast cancer, Hodgkin disease, lymphoma 1-4). 
Treatment in rheumatoid arthritis (RA) is since the last decennium characterized by earlier 
and more aggressive treatment with disease-modifying antirheumatic drugs (DMARDs), as 
this treatment strategy prevents joint damage and functional disability (5-7). In rheumato-
logical practice, the majority of patients that present with a recent onset arthritis have an 
undifferentiated arthritis (UA), arthritis in whom with the available classifi cation criteria 
no diagnosis can be made. From several inception cohort studies it is known that about 
40-50% of these UA-patients remit spontaneously, whereas one-third develops RA (8-10). 
Recent evidence indicates that treatment with methotrexate in patients with early UA 
hampers progression to RA and progression of joint damage (11), underscoring the need 
for guidance to start a clinically benefi cial but potential harmful drug in UA. Ideally, only 
the UA-patients that develop RA are treated with DMARDs in contrast to those that remit 
spontaneously. At present, although several risk factors for the development of RA have 
been identifi ed (8,12), a model that predicts the disease course specifi cally in patients with 
recent-onset UA is lacking. The present study aimed to develop a model that predicts the 
progression from UA to RA, using clinical variables that are easily assessed in daily clinical 
practice. The derived prediction rule was internally validated controlling for over-fi tting of 
the data, and subsequently externally validated in an independent cohort of UA-patients. 
METHODS
Patients
The prediction rule is derived using the Leiden Early Arthritis Clinic, an inception cohort 
containing more than 1900 patients with recent-onset arthritis of whom about 1700 have 
completed at least one-year follow-up. This cohort started in 1993 at the department 
of Rheumatology of the Leiden University Medical Center, the only referral center for 
rheumatology in a health care region of ~400,000 inhabitants in the Netherlands (13). 
General practitioners were encouraged to refer patients directly when arthritis was sus-
pected; patients were included if physical examination revealed arthritis. At fi rst visit 
various variables were collected. The rheumatologist answered a questionnaire inquiring 
about the initial symptoms as reported by the patient: type, localization and distribution 
of initial joint symptoms, symptom duration and course of start complaints. The smoking 








scale (0-100). For the present study, severity of morning stiffness was used instead of 
duration of morning stiffness as the fi rst is proven to be a better discriminator (14,15). 
The Health Assessment Questionnaire (HAQ) yielded an index of disability. A 44-joint 
count for tender and swollen joint was performed, scoring each joint on a 0-1 scale (16). 
Compression pain of metacarpophalangeal and metatalohalangeal joints was recorded. 
Baseline blood samples were taken for determination of ESR, C-Reactive protein (CRP), 
IgM rheumatoid factor (RF, ELISA), and antibodies to cyclic-citrullinated peptide 2 (CCP; 
ELISA, Immunoscan RA Mark 2, Euro-Diagnostica, Arnhem, The Netherlands). The cut-off 
level for anti-CCP positivity was 25 arbitrary units. Radiographs of hands and feet were 
made and scored according to Sharp-van der Heijde (17). Patients gave their informed 
consent and the local Ethical Committee approved the protocol.
Disease Outcome
570 patients had two weeks after inclusion (when results on laboratory and radiologi-
cal investigations were known) an arthritis that could not be classifi ed according to the 
ACR-criteria and were documented as undifferentiated arthritis (UA). After 1-year follow-
up the disease status of all UA-patients was examined to determine whether they had 
developed RA or other diagnosis according to the ACR-criteria. Inherent to the design of 
an inception cohort the duration of follow-up differed within the study population and at 
the moment of analysis (July 2005) the majority of UA-patients (94%) had been followed 
for more than one year (mean follow-up 8 years, SD 3 years). 
External validation cohort
Patients included in the placebo-arm of the PROMPT-trial, a double-blind placebo-con-
trolled randomized trial in which patients with recent onset UA were treated with either 
methotrexate or placebo, were used for validation (n=55) (11). Exclusion of the UA-pa-
tients that were also included in the EAC cohort resulted in 36 independent UA-patients. 
Two of these were lost to follow-up. For each patient the progression score at baseline was 
calculated and the development of RA after 1-year follow-up was assessed (11). 
Statistical analysis
The UA-patients that did or did not develop RA were compared using the Chi-square test for 
nominal variables and the student’s t-test for continuous variables. Symptom duration was 
categorized. Subsequently all clinical variables were entered as possible explanatory variables 
in a logistic regression analysis with the disease outcome (RA or non-RA) at one-year follow-
up as dependent variable. Using a backward selection procedure, the most signifi cant inde-
pendent variables were identifi ed, using p>0.10 as removal criteria. In the logistic regression 
model the predicted probability on RA is related to the covariates via the prognostic index: 
B1*x1+B2*x2+B3*x3…Bk*xk. The B (regression coeffi cient) of the covariate indicates an estimate 
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of the relative magnitude of the prognostic power of the concerning variable. Using the prog-
nostic index, for every subject the predicted probability on RA development was calculated. 
For continuous variables (age, VAS-score, tender and swollen joint count, CRP) the effect was 
studied both as continuous variable and categorized. Categories were made using clinically 
applied cut-off levels and percentiles. Categories were pooled if corresponding regression co-
effi cients were similar. Data on VAS morning stiffness were missing in 160 subjects, data on 
anti-CCP antibodies in 64 subjects and data on disease duration in 22 subjects. To prevent 
that these subjects were excluded from the logistic regression analysis, the median value was 
imputed. The multivariate regression analysis was performed using 562 UA patients as in 8 
patients one or more of the following variables were missing: rheumatoid factor (n=1), CRP 
(n=1), tender joint count (n=5), swollen joint count (n=4). To get a simplifi ed prediction 
rule, the regression coeffi cients of the predictive variables were rounded to the nearest num-
ber ending in .5 or .0 resulting in a weighted score; subsequently the independent predictive 
variables were summed. The calculated prediction scores were compared with the observed 
percentage progression to RA. The positive and negative predictive values were determined 
for several cut-off values of the prediction scores. To evaluate the diagnostic performance, 
a receiver-operating characteristic (ROC) curve was constructed. The area under the ROC 
curve (AUC) provided a measure of the overall discriminative ability of a model. For internal 
validation, cross-validation was performed to control for over-fi tting (18). Cross-validation 
mimics the prediction situation and yields for each observation a prediction score based on 
the other (n-1) observations (18). To validate the model a ROC-curve was made using the 
cross-validated predictions as well as the external validation cohort. The Statistical Package 
for Social Sciences (SPSS), version 10.0 (SPSS, Chicago, IL) was used.
RESULTS
Disease outcome
Of 570 UA-patients, 177 developed RA during the fi rst year of follow-up, 94 patients 
developed other rheumatological diseases, 149 patients remained unclassifi ed and 150 
patients achieved clinical remission defi ned as discharge from the outpatient clinic be-
cause of absence of arthritis without DMARDs. For further analysis, the patients with 
other rheumatological diagnosis, unclassifi ed arthritis and remission were assembled as 
the non-RA group (n= 393). 
Univariate analyses
Characteristics of UA-patients that did and did not develop RA are compared in Table 1. 









Multivariate analyses, derivation of prediction rule
In a logistic regression analysis the independent predictive variables for RA development 
were: age, gender, localization of joint complaints (small/big joints, symmetric/asymmet-
ric, upper/lower extremities), morning stiffness, tender and swollen joint count, CRP-lev-
el, RF and anti-CCP antibodies (Table 2). Age as continuous variable was more predictive 
than categorized; the other continuous variables were categorized. The resulting model 
had a fraction of explained variation (Nagelkerke R2) of 0.57 and, when taking a predicted 
Table 1. Characteristics at inclusion of UA-patient that did not and did progress to RA.
Patient characteristic Non-RA N=393 RA N=177 P
Age, mean (SD) 48.6 (17.0) 56.3 (15.3) <0.001
Female, n (%) 208 (53) 121 (68) 0.001
Positive family history for RA, n (%) 81 (21) 54 (31) 0.01
Course start complaints, n (%)
 acute <24 hr











Symptom duration at inclusion, n(%)
 < 6 weeks
 6 weeks – 3 months
 3- 6 months









Localisation affected joints, n(%)









Localisation affected joints, n(%) 
 symmetric 147 (37) 118 (67) <0.001










Morning stiffness (VAS), mean (SD) 35.5 (30.0) 53.3 (30.1) <0.001
Compression pain MCP joints, n(%) 159 (40) 116 (66) <0.001
Compression pain MTP joints, n(%) 134 (34) 103 (58) <0.001
Number tender joints, median (IQR) 3 (2-7) 8 (4-12) <0.001
Number swollen joints, median (IQR) 2 (1-4) 4 (2-7) <0.001
CRP level (mg/L), median (IQR) 8 (3-21) 14 (7-43) <0.001
ESR level (mm1st hr), median (IQR) 17 (8-38) 32 (19-53) <0.001
Rheumatoid factor positive, n (%) 56 (14) 84 (47) <0.001
Anti-CCP positive, n(%) 38 (11) 83 (51) <0.001
HAQ score, mean (SD) 0.7 (0.6) 1.0 (0.7) <0.001
Smoking, n(%) 187 (48) 84 (47) 1.0
Erosiveness, n(%) 29 (7) 29 (16) 0.001
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probability of 0.5 as cut off value, predicted 83% of patients correctly. The coeffi cients 
for the simplifi ed prediction score are listed in Table 2. Figure 1a presents a form to easily 
calculate the prediction score. The prediction score ranges between 0 and 14; a higher 
score indicates a higher risk to develop RA. For every UA-patient the prediction score was 
calculated. Figure 1b shows the predicted risk on RA as function of the prediction score 
(obtained from a logistic model with score as independent variable). Table 3 presents the 
observed percentage with progression to RA in relation to the calculated score. All UA-
patients with a prediction score ≤3 did not progress to RA during the one-year follow-up, 
and all UA-patients with a score ≥11 had progressed to RA. The patients with intermediate 
scores (4-10) had progressed to RA in increasing frequency at rising scores. Table 3 also 
shows the percentage of the patients that progressed to RA for several cut-off values of 
the prediction score. For example if the scores 5.0 and 9.0 were chosen as cut-off values, 
97% of UA-patients with a score a score ≤5.0 did not develop RA and a score ≥9.0 was as-
sociated with progression to RA in 84% of patients. If the cut-off values were 6.0 and 8.0, 
Table 2. Independent predictive variables for RA development resulting from multivariate 
regression analysis
Variable B * OR 95%CI P Points #
Gender 0.8 2.1 1.3-3.6 0.003 1
Age 0.02 1.02 1.01-1.04 0.011 0.02/yr
Localisation small joints hand/feet 0.6 1.8 1.1-3.1 0.024 0.5
Localisation symmetric 0.5 1.6 1.0-2.8 0.075 0.5
Localisation upper extremities





























































































RF positive 0.8 2.3 1.2-4.2 0.009 1
Anti-CCP positive 2.1 8.1 4.2-15.8 <0.001 2
* B means regression coeffi cient








91% of UA-patients with a score ≤ 6.0 did not develop RA (negative predictive value 91%, 
95%CI 88-94%) and a score ≥8.0 corresponded with progression to RA in 84% (positive 
predictive value 84%, 95%CI 75-91%). With these cut-off values 145 UA-patients (25%) 
had a score between 6.0 and 8.0, indicating that for these patients no adequate prediction 
could be made. Twenty-fi ve UA-patients did not fulfi ll the 1987 ACR-criteria for RA after 
one-year follow-up, but developed RA later in the disease course. These patients had a 
median prediction score of 5.7 (IQR 4.8-6.2); this value is in-between the scores of the 
UA-patients that did and did not develop RA during the fi rst year of follow-up (median 
score 7.7, IQR 6.6-8.8 and median score 4.6, IQR 3.3-5.9 respectively).
Discriminative ability
The discriminative ability of the logistic regression model and the prediction rule were 
evaluated with a ROC curve (Figure 2). Both had an AUC of 0.89 (SE 0.014). The fi nding 
that the AUC of the logistic regression model and the prediction rule were equal, indicates 
that the derivation of the prediction rule from the logistic regression model had not 
introduced a loss in discriminative ability.
Internal validation
Cross-validation was used to control for over-fi tting. This procedure yielded for every 
patient a predicted probability on RA, based on the model fi tted on the other patients 
1. What is the age in years? Multiply with 0.02 
2. What is the gender? In case female: 1 point
3. How is the distribution of involved joints?
In case small joints hands / feet: 0.5 point
In case symmetric: 0.5 point
In case upper extremities 1 point
or in case upper & lower extremities:1.5 points 
4. What is the length of the VAS morning stiffness (range 0-100 mm)?
In case 26-90 mm: 1 point
In case > 90 mm: 2 points
5. What is the number of tender joints?
In case 4-10: 0.5 point
In case 11 or higher: 1 point
6. What is the number of swollen joints?
In case 4-10: 0.5 point
In case 11 or more: 1 point
7. What is the C-reactive protein level (mg/L)?
In case 5-50: 0.5 point
In case 51 or higher: 1.5 points
8. Is the Rheumatoid factor positive? If yes: 1 point
9. Are the anti-CCP antibodies positive? If yes: 2 points
Total score


















Figure 1b. The subjects’ prediction scores 
plotted versus the predicted risk to 
develop RA.
Figure 1a. Form to calculate a patient’s 
prediction score
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(18). The AUC of the cross-validated predictions nearly equaled the AUC of the prediction 
score: 0.87 (SE 0.015, Figure 2), indicating that over-fi tting is not a major problem.
External validation
In the validation cohort 47% of UA-patients had progressed to RA after one-year fol-
low-up. The prediction scores of the UA-patients that did not and did develop RA are 
presented in Figure 3. The UA-patients who had progressed to RA had a median prediction 
score of 8.0 (IQR 6.1-9.1) and the patients who did not develop RA had a median predic-
tion score of 4.6 (IQR 3.5-5.5). 94% of the patients with a prediction score ≤6.0 had not 
progressed to RA and RA-development was observed in 83% of patients with a score >6. 
All patients with a score ≥8.0 had progressed to RA and 78% of patients with a score <8 did 
not develop RA. 17% of the UA-patients in the validation cohort had a prediction score 
Table 3. Prediction score and number (%) of patients that did not or did progress to RA, as well as 
several cut-off values for prediction scores with corresponding chances on RA development
Score* Non-RA n (%) RA n (%)
0 1 (100) 0 (0)
1 8 (100) 0 (0)
2 42 (100) 0 (0)
3 58 (100) 0 (0)
4 78 (93) 6 (7)
5 73 (85) 13 (15)
6 63 (74) 22 (26)
7 37 (49) 38 (51)
8 16 (33) 33 (67)
9 6 (14) 36 (86)
10 5 (23) 17 (77)
11 0 (0) 8 (100)
12 0 (0) 1 (100)






























* Prediction scores were rounded to the nearest number ending in .5 or.0. (i.e. scores ≤0.5 are in the 








between 6 and 8; two-third of them had not developed RA and one-third had developed 
RA. When treatment decisions were based on the prediction rule using the cutoff level ≥8 
for initiating treatment and ≤6 for withholding treatment, only 6% of the patients should 
have been inaccurately withheld from treatment and no patients should have been inac-
curately treated. The AUC of the validation cohort was 0.97 (SE 0.024). 
DISCUSSION
The currently developed rule predicts in UA-patients the risk to develop RA using nine 
clinical variables that are all commonly assessed during the fi rst visit: gender, age, local-
ization of joint symptoms, morning stiffness, counts for tender and swollen joints, CRP, 
rheumatoid factor and anti-CCP antibodies. The resulting prediction score corresponds 
with a chance on progression to RA. The positive and negative predictive values of the 
prediction score depend on the chosen cut-off values. The discriminative ability was ex-
cellent with an AUC of 0.89, and 0.87 after internal validation correcting for over-fi tting. 
The subsequent validation in a small independent cohort revealed an AUC of 0.97. As 
the developed prediction rule is accurate and easily assessed in daily clinical practice, 
the present model is an important step forward in achieving individualized treatment in 
patients with recent-onset UA.
As current evidence on treatment of RA is based on large trials using patients fulfi lling 



















Figure 2. Receiver operator curve of logistic 
regression model, prediction rule and cross-
validated prediction model. The AUC of the 
logistic regression model, prediction rule and cross-
validated prediction model were respectively 0.89, 0.89 
and 0.87.
Figure 3. The prediction scores of 
the patients included in the external 
validation cohort that did not and 
did develop RA.
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outcome measurements such as disease persistence or remission can be considered, but no 
generally accepted defi nitions for these disease states are present and there are no trials of 
patients with these disease states providing guidance in treatment decisions. Nevertheless, 
the use of fulfi lment of the ACR-criteria as outcome may lead to circularity as the items 
of the ACR-criteria are expected to result as predictive variables. However, several studies 
have shown that the ACR-criteria themselves have low discriminative value in patients 
with UA (12, 19-23) and only part of the variables of the present prediction rule are items 
of the ACR-criteria. In the end it will most likely not make a large difference whether the 
outcome of a prediction rule is the diagnosis RA or disease persistence, as the ACR-criteria 
are formulated based on RA-patients with longstanding/persistent disease (mean disease 
duration 8 years) and the reported remission rate in these patients is low: 10-15% (24,25).
Misclassifi cation may have occurred when patients who presented with UA were treated 
with any drug that has hampered the progression to RA. In case of misclassifi cation, pa-
tients that normally had progressed to RA are now classifi ed as non-RA. Exclusion of these 
eventual misclassifi ed patients, with supposedly high prediction scores as they were prone 
to develop RA, will result in an increased discriminative ability of the current prediction 
rule.
The presence of erosions on radiographs of hands and/or feet is reported to have a high 
specifi city (but low sensitivity) for discriminating between self-limiting and persistent 
disease (23). Although in univariate analysis erosions were signifi cantly more present in 
the UA-patients that developed RA compared to the UA-patients that did not (16% vs. 
7%), multivariate regression analysis revealed that the presence of erosions was not an 
independent prognostic variable. The presence of erosions appeared to be associated with 
a higher age (median 64 years in erosive versus 49 years in non-erosive disease), number 
of swollen joints (median 5 joints in erosive versus 2 joints in non-erosive disease) and 
presence of rheumatoid factor (46% in erosive versus 23% in non-erosive disease). As the 
presence of erosions was not identifi ed as a variable with an independent predictive value, 
data on erosions were not included in the prediction rule. 
A model for the prediction of a self-limiting, persisting or erosive arthritis exists (23). 
For this model’s development all consecutive patients referred with arthritis were incor-
porated, including the patients in whom during the fi rst weeks a defi nite diagnosis was 
made. Decisions on initiation of DMARDS are seldom problematic in these patients. At 
present, support in treatment decisions is needed in patients with recent onset UA (26), 
as the disease outcome in these patients is variable. The present study therefore selected 
the patients with UA from a total number of 1700 consecutive patients and developed a 








The positive and negative predictive values of the prediction score depend on the chosen 
cut-off level. If the upper and lower cut-off values were 8.0 and 6.0, the corresponding 
positive predictive value and negative predictive value were respectively 84% and 91%. 
In the original cohort 25% of patients had a prediction score between 6.0 and 8.0; these 
patients had an equal chance to develop RA or not. Apparently, clinical characteristics are 
in these patients insuffi cient to predict the disease outcome. In the validation cohort, the 
prediction score discriminated even better: a hundred percent of patients with a score of 
8.0 or higher had progressed to RA and 94% of patients with a score of 6.0 or lower did not 
develop RA. This indicates that when treatment decisions were based on the prediction 
rule using the cutoff level ≥8 for initiating treatment and ≤6 for withholding treatment, 
only 6% of the patients should have been inaccurately withheld from treatment and no 
patients should have been inaccurately treated. In the validation cohort 17% of patients 
had a prediction score between 6.0 and 8.0; for treatment decisions in these patients the 
observed risk to progress to RA can be weighted against the individual risk profi le for 
treatment toxicity. Although the validation cohort is relatively small and the current pre-
diction rule should be evaluated in other early arthritis cohorts, we feel that the current 
model allows physicians and patients an evidence-based choice whether or not to initiate 
DMARDs in the majority of patients presenting with UA.
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Summary and Discussion 191
Rheumatoid arthritis is a chronic and self-amplifying autoimmune process that ultimate-
ly leads to the destruction of cartilage and bone. The pathophysiologic development of 
infl ammation in RA is complex and involves both the adaptive and the innate arms of 
the immune system. The events triggering the autoimmune mechanisms are thought to 
be a combination of genetic and environmental factors and the process is best described 
by a multiple hit model.
The most important genetic risk factor for RA, the HLA-DRB1 alleles encoding for the 
shared epitope motif, was recognized three decades ago (1). In this thesis the shared epi-
tope alleles are investigated in the perspective of the presence and absence of another 
important risk factor, the autoantibodies. The shared epitope alleles appeared to predis-
pose only to RA-patients that carry anti-CCP antibodies and not to anti-CCP negative 
RA (chapter 7). This fi nding led to the hypothesis that the shared epitope alleles confer 
risk to anti-CCP antibodies, rather than to (anti-CCP positive) RA. To investigate this 
assumption, the progression from recent-onset UA to RA was studied in relation with the 
HLA-DRB1 alleles and autoantibodies (chapter 10). In patients that presented with UA, 
the shared epitope alleles were associated with anti-CCP antibodies, but after correction 
for the presence of anti-CCP antibodies the share epitope alleles were not an independent 
risk factor for progression to RA. Furthermore, the shared epitope alleles were primarily 
associated with the anti-CCP antibodies and not with RF. Although no formal conclusions 
on causality can be drawn from this association study, the fi ndings presented in this 
chapter suggest that the shared epitope alleles confer risk to anti-CCP antibodies and that 
these antibodies mediate the association between the shared epitope alleles and RA. 
Next, the best-known environmental risk factor for RA, smoking, was studied. The pres-
ence of both shared-epitope alleles and smoking resulted in a gene-environmental inter-
action for the presence of anti-CCP antibodies (chapter 9). The data of this study indi-
cate that the gene-environmental interaction is more pronounced for the development 
of anti-CCP antibodies than for the development of RF. Further analysis revealed that 
tobacco exposure in the presence of shared epitope alleles did not signifi cantly increase 
the risk for anti-CCP antibodies among patients with after one-year follow-up persistent 
undifferentiated arthritis (UA). This might indicate that the gene-environmental interac-
tion is specifi c for RA. On the other hand, the gene-environmental interaction seems 
specifi c for anti-CCP antibodies and, in that case, the interaction should not be depended 
on a clinical diagnosis. Considering the small number of (anti-CCP positive) patients with 
persistent undifferentiated arthritis in this study, the power of the present study was prob-
ably inadequate to conclude defi nitely on the presence/absence of a gene-environmental 
interaction in UA.
The fi nding that the shared epitope alleles primarily associate with RA in the presence 








associated with other, non-shared epitope encoding, HLA-DRB1 alleles. Analysis revealed 
that HLA-DR3 was more frequently present in the anti-CCP-negative RA and anti-CCP 
negative UA patients compared to controls, indicating that HLA-DR3 is associated with 
anti-CCP negative arthritis (Chapter 8). 
The observation that anti-CCP positive and negative RA have different genetic risk 
factors indicates that different pathogenetic mechanisms underlie anti-CCP-positive and 
anti-CCP-negative disease. Therefore, it is conceivable that anti-CCP positive and nega-
tive RA are different disease entities and thus have different phenotypical properties. An 
extensive comparison of clinical characteristics at fi rst presentation between anti-CCP 
positive and negative RA patients (evaluating among others morning stiffness, type and 
distribution of early symptoms, C-reactive protein level, tender and swollen joint count) 
revealed no signifi cant differences. Nevertheless, during the disease course RA patients 
with anti-CCP antibodies had more swollen joints and more radiological joint destruction 
compared to RA patients without anti-CCP antibodies (chapter 11). Thus, although dif-
ferent risk factors are associated with anti-CCP positive and negative RA, the presence or 
absence of anti-CCP antibodies is not associated with a distinguishable clinical phenotype 
at the fi rst presentation of the disease. 
Considering the results of the above mentioned association studies, and the fi ndings that 
citrullinated antigens are found in infl amed joints, anti-CCP antibodies are specifi c for 
RA and anti-CCP antibodies are generally present before the onset of clinical symptoms, 
it seems likely that the anti-CCP antibodies are important in the pathogenesis of RA. So 
far, there little evidence demonstrating that anti-CCP antibodies induce or mediate the 
development of chronic joint infl ammation. Kuhn and collegues injected monoclonal 
antibodies reactive to citrullinated fi brinogen in mice and observed an exacerbation of 
arthritis. They also showed in a collagen-induced arthritis model that tolerization of CCP-
specifi c immune responses resulted in a strong inhibition of arthritis severity (24). As 
these results are not yet replicated, the issue whether anti-CCP antibodies are involved 
in RA pathogenesis or are a byproduct of a more general immunological reaction is not 
clarifi ed. 
The Shared Epitope hypothesis postulates that the shared epitope motif is directly in-
volved in the pathogenesis of RA. Data providing evidence that this hypothesis is correct 
is lacking. Since its initial description, the Shared Epitope hypothesis has been proven 
robust because of its consistent association with RA susceptibility and severity among 
varied ethnic populations, but so far a specifi c athritogenic peptide that binds to the HLA-
DR proteins and induces a T cell response has not been found. 
Since the identifi cation of citrullinated proteins and anti-CCP antibodies it has been 
proposed that in genetically predisposed (shared epitope positive) subjects and an infl am-
matory environment citrullinated proteins break immunologic tolerance and initiate an 
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HLA-class II restricted T cell response (2,3). Subsequently, the help provided by T cells 
might allow maturation and switching of B cells, resulting in further maturation of the 
anti-CCP immunoglobulin response (2). With this hypothesis in mind, it is interesting to 
note that the data presented in chapter 7 show that carrying two copies of shared epitope 
alleles confers a signifi cant higher risk on anti-CCP positive RA than the presence of one 
shared epitope allele (odds ratio 12 and 4 respectively). Compare these fi ndings with the 
data presented in chapter 10. This chapter reveals that the presence of two shared epitope 
alleles is not associated with higher anti-CCP antibody levels compared to the presence 
of one shared epitope allele (the shared epitope alleles act like the previously described 
immune response genes). At fi rst sight these observations seem contradicting, but this 
might be explained as follows. In the presence of more shared epitope alleles/ more HLA 
molecules, more antigen can be presented and immune tolerance is broken more easily, 
leading to a dose-response relation between the shared epitope alleles and the presence 
of anti-CCP antibodies. Conversely, antigen presentation might not be the limiting factor 
that determines the antibody level and the level of autoantibodies might be infl uenced by 
other factors. Nonetheless, it must be realized that at present no convincing experimental 
data exist showing that in shared epitope positive humans the presence of citrullinated 
peptides induces T cell proliferation. Currently, there are two studies that assess the effect 
of citrullination on T cell activation in relation with MHC molecules. Hill et al showed 
in mice transgenic for MHC-DRB1*0401 a vimentin peptide citrullinated in a region with 
contact to SE-binding site harboured a higher affi nity for the MHC-DRB1*0401 molecule 
resulting in a better T cell acitivation compared to its noncitrullinated counterpart (4). 
Ireland et al used hen egg-white lysozyme as a model antigen and demonstrated the oc-
currence of a specifi c T cell response after citrullination (5). Both studies were performed 
in mice and the immunopathologic role of citrullinated peptides in humans needs further 
investigation. 
This thesis considered not only the shared epitope alleles but also four other genetic risk 
factors for RA. The fi rst is also located on the HLA class II alleles and is positioned on the 
same locus. It concerns the alleles encoding for the amino acids D70ERAA. From previous 
(smaller) studies it was not clear whether the presence of DERAA was really protective or 
whether the observed effect was the result of the absence of predisposing shared epitope 
alleles. By comparing subgroups of RA-patients and controls with an equal amount of 
shared epitope alleles, we were able to show that the presence of the DERAA-encoding 
alleles had a protective effect on RA that was independent from the presence/absence of 
shared epitope alleles (Chapter 2). The presence of DERAA was associated with both a 
lower risk to develop RA and a less severe disease course. The protective effect of DERAA 
on susceptibility was not confi ned to anti-CCP positive RA, but seemed stronger for anti-








Considering the severity of RA, the protective effect of DERAA was most pronounced in 
the patients that were shared epitope positive, smoked or had anti-CCP antibodies. We re-
alize now that these risk factors all infl uence the same pathway. Thus, the protective infl u-
ence of DERAA can be detected best in patients that are prone to severe disease (Chapter 
2). It is remarkable that although the presence of DERAA was evidently associated with 
less severe joint destruction and the (small group of) RA patients that were homozy-
gous for DERAA had a non-destructive disease course, the presence of DERAA was not 
associated with a higher rate of clinical remission. Speculatively, the pathways associated 
with the expression of DERAA-encoding HLA-alleles are able to dampen the pathways 
underlying bone and cartilage destruction, but do not affect the principal pathway that 
drives chronicity. It has been demonstrated that peptides carrying the DERAA motif are 
naturally processed by human antigen-presenting cells (6). As discussed in chapter 2 the 
protective effect of DERAA might be due to the activation of regulatory T cells. These T 
cells are believed to play a key role in mediating transplantation tolerance and inhibiting 
the induction of tumor immunity; and might likewise suppress the immune response 
in RA. There are however other presumptions on the pathways underlying the effects 
of DERAA. The amino acid sequence DERAA is present in several microorganisms, such 
as mycobacteria, Haemophilus infl uenzae, Salmonella, and is also present in vinculin, 
a protein localized in the cell’s cytoplasma. It can be speculated that patients that carry 
DERAA-encoding alleles are immunotolerant for DERAA when encountered during infec-
tions, but that DERAA-negative individuals develop an immune reaction against DERAA. 
During apoptosis vinculin, a part of the cytoskeleton, will be degraded, possibly leading 
to its presentation in the context of MHC-molecules. Indeed, it has been described that 
apoptotic cells overexpress vinculin and after ingestion by dendritic cells can be presented 
toward T cells under certain pathophysiological conditions (8). It is conceivable that DE-
RAA-negative patients harbouring a DERAA-directed T cell response against all sorts of 
pathogens experience an accelerated disease progression as a consequence of T cell cross 
reactivity with vinculin-DERAA that is perhaps chronically presented in the infl amed 
joint in RA. According to this hypothesis, the presence of DERAA does not result in im-
munosuppression/protection but the absence of DERAA enforces the immune reaction 
and thereby disease progression. Currently, laboratory experiments are being undertaken 
to investigate this hypothesis.
The fi ndings presented in chapter 2 lead to the question whether the presence of DERAA is 
helpful in predicting the development of RA in patients with UA. Analysis (not described 
in this thesis) revealed that in univariate analysis the presence of DERAA-encoding alleles 
in patients with recent-onset UA was signifi cantly associated with a lower rate of progres-
sion towards RA. In multivariate analysis the absence of DERAA-encoding alleles appeared 
not to be an independent risk factor for the development of RA. Further analysis showed 
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that the presence of DERAA was associated with a lower number of tender and swollen 
joints, a lower level of C-reactive protein and a lower frequency of anti-CCP and RF posi-
tivity. This implies that the DERAA-encoding alleles associate with a milder phenotype 
and that the clinical and serological factors are stronger predictors for the disease course 
in UA-patients than the DERAA-encoding alleles. The determination of the DERAA-en-
coding alleles therefore does not add to the discriminative ability of the prediction model 
described in chapter 16.
Non-HLA genetic risk factors that are investigated in this thesis are single nucleotide 
polymophisms in the genes encoding for PTPN22, TNFR2 and RAGE.
The C1858T SNP in the PTPN22 gene encoding for a lymphoid tyrosine phosphatase 
(Lyp) is associated with RA susceptibility, which was fi rst identifi ed by Begovich et al (9). 
This intracellular Lyp binds a Csk kinase and Csk-Lyp inhibits T-cell-receptor signaling. In 
vitro experiments have shown that in T-allele carriers Lyp binds less effi ciently to Csk sug-
gesting that T cells expressing the T-allele might be hyperresponsive (9). Knocking out the 
murine homologue of PTPN22 resulted in lower thresholds for T-cell-receptor signaling 
(25). A recent study revealed a more active phosphatase in T-allele carriers and the authors 
suggested that the increased effi cacy to inhibit T-cell-receptor signaling may lead to insuf-
fi cient activity of regulatory T cells (26). The study described in chapter 4 replicates 
the association between PTPN22 and RA, but shows that compared to healthy controls 
the 1858 T-allele confers risk to only anti-CCP antibody positive RA and not to anti-CCP 
negative RA. A similar fi nding has been described for rheumatoid factor (10, chapter 4). 
In addition, the present study observed no correlation between PTPN22 and the degree 
of radiological joint destruction in RA. This seems unsuspected regarding the fi nding 
that PTPN22 associates with anti-CCP positive RA and anti-CCP antibodies are associated 
with severe disease. The most likely clarifi cation for this fi nding is mathematical: 48 of 
76 patients (63%) carrying the genotype CT or TT had anti-CCP antibodies compared to 
149 of 274 (54%) patients with genotype CC. Thus, the percentages anti-CCP positivity 
were in the same range (and not signifi cantly different), making it comprehensible that 
no signifi cant difference in the degree of joint destruction was observed between these 
two groups of RA-patients. It is not excluded that, considering the small ORs of the effect 
of PTPN22, the number of RA-patients was too small to discern an effect of PTPN22 on RA 
severity. Finally, this study showed that PTPN22 is not only a risk factor for RA but also 
for (persistent) UA. This is in line with reports showing that the 1858 T-allele is associated 
with multiple autoimmune diseases as SLE, type 1 diabetes and Graves disease (11-14).
The investigated SNPs in the TNFR2 and RAGE genes were not associated with RA. 
In chapter 3 the TNFR2 196M/R genotypes of the patients with the most severe joint 
destruction and with clinical remission were similar. An effect of this SNP on RA severity, 








The absence of an association between TNFR2 196 M/R and RA severity is replicated by 
the French (15). Interestingly, one of the two reports that initially observed an association 
between this TNFR2 SNP and susceptibility to familial RA was recently corrected, as the 
described fi nding appeared to be due to an error in genotyping (16).
There are fi ndings that suggest a role for receptor for advanced glycosylation end prod-
ucts (RAGE) signaling in the pathogenesis of RA. RAGE is upregulated in synovial tis-
sue macrophages in active RA (17) and activation of RAGE may lead to upregulation of 
adhesion molecules and expression of pro-infl ammatory cytokines (18). Although initial 
fi ndings suggested an association between the G82S SNP and RA susceptibility, this as-
sociation is depended on the strong linkage disequilibrium between RAGE and the HLA-
DR4 allele (chapter 5).
In conclusion, the genetic risk factors that associate with RA susceptibility and are de-
scribed in this thesis are the shared epitope HLA-DRB1 alleles and the C1858T PTPN22
SNP (predisposing effects) and the DERAA encoding HLA-DRB1 alleles (protective effects). 
Considering that the heritability of RA is estimated to be 50-60% (19) and that the identi-
fi ed genetic factors account for at most half of this percentage, more genetic risk factors 
for RA susceptibility are likely to be identifi ed. 
The genetic factors that associate with RA severity and are identifi ed so far are the HLA-
DRB1 alleles that encode for the shared epitope motif (effect via anti-CCP antibodies) or 
encode for DERAA. The heritability of RA severity is not known. The observation of an in-
crease in variation of radiological joint destruction comparing respectively monozygotic 
twins, dizygotic twins and unrelated pairs of RA patients (after correction for differences 
in disease duration and autoantibody status) indicates that genetic factors are important 
for RA severity (chapter 13). More extensive twin studies are needed to quantify the 
genetic contribution to RA severity.
The level of joint destruction in RA patients correlated with the degree of in vitro mea-
sured invasiveness of fi broblast-like synoviocytes in a matrigel matrix (chapter 12). This 
study provides the fi rst evidence that the in vitro measured invasiveness of fi broblast-like 
synoviocytes might be of relevance for the pathophysiology of RA.
The described genetic and environmental risk factors for the development of both UA and 
RA and for RA severity can be positioned in a multiple hit model, see Figure 1. 
From the patients’ and clinicians’ perspective, an increased understanding of the 
pathogenesis of RA is particularly relevant when it has implications for (the treatment of) 
individual patients. Both UA and RA are diseases with a heterogeneous course. Achiev-
ing individualized treatment decisions in these patients is an important challenge for 
the nearby future. This signifi es that for individual patients the predicted prognosis is 
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weighted against the possible desired and toxic effects of various treatments. For early 
UA, recent evidence indicates that treatment with methotrexate hampers progression to 
RA (20). However, from several inception cohorts it is known that only about one third 
of the patients that present with UA progress to RA and 40-50% remits spontaneously 
(20-23); these patients are preferably not treated with methotrexate. This underscores the 
need for a model that identifi es the UA-patients with a high risk to progress to RA. The 
development of such a model is described in chapter 16. The derived model predicts 
in UA-patients the risk to develop RA using nine clinical variables that are all commonly 
assessed during daily clinical practice (gender, age, localisation of joints symptoms, morn-
ing stiffness, counts for tender and swollen joints, CRP, RF and anti-CCP antibodies). 
The resulting prediction score (a value between 0 and 14) corresponds with a chance on 
progression to RA. The positive and negative predictive values depended on the chosen 
cut-off values. If the upper and lower cut-off value were 8.0 and 6.0, the corresponding 
positive and negative predictive values were 84% and 91%. Twenty-fi ve percent of the 
patients had a score between 6.0 and 8.0; in these patients no adequate prediction was 
made. Clinical characteristics are apparently insuffi cient to predict the disease outcome 
for these patients and it would be of interest to assess whether the addition of genetic fac-
tors increases the predictive ability. The known genetic risk factors for RA susceptibility, 
HLA-DRB1 alleles and PTPN22, do not have additive predictive value in this model, as the 
shared epitope encoding alleles correspond with the presence of anti-CCP antibodies that 
are already included in the prediction model and PTPN22 confers risk both to UA and RA. 
Overall, the discriminative ability of the model was excellent with an area under the re-
ceiver operator curve of 0.87 after internal validation and 0.97 for external validation. As 
the cohort used for external validation was relatively small, the developed prediction rule 
needs to be validated in other cohorts of patients with UA. Since the developed prediction 
rule is accurate and easily assessed in clinical practice, the present model might prove to 
be an important step forward in achieving individualised decision-making in patients 
with UA. For the future it is hoped and expected that early treatment of the UA-patients 
with a high risk to develop RA will hamper the progression to RA. As the social impact 
of RA is nowadays still considerable (see introduction), the goal of such a therapeutic 














* Predisposing effect on susceptibility to RA (chapter 7) and UA and development from 
UA to RA (chapter 10,16). Association with destructive disease (chapter 11). Interaction 
with smoking (chapter 9).
¶ Predisposing effect on anti-CCP negative RA (chapter 8).
# Protective effect on susceptibility to UA (discussion), susceptibility to RA (chapter 2) 
and severity of RA (chapter 2).






Shared epitope HLA-DRB1 alleles
HLA-DRB1*03 ¶
Figure 1. Multiple hit model for the development of RA.
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Het onderwerp van dit proefschrift is reumatoïde artritis. Bij deze ziekte staat ontsteking 
centraal. Het meest frequent zijn de gewrichten van de handen en voeten betrokken, 
maar alle gewrichten kunnen bij deze ziekte aangedaan zijn. De ontsteking richt zich 
tegen de bekleding van het gewrichtskapsel, het synovium. De ontstekingsreactie van het 
synovium zorgt voor een gezwollen, pijnlijk gewricht. De ontsteking van het synovium 
tast ook het kraakbeen en het bot aan; deze botaantasting is op röntgenfoto’s te zien. Het 
beloop van reumatoïde artritis is wisselend: sommige patiënten hebben weinig gezwollen 
of pijnlijke gewrichten en nauwelijks of geen beschadigingen, terwijl andere patiënten 
vaak gezwollen gewrichten hebben met veel botaantasting op de röntgenfoto. De gevol-
gen van reumatoïde artritis zijn enorm. Een onderzoek uitgevoerd onder Nederlandse 
patiënten met reumatoïde artritis liet zien dat 42% van de patiënten problemen had met 
werken, 40% overdag extra rust moest nemen en 50-60% van de patiënten belemmerd 
was in de vrije tijdsbesteding. Volgens een recent overzicht van TNO komt reumatoïde 
artritis voor bij 1 op de 1000 mannen en 2 op de 1000 vrouwen in Nederland. Het grote 
aantal patiënten gecombineerd met de forse beperkingen ten gevolge van de ziekte heeft 
ook fi nanciële consequenties. De directe kosten die uit de ziekte voortvloeien worden in 
Nederland op €5250 per patiënt per jaar geschat. Het laatste decennium is de behandeling 
van reumatoïde artritis veranderd. Er wordt in een eerder stadium gestart met krachtiger 
medicijnen, wat leidt tot een betere controle van de ziekte. Er is reeds bewijs dat deze 
manier van behandelen gunstige effecten heeft op zowel de mate van botbeschadiging als 
op het functioneren van patiënten.
Voordat de diagnose reumatoïde artritis gesteld mag worden, moet aan 4 van 7 opgestelde 
criteria voldaan zijn. Deze criteria zijn: 1) het hebben van ochtendstijfheid, 2) het heb-
ben van ontsteking van 3 of meer gewrichten, 3) betrokkenheid van handgewrichten, 4) 
symmetrische gewrichtsontsteking, 5) het hebben van reumanoduli, 6) het hebben van 
reumafactor in het bloed en 7) het hebben van botaantasting op de röntgenfoto. Ten tijde 
van het eerste bezoek bij de reumatoloog hebben sommige patiënten direct voldoende 
kenmerken om de diagnose reumatoïde artritis te stellen (22%). In 40% van de patiënten 
zijn er wel gewrichtsontstekingen maar kan geen diagnose worden gesteld. Het ziektebeeld 
bij deze patiënten wordt ongedifferentieerde artritis genoemd. De uitkomst van ongedif-
ferentieerde artritis is divers: ongeveer eenderde van de patiënten ontwikkelt reumatoïde 
artritis en in 40-50% verdwijnt de gewrichtsontsteking spontaan. Hoewel de behandeling 
van reumatoïde artritis momenteel effectiever is dan een decennium geleden, is het streven 
in toekomst om de gewrichtsontsteking op een vroeg moment te remmen, bijvoorbeeld 
in de fase van ongedifferentieerde artritis, zodat verdere progressie tot reumatoïde artritis 
voorkomen wordt. Voor het ontwikkelen van een dergelijke behandeling is het van be-
lang dat het ontstaan van reumatoïde artritis beter begrepen wordt. Daarnaast is het van 








hoge kans hebben om reumatoïde artritis te krijgen. Dit voorkomt dat patiënten met een 
ongedifferentieerde artritis waarbij de kans groot is dat de gewrichtsontsteking spontaan 
verdwijnt onnodig behandeld worden. Dit proefschrift probeert in de eerste plaats een 
bijdrage te leveren aan het begrip over de ontstaanswijze van en risicofactoren voor het 
ontwikkelen van reumatoïde artritis. Ten tweede beschrijft dit proefschrift een model dat 
bij individuele patiënten met een ongedifferentieerde artritis gebruikt kan worden om de 
kans op progressie tot reumatoïde artritis te voorspellen.
In het eerste deel van het proefschrift wordt het verband van 4 genetische factoren en 
reumatoïde artritis beschreven. Hoofdstuk 2 laat zien dat mensen die bepaalde genen 
hebben, HLA-genen die coderen voor een bepaalde aminozuurvolgorde (DERAA), een 
verlaagd risico hebben om reumatoïde artritis te krijgen. Indien mensen met deze genen 
reumatoïde artritis krijgen verloopt de ziekte ook milder en treedt er minder botbeschadi-
ging op. In hoofdstuk 4 wordt een tweede genetische risicofactor voor reumatoïde artritis 
beschreven, genaamd PTPN22. Het blijkt dat mensen die een bepaalde variant van deze 
genetische factor hebben vaker reumatoïde artritis en ongedifferentieerde artritis krijgen 
dan mensen zonder deze genetische variant. In de hoofdstukken 3 en 5 worden twee 
genetische factoren (het betreft de genen coderend voor TNFR2 en RAGE) beschreven die 
niet geassocieerd bleken te zijn met respectievelijk de ernst en het optreden van reuma-
toïde artritis. 
De belangrijkste genetische risicofactor voor reumatoïde artritis is zo’n 30 jaar bekend en 
bestaat uit bepaalde HLA-genen die coderen voor een gemeenschappelijke structuur die 
‘shared epitope’ genoemd wordt (hierna kortweg HLA-shared epitope). Reumatoïde artritis 
wordt beschouwd als een auto-immuun ziekte omdat het kenmerken heeft van een afweer 
die tegen het eigen lichaam is gericht. Een voorbeeld hiervan is de aanwezigheid van 
reumafactor, een antistof die bij ongeveer 60% van de patiënten met reumatoïde artritis 
voorkomt en gericht is tegen een onderdeel van bepaalde andere antistoffen. Reumafactor 
kan echter ook in het bloed aanwezig zijn bij andere ziekten of bij gezonde mensen. De 
laatste jaren is er veel belangstelling voor een tweede antistof, de anti-CCP antistoffen, die 
gericht tegen bepaalde (gecitrullineerde) eiwitten. Deze antistoffen lijken veel specifi eker 
voor reumatoïde artritis te zijn dan reumafactor is. Het tweede deel van dit proefschrift 
onderzoekt de relatie tussen de HLA-shared epitope genen en de anti-CCP antistoffen. 
De analyse beschreven in hoofdstuk 7 laat zien dat de HLA-shared epitope genen alleen 
een risicofactor zijn voor reumatoïde artritis patiënten die anti-CCP antistoffen hebben 
en niet voor reumatoïde artritis patiënten zonder deze antistoffen. Een verdere analyse 
beschreven in hoofdstuk 10 geeft aanleiding te veronderstellen dat de HLA-shared epitope 
genen niet een directe risicofactor zijn voor het ontwikkelen van reumatoïde artritis maar 
primair geassocieerd zijn met de aanwezigheid van anti-CCP antistoffen, die vervolgens 
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gecorreleerd zijn met reumatoïde artritis. Het onderzoek beschreven in hoofdstuk 9 laat 
zien dat roken door mensen die HLA-shared epitope genen hebben een extra groot risico 
geeft op het ontwikkelen van anti-CCP antistoffen. Gezien de bevindingen van hoofdstuk 
7-10 lijkt het erop dat de risicofactoren voor reumatoïde artritis verschillend zijn voor pa-
tiënten met en zonder anti-CCP antistoffen. Om die reden is in hoofdstuk 11 vergeleken 
of de aard van de klachten en de kenmerken bij het lichamelijk onderzoek bij de eerste 
ziektepresentatie tussen beide groepen patiënten verschillend is. Dit bleek niet zo te zijn. 
Wel bleken de mensen met anti-CCP antistoffen een ernstiger ziektebeloop te hebben met 
meer gezwollen gewrichten en meer botbeschadigingen op de röntgenfoto’s.
In het derde deel van dit proefschrift worden twee aspecten die samenhangen met de 
ernst van reumatoïde artritis beschreven. In hoofdstuk 12 wordt bekeken of de in het la-
boratorium gemeten ingroei van bepaalde cellen uit de gewrichtsbekleding (fi broblast-like 
synoviocytes) in een kraakbeenmodel correleert met de mate van kraakbeendestructie en 
botbeschadiging bij patiënten gemeten op röntgenfoto’s. Deze correlatie bleek inderdaad 
aanwezig te zijn, wat suggereert dat deze fi broblast-like synoviocytes betrokken zijn bij het 
ontstaan van gewrichtsaantasting in reumatoïde artritis. In hoofdstuk 13 wordt gekeken 
of er aanwijzingen zijn dat genetische factoren invloed hebben op de ernst van de ziekte. 
Hiertoe is de mate van gewrichtsaantasting van eeneiige tweelingen, twee-eiige tweelingen 
en niet-verwante patiëntparen met reumatoïde artritis vergeleken. De achtergrond is dat 
eeneiige tweelingen 100% identieke genen hebben, twee-eiige tweelingen gemiddeld 50% 
identieke genen en niet-verwante patiënten minder dan 50% identieke genen. Het bleek 
dat de variatie in gewrichtsaantasting het grootst was in de niet-verwante patiëntparen en 
het kleinst in de eeneiige tweelingen. Deze bevinding geeft aanleiding te veronderstellen 
dat genetische factoren van belang zijn voor de mate van ernst van reumatoïde artritis.
Het vierde deel van dit proefschrift gaat over het voorspellen van het beloop van de ziekte. 
Hoofdstuk 14 geeft een overzicht van de beschreven risicofactoren voor reumatoïde ar-
tritis en beschrijft voorwaarden waaraan een voorspelmodel moet voldoen. In hoofdstuk 
15 is onderzocht of de verdeling van ontstoken gewrichten een voorspellende waarde 
heeft. Het blijkt dat het hebben van een gewrichtsontsteking van de knie bij de eerste 
ziektepresentatie gepaard gaat met een grotere kans op botbeschadigingen tijdens het ver-
loop van reumatoïde artritis. In hoofdstuk 16 is de ontwikkeling van een voorspelmodel 
beschreven. Dit model voorspelt bij patiënten met een ongedifferentieerde artritis de kans 
op progressie tot reumatoïde artritis. Het model lijkt een adequaat voorspellend vermogen 
te hebben. Een voordeel van dit model is dat de benodigde gegevens om de kans op pro-
gressie tot RA te berekenen gebruikelijk verzameld worden tijdens het gesprek, lichamelijk 
onderzoek en laboratorium onderzoek op de polikliniek en het model daardoor makkelijk 








onafhankelijke groep patienten met ongedifferentieerde artritis en het voornemen is om 
dit model ook in andere groepen patiënten met ongedifferentieerde artritis te toetsen. Er 
vanuit gaande dat ook in deze patiënten het ontwikkelde model het ziektebeloop goed zal 
voorspellen, biedt het in hoofdstuk 16 beschreven model een belangrijke hulp voor zowel 
artsen als patiënten bij het nemen van behandelbeslissingen in geval van een vroege 
ongedifferentieerde artritis. De hoop en verwachting voor de toekomst is dat een vroege 
behandeling van patiënten die een hoge kans hebben om reumatoïde artritis te ontwik-
kelen, bijvoorbeeld in het stadium van een ongedifferentieerde artritis, daadwerkelijk 
progressie naar reumatoïde artritis voorkomt. Het doel van een dergelijke behandeling is 
om de impact van een chronische gewrichtsziekte als reumatoïde artritis op het werkzame 
en sociale leven te verminderen.
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